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Introduction
1.1 Preamble
This volume concerns the potential of drug- loaded polymer nanofibres 
in pharmaceutics. It is designed to act as a primer for those about to start 
research in this area, be they new MSc or PhD students or more experienced 
researchers looking to move into the field. It places significant emphasis on 
the experimental aspects of fibre production, and provides hints and tips 
based on the authors’ experience throughout to guide readers as they initiate 
their own experiments. The book can be read as a whole to give a detailed 
background on pharmaceutical nanofibres, with both experimental insight 
and an in- depth survey of the key results to emerge from the significant 
body of literature in this area. Alternatively, it may act as a reference volume 
to be consulted when embarking on a new series of experiments.
We will begin in this chapter with a brief introduction to the key 
concepts in pharmaceutical science with which the reader is likely to 
need to be familiar, including key notions in drug delivery and methods 
of materials characterisation. In subsequent chapters we will discuss the 
methods by which nanofibres can be produced, and review some of the 
most exciting results from this field of research.
1.2 Nanofibres
The convention generally adopted in the literature is that a nanofibre is 
one which has a diameter of below 1 µm, though definitions can vary 
between disciplines. For example, a broader definition is adopted in 
industry and engineering disciplines, and submicron fibres are often 
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called nanofibres, whereas a stricter definition is employed in biology, 
and a nanofibre more frequently refers to a fibre with diameter below 
100 nm.1 Depending on their lengths, fibres are categorised as continuous 
or discontinuous/ short fibres, where continuous fibres are defined as 
having an aspect ratio (length divided by diameter) above 200.
A collection of nanofibres is often referred to as a mat or a mesh. 
A mat is termed as either woven or non- woven, where the former consists 
of fibres oriented in highly regular patterns, and the latter is randomly 
orientated. Conventional electrospinning creates a non- woven mat made 
of a continuous fibre.2 Schematic illustrations of fibre mats are given in 
Figure 1.1, together with a microscope image of a real fibre mat.
Continuous nanofibrous mats have very high surface- area- to- volume 
ratios and offer the advantage of very high porosity, typically ranging 
between 50% and 99%. By controlling the spinning process, systems with 
a wide range of fibre size and porosity characteristics can be produced, 
yielding materials with multiple functionalities. Fibres can be prepared as 
monolithic systems, where the fibre composition is the same throughout, 
as core/ shell systems with different interior and exterior compartments, 
or with more exotic multi- component architectures. These properties 
have caused them to be much explored in the drug delivery setting, as will 
be discussed subsequently in this volume. Fibres can be prepared from a 
wide variety of materials, but in the drug delivery context they typically 
comprise a filament- forming polymer carrier loaded with a drug.
1.3 Key concepts in drug delivery
1.3.1 The therapeutic window and bioavailability
In order to be effective, a drug must be delivered to the right part of the 
body, at the correct time, and in an appropriate amount. If any one of 
Figure 1.1  Schematic illustrations of (a) woven and (b) non- woven 
fibre mats, with (c) a microscope image showing a real- life mat (with 
thanks to Benjamin Yik for the image).
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these three criteria is not met, then the medicine will be ineffective or 
even dangerous. Very frequently, we require the drug to enter the sys-
temic circulation (the bloodstream) for onward transport to its site of 
action. It is helpful to consider the concept of the therapeutic window 
(Figure 1.2) to understand the issues here.
If the drug concentration is below the bottom line in Figure  1.2, 
then insufficient drug is present in the bloodstream to relieve symptoms 
effectively and treat the disease (underdosing). If the drug concentra-
tion rises above the upper line, then there is an excess of drug present 
and (potentially dangerous) side effects can arise; this is known as over-
dosing. The aim in drug delivery is to maintain the drug concentration 
between these limits (the therapeutic window) to ensure effective yet safe 
treatment of the patient.
The change in concentration with time which arises with a trad-
itional tablet or capsule formulation is also illustrated in Figure 1.2. The 
drug concentration rapidly increases to bring the concentration into the 
therapeutic window, but then the concentration continues to rise until 
overdosing occurs. The concentration next declines back into the safe 
region, before dropping below the lower limit of the window. Another 
dose of medicine will be required at this point in order for the patient to 
feel continuing relief of symptoms.
Drug concentraon
Time
Too lile (underdosing)
Too much (overdosing)
Figure 1.2  An illustration of the therapeutic window. The lower 
dashed line indicates the minimum plasma concentration required to 
be therapeutically effective, and the upper line the concentration above 
which side effects are likely to be experienced. The red line indicates the 
change in concentration observed with a traditional formulation.
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At this point, it is helpful to introduce the concept of bioavailability. 
This is a measure of how much of an administered drug reaches the sys-
temic circulation. If a drug is administered intravenously (IV), then the 
bioavailability is by definition 100%. The absolute bioavailability for a 
formulation given via another route will be less, and is described rela-
tive to the IV value (that is, bioavailability of the drug from formulation 
x = 100 × amount of drug in systemic circulation with formulation x / 
amount of drug in systemic circulation if drug is given IV).
1.3.2 Modified- release systems
The most convenient way to administer a medicine to a patient is through 
the oral route. Patients are familiar with taking medicines by mouth: this 
delivery route thus leads to high levels of compliance with the dosage 
regimen, and is preferred unless there are particular reasons why it is not 
suitable (e.g. when local delivery is required). More than 70% of medicines 
are given orally. The majority of these are conventional or immediate- release 
dosage forms: such formulations rapidly release the drug in the stomach 
to provide a swift onset of action. This can be very beneficial when, for 
instance, the patient is suffering from pain and requires fast alleviation 
of symptoms. However, in other circumstances such rapid drug release is 
inappropriate, and other release modalities are required. For instance, for 
the treatment of maladies lasting longer than a few hours multiple doses 
will be required using immediate- release formulations.
It is often more desirable to maintain the concentration in the 
therapeutic window over a prolonged period of time (e.g. 24 h, such that 
only one dose a day is required), thereby facilitating patient compliance. 
The term modified- release (MR) is used to describe formulations which 
seek to release the active pharmaceutical ingredient (API) at a particular 
rate, at particular time points, or to specified sites in the gastrointestinal 
tract. The major types of MR dosage form are those which are delayed- 
release (which do not release the drug immediately upon application, 
but rather at some later point in time), extended- release (which maintain 
the plasma concentrations of the API over a prolonged period of time to 
permit longer intervals between dosing) and gastro- resistant (precluding 
drug release in the stomach, and instead targeting it to a later stage of the 
gastrointestinal (GI) tract when a particular pH level is met).
MR dosage forms have a number of benefits. Extended- release 
formulations maintain the plasma drug concentration in the therapeutic 
window for much longer than immediate- release preparations, including 
overnight when the patient will not be awake to take multiple doses. 
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Further, extended- and delayed- release systems can permit APIs to be 
released when required to match the body’s natural circadian rhythms 
(for instance, diseases such as arthritis are worse in the morning). Side 
effects can be reduced:  in immediate- release formulations, the max-
imum plasma concentration tends to spike above the upper limit of the 
therapeutic window, leading to adverse side effects. MR systems ameli-
orate this problem, reducing the maximum concentration to ensure it 
lies within the therapeutic window. Reducing the dosing frequency to, 
for instance, once daily will usually improve patient compliance as the 
regimen becomes more convenient for the user. Treatment can also be 
localised to particular regions of the GI tract, which can be required for 
conditions such as inflammatory bowel disease.
Modified- release systems can be classified conveniently into res-
ervoir and matrix systems. In a reservoir system, the drug content is 
surrounded by a membrane which controls the rate of release. In a matrix 
system, the drug is dispersed evenly throughout a (typically polymer) 
matrix. This is illustrated in Figure 1.3. These systems can be:
• diffusion- controlled, where the rate of release is determined by how 
rapidly the drug molecules can diffuse through the rate- controlling 
membrane or the polymer matrix;
• dissolution- controlled, where the release rate is governed by the 
speed at which the polymer membrane or matrix dissolves;
• erosion- controlled, where the polymer is not soluble in physio-
logical media but instead is gradually worn away to free the drug 
loading.
MR dosage forms are often expensive to develop, but they add to 
the spectrum of treatment options available to healthcare professionals 
Figure 1.3  Schematic illustrations of (a) reservoir and (b) matrix 
systems.
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and can allow a company to continue to profit from an old and out- of- 
patent API. They can additionally reduce costs for healthcare systems 
by improving the quality of disease management. Nanofibres have been 
used to develop a range of MR formulations, which will be discussed in 
subsequent chapters.
1.3.3 Dissolution, solubility and permeability
Most frequently, oral formulations are administered in the form of 
solid materials (e.g. as tablets or capsules). These are convenient for 
the patient, resulting in typically high compliance with the dosage 
regimen. Industry also has a wealth of experience in their design, prep-
aration and testing. However, in order to be effective a drug needs to be 
in solution (individual drug molecules dispersed throughout a liquid 
solvent):  a solid formulation must thus dissolve into solution to be 
effective in vivo. This requires the drug molecules in the solid form to be 
prised apart, overcoming any intermolecular forces between them, and 
mixed with the solvent. The strength of the forces between the drug 
molecules in the solid state will thus help to determine how easy this 
transition is.
Since physiological fluids comprise mostly water, we require the 
drug to be water- soluble. Once in solution, however, in the majority 
of cases the drug then needs to pass through lipid- based biological 
membranes to reach the systemic circulation. The ability of a drug to 
achieve the latter is known as its permeability.
When considering the dissolution process, two concepts are 
important:  the solubility and the dissolution rate. Solubility is a cap-
acity term:  it refers to the maximum concentration of drug in solution 
when a solid drug/ solvent mixture has been allowed to reach equilib-
rium. Dissolution rate is a kinetic term, and details how quickly the drug 
dissolves into solution. The two are distinct but related – it is usual for a 
highly soluble drug to dissolve quickly, and an insoluble drug to dissolve 
slowly – and both need to be considered. For a medicine to be effective it 
is necessary that a therapeutic concentration of drug in solution can be 
obtained (i.e. a certain solubility is required), and also that the dissol-
ution happens on timescales appropriate for the time the medicine will 
spend in the digestive tract (so the dissolution rate must also be greater 
than a certain value).
The permeability/ solubility properties of an API are conveniently 
summarised using the Biopharmaceutical Classification System (BCS; 
Table 1.1).
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Class  I  drugs, with high solubility and high permeability, can 
be formulated into medicines relatively easily. Class  II drugs require 
careful formulation in order to get them into solution, but once in solu-
tion will permeate easily. Class III drugs dissolve easily, but permeation 
enhancers are required to permit them to pass to the systemic circula-
tion. Class IV drugs are extremely challenging to convert into medicines, 
since challenges in both solubility and permeability must be overcome. 
Approximately 35% of drugs on the market fall in class I, with 30%, 25% 
and 10% in classes II, III and IV, respectively. Increasingly, however, new 
drug entities fall into classes II, III or IV, leading to numerous challenges 
in their formulation.
1.3.4 Physical form
Most APIs, in the solid state, are crystalline materials. This means that the 
solid form contains a regular, repeating arrangement of drug molecules 
extending in three dimensions. The simplest unit or ‘building block’ of 
the structure is known as the unit cell. If more than one arrangement of 
molecules is possible in the solid state, then the different arrangements are 
referred to as polymorphs. This is illustrated schematically in Figure 1.4. 
Different polymorphs will have different unit cells, and because the 
molecules are arranged differently in the varied polymorphs the inter-
molecular forces between them (hydrogen bonding, van der Waals 
interactions, etc.) are also different. This results in different polymorphs 
having different solubilities and dissolution rates.
Solid- state phases are also possible, in which there are regular 
arrangements of more than one molecule (or ion) (Figure  1.4). In the 
pharmaceutical setting, this leads to pseudopolymorphs. These con-
tain both the API and a second component in the unit cell. If the API is 
ionised then a charge- balancing counterion will be present, and we term 
such phases salts. Alternatively, it might be that there is a stoichiometric 
amount of water (a hydrate) or another solvent (a solvate) present in the 
Table 1.1 The Biopharmaceutical Classification System
Class Solubility Permeability
I High High
II Low High
III High Low
IV Low Low
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unit cell. With hydrates and solvates, the co- former is a liquid at room 
temperature and pressure. If the co- former is a solid at room temperature 
and pressure, the material is known as a co- crystal. Introducing the second 
component into the solid state causes the intermolecular interactions pre-
sent to change, and thus pseudopolymorphs will have different solubilities 
and dissolution rates to crystals of the pure API. As a result, by changing 
the physical form of the drug, we can alter the in vivo performance.
Both for polymorphs and pseudopolymorphs, as well as the 
arrangement of species in the solid state (the intrinsic properties), it is 
also necessary to consider the particle size and crystal habit. Dissolution 
rate is directly related to the surface area (the larger the surface area, 
the more rapid dissolution will be) and hence is inversely correlated to 
particle size (via the Noyes– Whitney equation). Thus, reducing the par-
ticle size of a drug should increase dissolution rate and improve bioavail-
ability. Further, the equilibrium solubility of a particle is also inversely 
related to its particle size (through the Ostwald– Freundlich equation), 
although this effect is only significant for particles less than 1 µm in size. 
The crystal habit refers to the particle shape, which can again influence 
dissolution rate because some faces (sides) of a crystal will dissolve more 
quickly than others.
The presence of intermolecular forces between molecules in the 
solid state leads to an energy barrier to dissolution, which must be over-
come for the drug to transition from the solid to the solution state. The 
greater this energy barrier, the lower the solubility and the dissolution 
rate will be. If the energy barrier could be reduced to zero, then we would 
expect to see very fast dissolution and very high solubility. This can be 
achieved by converting the API into the amorphous form. Here, the drug 
molecules are arranged in a random manner in the solid state, and there 
is no long- range order (Figure 1.4). 
Polymorph I Polymorph II Pseudopolymorph Amorphous
Figure 1.4  Schematic diagrams of two polymorphic forms of an active 
pharmaceutical ingredient, a pseudopolymorph and the amorphous 
form. The unit cell is marked in red where applicable.
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The amorphous form can be very attractive to pharmaceutical 
scientists, but there is a problem:  it is inherently thermodynamically 
unstable, and thus over time the amorphous form will ‘relax’ to give a 
crystalline material. Thus, great care must be taken when making such 
formulations to ensure that the medicine taken by the patient has the 
same physical form as that produced in the factory. One way to do this 
is to blend the drug with a polymer in an amorphous solid dispersion 
(ASD), as illustrated in Figure  1.5. This can stabilise the amorphous 
form because the polymer provides steric hindrance to the translational 
movement and reorientation of molecules which are required to trans-
form to the crystalline phase. Polymer- based nanofibres have been used 
extensively to generate such ASDs.
1.4 Nanofibre characterisation
1.4.1 electron microscopy
Microscopy allows us to magnify a sample and to inspect features which 
are invisible to the naked eye. While traditional light microscopy can be of 
use in the preliminary characterisation of nanofibres, allowing us to con-
firm the successful formation of fibres (or not), their nanoscale diameters 
(particularly when below 200 nm) mean that a detailed inspection of the 
surface morphology or diameter quantification is not possible using this 
technique. A typical light microscopy image of some fibres of diameter 
x
(a)
(b)
Figure 1.5  (a) A schematic of an amorphous solid dispersion showing 
the polymer matrix in orange and the drug molecules in blue and (b) an 
illustration of how the polymer chains block movement of the drug 
molecules and thus stabilise the amorphous form.
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Figure 1.6  Sample (a) scanning electron microscopy (SEM) and 
(b) transmission electron microscopy (TEM) images of nanofibres. 
The SEM image provides a clear visualisation of the sample surface, 
and permits a large area of the sample to be imaged. In contrast, the 
TEM image considers a much smaller area but allows the interior 
structure of the fibres to be elucidated. (Reprinted with permission from 
Illangakoon, U. E.; Yu, D. G.; Ahmad, B. S.; Chatterton, N. P.; Williams, 
G. R. ‘5- Fluorouracil loaded Eudragit fibers prepared by electrospinning.’ 
Int. J. Pharm. 495 (2015): 895– 902. Copyright Elsevier 2015.)
ca. 1 µm is given in Figure 1.1(c). The presence of fibres is clear, but even 
with these relatively large fibres their surfaces cannot clearly be resolved.
Light microscopy allows us to magnify samples by up to 1000- fold 
(but 100- fold is much more common); to gain more insight, electron 
microscopy is required. This permits magnification of 100,000- fold to 
200,000- fold and nm- scale resolution. Both scanning and transition elec-
tron microscopy (SEM and TEM) are used in nanofibre characterisation, 
with the former being employed to study the fibre surfaces and the latter 
the interior structure. SEM uses the reflectance of an electron beam from 
the sample, and requires the sample under investigation to have a con-
ductive surface. This is achieved for polymer fibres by coating them with 
a thin layer (5– 20 nm) of metal, typically gold. SEM allows us to study 
thicker samples than TEM, since for the latter the electrons need to pass 
through the sample. However, only with TEM can we explore the interior 
structure of the materials. Typical SEM and TEM images of nanofibres are 
shown in Figure 1.6.
1.4.2 X- ray diffraction
X- ray diffraction (XRD) is a widely used technique in solid- state materials 
characterisation. It relies on the diffraction of a beam of X- rays by a 
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regularly arranged lattice array of atoms or molecules. Because the dis-
tance between atoms or molecules in the solid state is comparable to the 
wavelength of an X- ray, the particular manner in which the components 
are arranged will lead to a distinct series of diffraction peaks (we term 
these Bragg reflections). These form an XRD pattern, a plot of intensity vs. 
diffraction angle (2θ). Thus, a crystalline material will have a particular 
diffraction pattern which can be used as a diagnostic tool to identify it. 
Different APIs will have different patterns, as will different polymorphs 
or pseudopolymorphs of a given drug, and through XRD all of these phys-
ical forms can be identified.
We can also use XRD to quantify the amounts of phases present in 
a mixture, and to identify the amorphous form (since there is no regular 
arrangement of atoms or molecules here, there is no diffraction and 
no reflections are observed in the pattern). Some exemplar diffraction 
patterns are depicted in Figure  1.7. In the context of nanofibre drug 
delivery systems, we employ XRD to determine the physical form of the 
API in the formulation (most commonly, to discern if it is crystalline or 
amorphous).
1.4.3 Thermal methods
Differential scanning calorimetry (DSC) is a method by which we can 
determine the temperature at which a transition happens and the energy 
associated with it. A sample is loaded into a small metal container (the 
pan), heated at a particular rate and the energy flow is measured during 
heating. The technique uses a sample pan and a reference pan  (which 
is empty), and both are heated under the same conditions. The amount 
of energy (heat flow) required to heat the pan loaded with the sample 
10 20 30 40 2θ / ° 2θ / °10 20 30 40
(a) (b) (c)
2θ / °10 20 30 40
Figure 1.7  X- ray diffraction patterns of (a) paracetamol polymorph I, 
(b) paracetamol polymorph II and (c) an amorphous material. From a 
simple comparison of the patterns in (a) and (b) with the literature, it is 
easy to determine which form is present. Similarly, the amorphous form 
can easily be identified from its ‘halo’ appearance and the lack of distinct 
Bragg reflections.
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Figure 1.8  Schematic differential scanning calorimetry traces showing 
(a) melting, (b) recrystallisation and (c) a glass transition. ‘Exo’ denotes 
the exothermic direction (heat being given out by the sample).
is compared with the reference pan. Phase transitions such as melting 
(where a solid material is liquefied) and recrystallisation (the forma-
tion of a solid from a molten material) can easily be visualised. This is 
because, when an API melts, heat must be supplied to break the inter-
molecular bonds between the drug molecules. This is termed an endo-
thermic transition, and requires the DSC instrument to apply extra 
energy both to heat the sample and break these bonds. Similarly, if a sub-
stance crystallises, intermolecular bonds are formed, and thus energy is 
given out. These events are manifested as signals in the DSC trace, as 
illustrated in Figure 1.8.
When working with amorphous systems, there exists another very 
important event which can be detected by DSC: the glass transition tem-
perature (Tg). This is the temperature at which an amorphous material 
changes from being brittle to being rubber- like, and is manifested as a 
change in the baseline of the DSC thermogram (Figure 1.8(c)). Below 
the Tg, a polymer has low molecular mobility and thus is very brittle and 
easy to snap. Above Tg, molecular mobility is much higher, and so the 
material is rubbery and flexible.
DSC is widely used in the characterisation of drug- loaded 
nanofibres because it allows us to determine what physical form the 
drug takes (crystalline or amorphous; if crystalline, which polymorph or 
pseudopolymorph?). We can also use it to observe the presence of water 
or other solvents in the formulations. If water is present in a hydrate (i.e. 
there is water inside the unit cell of the crystalline structure), then we 
will usually see an endotherm at around 100ºC followed by an exotherm. 
These events arise because energy needs to be put into the material to 
drive away the water, and then the drug molecules will rearrange them-
selves to form an anhydrous crystal, giving out energy when intermo-
lecular bonds are formed. If water is simply absorbed to the surface or 
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adsorbed inside the body of the fibres, then a broad endotherm will be 
visible below 100ºC, with no subsequent exotherm. Similar consider-
ations apply to other solvents; for instance, ethanol boils at 78ºC and so 
an ethanolate will usually show an endotherm/ exotherm pattern at this 
temperature, while adsorbed or absorbed ethanol will only lead to an 
endotherm, which will occur at lower temperatures.
To verify the findings of DSC with regard to solvent inclusion, 
a widely used technique is thermogravimetric analysis (TGA). This 
measures the mass of a sample as a function of temperature. If a volatile 
component such as water or another solvent is present in a formulation 
it will be evaporated upon heating, leading to mass loss. TGA thus allows 
the amount of the volatile component to be quantified. The temperature 
at which this occurs (and the ratio of API:volatile component) can be 
used to verify whether the solvent is present in the unit cell of the crystal 
or is merely adsorbed or absorbed. The disadvantage of this technique is 
that, while weight changes can clearly be seen, it is not always possible 
to determine what may have caused the change leading to possible mis-
interpretation of results. The combination of TGA with a mass spectro-
meter or infrared (IR) spectrometer allows an evolved gas to be analysed 
and its identity confirmed.
1.4.4 infrared spectroscopy
When molecules absorb IR radiation, the bonds in them vibrate (bend 
and stretch). Different types of bonds will require different amounts of 
energy to vibrate, and so the exact wavelength of IR absorbed to cause 
these transitions is correlated with the types of bonds present. IR spec-
troscopy thus provides information on the structure of a molecule, since 
the presence of, for example, C=O, - OH, or - NH2 groups can be discerned. 
An IR spectrum is a plot of absorbance or transmittance (the two are 
related through the Beer– Lambert law, T  =  10– A) vs. the wavenumber 
(1/ λ) of radiation absorbed. The typical IR frequencies of commonly 
encountered groups are summarised in Table 1.2.
For solid- state materials, the vibrations of intermolecular bonds 
between molecules can also be seen through IR spectroscopy. These are 
referred to as phonon vibrations and occur below 1000  cm– 1. Typically 
the pattern of phonon peaks is too complex to unravel fully. In the con-
text of drug- loaded polymer fibres, IR is most commonly used to provide 
additional evidence on the physical form of the API in the formulation, 
and to seek insight into any intermolecular interactions present. If the 
API is amorphously distributed in the carrier, then there will be no or 
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Table 1.2 The infrared wavenumbers at which common functional groups 
are seen
Group Wavenumber / cm– 1 Group Wavenumber / cm– 1
O- H stretch 3500– 3200 C=C stretch 1680– 1640
N- H stretch 3400– 3250 N- H bend 1650– 1580
C- H stretch 3330– 2850 C- H bend 1470– 1450
C≡N stretch 2260– 2210 C- N stretch 1335– 1020
C≡C stretch 2260– 2100 C- O stretch 1320– 1000
C=O stretch 1760– 1665 C- Cl stretch 850– 550
minimal API– API interactions, and thus the phonon vibrations of the raw 
API will not be visible in the IR spectrum. The formation of hydrogen 
bonds or other intermolecular interactions will result in the change in 
position or the disappearance of peaks. For instance, where an API has 
COOH groups, the characteristic C=O stretches will shift in position as a 
result of H- bonding.
By way of an example, IR spectra for fibres prepared from poly(vinyl 
pyrrolidone) (PVP) and indomethacin, together with the chemical 
structures, are presented in Figure  1.9. The full- length spectrum in 
Figure  1.9(a) demonstrates that indomethacin has many peaks below 
1000 cm– 1, a number of which will be due to the phonon vibrations of this 
crystalline material. PVP, an amorphous polymer, has only a few peaks in 
this region, and most of the API phonon peaks are clearly absent in the 
spectrum of the drug/ polymer fibres. This indicates that the indometh-
acin was amorphously distributed in the fibres, a hypothesis which was 
validated using DSC and XRD.3 The enlargement of the 1800– 1500 cm– 1 
(carboxylate) region in Figure 1.9(b) shows that indomethacin has two 
peaks in this region, at 1712 and 1689 cm– 1 arising from the COOH and 
amide groups (Figure 1.9(c)). PVP has a single band at 1654 cm– 1 from 
its C=O group. In the spectrum of the fibres, these various carboxylate 
peaks have merged into a single band at 1660 cm– 1, indicating the exist-
ence of intermolecular interactions between the API and polymer.
IR spectroscopy is thus very useful to provide insight into both phys-
ical form and intermolecular forces. Molecular modelling approaches, 
in which computational calculations are used to explore the possi-
bility of interactions between species, can be helpful in confirming the 
interactions suggested from IR spectroscopy. At this point, we should 
briefly touch on Raman spectroscopy:  this is a technique similar to IR 
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spectroscopy, but whereas IR spectroscopy uses the absorption of light to 
generate a spectrum, Raman spectroscopy exploits the scattering of light 
by vibrating molecules. Both can be used to explore drug- loaded fibres 
and provide similar information on the stretching and bending of bonds.
1.4.5 functional performance
1.4.5.1 Dissolution and permeability testing
One of the most crucial attributes of a formulation to be tested is its func-
tional performance. For drug- loaded nanofibres we are typically most 
interested in the drug release profile, and the amount of drug which can 
permeate through biological membranes. Exactly how the drug release 
profile is measured will depend on the application intended: a formula-
tion intended as an oral fast- dissolving system should not be subject to 
the same release test as one designed for extended release in the small 
intestine. More details of the precise tests which have been used will be 
given in subsequent chapters, but one very common assay is dissolution 
testing.
Dissolution, the transition of drug molecules from the solid state 
into solution, is often the rate- limiting step to drug absorption in the body, 
and thus an understanding of this can give us an idea of how a formula-
tion will perform in vivo. Most often, dissolution testing seeks to mimic 
the transit of the drug through the GI tract following oral administration. 
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Figure 1.9  Infrared spectra of fibres containing poly(vinyl pyrrolidone) 
(PVP) and indomethacin, together with chemical structures. The full- 
length spectra are shown in (a), with an enlarged region in (b) and 
chemical structures in (c). (Lopez, F. L.; Shearman, G. C.; Gaisford, 
S.; Williams, G. R. ‘Amorphous formulations of indomethacin and 
griseofulvin prepared by electrospinning.’ Mol. Pharm. 11 (2014): 4327– 
4338. This is an open access article published under a Creative 
Commons Attribution (CC- BY) License.)
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There are well- established tests stipulated in pharmacopoeias which 
allow for quality control between batches to be maintained, and go 
some way towards mimicking in vivo events. Typically, a formulation is 
immersed for 2 h in 0.1 M HCl solution (pH 1.0) to simulate the pH of the 
stomach, and then (if required) in a pH 6.8 phosphate buffer represen-
tative of the lower parts of the GI tract. Often this is achieved by starting 
with 750 mL of the acidic solution and after 2 h adding to that a sodium 
phosphate solution to raise the pH to 6.8.
The US Pharmacopoeia (USP) lists four different types of dissol-
ution test, of which the most commonly used is probably method II, the 
paddle method. The apparatus required for this experiment is given in 
Figure 1.10. In USPII experiments, a formulation is stirred at 50 rpm 
and 37ºC at the required pH. At periodic intervals, an aliquot is removed 
and the concentration of drug determined using a technique such as 
ultraviolet (UV) spectroscopy or high- performance liquid chromatog-
raphy (HPLC). We then construct a plot of percentage release vs. time, 
which helps us to understand how and where the drug will be released 
in the body. These tests are not truly representative of what happens 
in the body – they replace the complex physiology of the GI tract with 
a litre of a buffer, and do not take into account the precise make- up of 
the gastric fluids in the body – but because the tests are standardised 
they permit easy comparison of different formulations. Further, the 
pharmacopoeias stipulate certain requirements for different dosage 
forms (e.g. for immediate release, the British Pharmacopoeia states 
that 80% of the drug should be released within 15 min in the stomach), 
and dissolution testing allows new materials to be assessed against 
these standards.
Rotang paddle
Heated buffer
soluon
Formulaon
under test
Figure 1.10  A schematic illustration of the US Pharmacopoeia method 
II dissolution apparatus.
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An API, if given orally, must both dissolve into solution from a solid 
dosage form and also permeate through the biological membranes in 
the intestine to enter the bloodstream and have systemic activity. Thus, 
a second commonly performed test is a permeation test. These vary 
in nature depending on the exact formulation being developed, but 
all involve investigating the passage of the drug through a biological 
membrane (or an artificial mimic thereof). Often, porcine intestines 
are obtained and cut into sections for permeation tests. The formula-
tion is placed in a donor chamber, which is separated from a receptor 
chamber by the biomembrane; a schematic illustration of this is given in 
Figure 1.11. A Franz cell is often used for these experiments, but alterna-
tive apparatus is also available. Samples are taken periodically from the 
receptor component to quantify the amount of drug which has passed 
through the membrane.
1.4.5.2 API quantification
Both the assays described above in section 1.4.5.1 require the amount of 
API in solution to be quantified. This is achieved using UV- visible spec-
troscopy or HPLC in the vast majority of cases. UV spectroscopy relies on 
the fact that APIs usually possess a chromophore (a system of alternating 
single and double bonds which absorb light in the UV- visible window). 
The amount of light absorbed is directly proportional to concentration, 
which means that once a suitable calibration curve has been plotted, 
UV spectroscopy allows the rapid determination of drug content. Much 
Srrer bar
Water bath
Formulaon 
under testBiomembrane
Sampling port
Donor compartment
Receptor 
compartment
Figure 1.11  A schematic of the typical Franz cell equipment used for 
permeability testing.
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contemporary dissolution apparatus comes with inline UV monitoring, 
permitting automated determination of the drug release profile.
In some cases  – such as for the simultaneous monitoring of two 
APIs being released from the same formulation – it can be advantageous 
to use HPLC. This typically uses a UV detector to quantify the drug con-
centration, but rather than a sample being directly placed in a UV spec-
trometer, in HPLC the analyte is first loaded on to a stationary phase (the 
column), a solid material to which the various components of the sample 
being analysed will adhere with different strengths. A  mobile phase 
(solvent) is flowed through the column, and depending on the strength 
of interactions between the API and the column the drug will be freed 
from the stationary phase at a particular time. A UV detector positioned 
at the end of the column records the concentration of drug exiting the 
column as a function of time. HPLC is beneficial because it allows two 
substances with similar UV spectra to be separated and quantified, and 
can also lead to more sensitive and accurate detection.
1.4.6 stability studies
The stability of a formulation is of paramount importance. Inevitably, 
there will be some degradation of a product upon storage, and it is 
necessary to understand the rate at which this happens and to set 
acceptable limits to allow a shelf- life to be stipulated. Degradation could 
take many forms, including chemical degradation of the active ingre-
dient, crystallisation of an amorphous material or microbial contam-
ination. Pharmaceutical scientists often make use of accelerated ageing 
studies to gain rapid insight into these processes and their rates. In such 
experiments, a formulation is exposed to stress conditions comprising 
elevated temperatures and relative humidities (RH). These will typically 
increase the rate at which degradation processes occur – for instance, the 
amorphous form will convert to a crystalline material more rapidly at 
80ºC and 80% RH than at room temperature and 50% RH.
The formulation is monitored over a period of time, and the extent 
of the degradation process at each time is determined using analytical 
techniques such as those detailed above. This permits the rate of the pro-
cess to be determined, and the Arrhenius equation (k = Ae– Ea/ RT) can be 
used to back- calculate the rate at room temperature, and thus estimate 
the ultimate shelf- life of the material. This method is far from perfect, 
because changing the temperature and humidity conditions can change 
the processes which occur as well as their rates, but it is widely used 
in the early stages of formulation development to obtain data rapidly. 
Ultimately the final dosage form will need to be studied under normal 
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storage conditions, but such experiments can take years and are thus not 
practicable in the early development stages.
1.5 An overview of contemporary pharmaceutical 
technology
In essence, we can regard the vast majority of drug- loaded fibres as 
solid polymer/ drug composite systems. The simplest way to gen-
erate such composites is to use film casting, a technique in which a co- 
dissolving solution of drug and polymer is prepared and the solvent 
allowed to evaporate to give a film. This is attractive in its simplicity, 
but suffers from a number of drawbacks in that the process is inherently 
rather slow (and thus inefficient from an industrial viewpoint) and as a 
result segregation between drug and polymer can arise. Consequently, 
researchers have developed a number of alternative methods to accel-
erate and control the drying process and generate drug/ polymer 
composites from solutions.
At the present time, although drug- loaded nanofibres hold great 
promise as dosage forms, there are no marketed products based on this 
technology. It therefore behoves us to consider briefly the most common 
contemporary pharmaceutical technologies used to prepare polymer/ 
drug composites.
1.5.1 Hot melt extrusion
Hot melt extrusion (HME) has been known as a polymer- processing tech-
nique since the early 1930s, and was first explored in the pharmaceutical 
industry in the 1970s. However, only in the past 20  years or so has it 
gained significant attention in the drug delivery field. HME has several 
advantages over traditional pharmaceutical manufacturing processes, 
including solvent- free processing, rapid fabrication of the final product 
and the ability to produce formulations able to achieve a wide range 
of drug delivery patterns.4 The technique involves heating a mixture 
of a polymer and API (plus potentially other excipients too) to a point 
at which it can flow (this could be such that the polymer is heated to 
above its melting point, Tm, or it may just be heated above its glass tran-
sition temperature, Tg). The resultant blend is forced through an aper-
ture under pressure, which both shapes the material and allows intimate 
mixing between the components. This results in an extended strand of 
polymer/ API blend. Because the extrusion process is continuous it is 
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amenable to scaling up, and the extruded strand can be used as is or 
undergo secondary processing to give pellets or tablets.
Depending on the polymer used, systems can be prepared which 
allow for extended release, targeted release, or very rapid release of a 
poorly soluble active (particularly in the form of an ASD). A  number 
of marketed products are based on HME materials.5 For instance, 
Zoladex is an implant based on poly(lactic- co- glycolic acid) produced 
by AstraZeneca through HME. It contains goserelin acetate as the API, 
and this is released over up to 90  days for the treatment of prostate 
cancer. Tablet formulations available include Kaletra (Abbott), a PVP/ 
poly(vinylalcohol)- based system which releases lopinavir and ritonavir 
over 6 h for the treatment of human immunodeficiency virus (HIV).
1.5.2 spray drying
Spray drying is another route widely used to prepare polymer/ drug 
composites. A co- dissolving solution of polymer and API (plus any other 
excipients desired) is first prepared, and then ejected through an atom-
iser which generates fine droplets from the bulk solution. The droplets 
pass into a drying chamber and warm air (or an inert gas) is blown 
over them. This causes rapid solvent evaporation and results in spher-
ical particles which are recovered in a cyclone unit. The droplets formed 
during spray drying typically have sizes ranging from less than 10 μm to 
upwards of 100 μm, which translates to a dry- particle diameter range of 
0.5– 50 μm.6 Spray drying is therefore very useful for producing materials 
for pulmonary administration, where a particle size of 2– 5 µm is required 
for effective delivery to the lung.
Typically, the drug is amorphously distributed in the polymer 
matrix. By careful control of the inlet temperature, the air flow rate, the 
humidity of the drying chamber, the type of atomiser and the solution 
parameters (solvent system, concentration, etc.) it is possible to achieve 
near- monodispersity in the particle size distribution.7 Spray- dried 
excipients are widely used in tablet production, and several marketed 
medicines also rely on particles produced in this manner. These include 
Zortress (Novartis; used to prevent organ rejection), Kalydeco (Vertex 
Pharmaceuticals; indicated for the treatment of cystic fibrosis) and 
Intelence (Janssen Therapeutics; employed to treat HIV infections).
1.5.3 freeze drying
Freeze drying (or lyophilisation) is also frequently employed in the 
pharmaceutical setting. It involves the preparation of a (typically 
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aqueous) solution of drug and polymer, freezing this, and then reducing 
the pressure such that the water is sublimed to yield a solid drug/ excipient 
composite. The technique is easily scalable, but is rather high- cost and the 
drying time can be prolonged. Freeze drying is particularly widely used 
in the preparation of biopharmaceuticals, where maintaining the three- 
dimensional structure of the active ingredient is both vital and challen-
ging. Medicines such as Synagis (MedImmune; a humanised monoclonal 
antibody treatment for respiratory syncytial virus) are prepared in this 
manner, as are some very fast- dissolving formulations such as Nurofen 
Meltlets (an ibuprofen- containing medicine manufactured by Reckitt 
Benckiser).
1.5.4 nanofibre manufacturing
The most common route used to prepare drug- loaded nanofibres is 
known as electrospinning. This is an electrohydrodynamic (EHD) pro-
cess in which electrostatic forces are employed to reduce a bulk liquid 
material down to nanometre dimensions. The details of the process will 
be discussed in Chapters 2– 5, but the basic principles are as follows:
• In the most common process, monoaxial solution electrospinning, 
a co- dissolving solution of a filament- forming polymer and func-
tional component (API) is prepared in a relatively volatile solvent.
• This is then extruded at a controlled flow rate through a narrow- 
bore blunt- end metal needle (the spinneret) pointing towards a 
metal collector, which is usually located at a distance of 10– 20 cm.
• A high potential difference (commonly 5– 25 kV) is applied between 
the spinneret and the collector, with the former typically being 
positively charged and the latter grounded.
• The potential difference causes the polymer solution at the spin-
neret to stretch rapidly while travelling towards the collector, and 
generates continuous fibres with diameters typically of the order of 
nm or µm.
A wide range of modifications can be made to the process to control 
the morphology and properties of the fibres, and Chapters 3– 5 will be 
devoted to a detailed consideration of these. There also exist other fibre 
production technologies such as solution blowing, island- sea spinning, 
melt blowing, centrifugal spinning and electro- centrifugal spinning, 
which will be discussed in Chapter 6. Several of the processes, including 
electrospinning, solution blowing and centrifugal spinning, potentially 
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have a number of advantages over more traditional pharmaceutical 
manufacturing technologies because heat is not required to facilitate 
solvent evaporation. This can be beneficial in cost terms and allows for 
easier processing of drugs which are heat- labile. The EHD process is 
also very rapid, with the solvent evaporating in well under 1 s, which 
can ameliorate some of the issues encountered with freeze drying (see 
section 1.5.3).
There are, however, a number of challenges which must be over-
come. Electrospinning is known to be scalable, but because it  often 
relies on volatile solvents there are a number of health and safety 
issues which must be addressed to implement it on an industrial 
scale. Many of the solvents which work best for electrospinning could 
have undesirable side effects in humans, and thus great care must be 
taken to ensure that all the solvent has evaporated during the pro-
cess. Further, for clinical applications it is vital to ensure that there 
are very high levels of batch- to- batch consistency, and robust quality 
control measures must be implemented. We will address some of these 
challenges in Chapter 7.
1.6 Summary
In this chapter, we have presented a brief overview of the key aspects 
of pharmaceutical formulation science and technology with which the 
reader ought to be familiar in order to benefit from the remainder of this 
book. This has necessarily been a rather superficial treatment, and for 
more detail we recommend consulting the excellent works detailed in 
the bibliography below. In the remainder of this volume, we will discuss 
in more detail the formation of pharmaceutical nanofibres and their use 
in drug delivery.
Chapter  2 will introduce in detail the fundamentals of the 
electrospinning technique (the most widely used approach to prepare 
drug- loaded nanofibres), presenting a discussion of the underlying theory 
and describing the implementation of electrospinning experiments.
We will then move on to survey the literature to review the most 
exciting results obtained using electrospun formulations in drug 
delivery. This will be undertaken starting with the simplest systems, with 
Chapter 3 considering monolithic fibres (with homogeneous structures 
throughout), Chapter 4 core/ shell materials (with separate inner (core) 
and outer (shell) compartments), and Chapter  5 Janus fibres (where 
the two sides of the fibre are different). Chapter  6 is concerned with 
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alternative routes to nano- and microfibre manufacture; it will consider 
the various approaches available, with examples of the materials which 
have been prepared using them. Chapter 7 focuses on the next steps for 
drug- loaded fibres, and will address matters of scale- up and industrial 
translatability.
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Electrospinning fundamentals
2.1 Background
Electrospinning applies a strong electric field (kV range) to disperse 
liquids into fine jets. For the purposes of this volume, these liquids will 
comprise polymer solutions, emulsions, suspensions or polymer melts 
containing one or more active ingredients. Electrospinning, together 
with electrospraying, are sister electrohydrodynamic (EHD) processes, 
and both involve charged liquid jets. Depending on the properties of 
the liquid being handled, the application of electrical energy may yield 
either fibres (electrospinning) or particles (electrospraying or EHD atom-
isation). This volume focuses on fibres, and thus most attention will be 
paid to the former. The difference between the two EHD processes will be 
discussed in more detail in subsequent sections.
Electrospinning at the laboratory scale is a low- cost route to 
manufacture near- monodisperse micro-/ nanofibres with a high sur-
face- area- to- volume ratio and highly tuneable properties. This lends 
them to a wealth of applications, including biomedical and healthcare 
products, photovoltaics and photocatalytic materials, stimuli- respon-
sive and smart robotics, optical and chemical sensors and antimicro-
bial filters, to list but a few.1 As a result electrospun fibres have been 
explored in a broad gamut of research areas  – for instance, materials 
science, life sciences and clinical medicine. Electrospinning is highly ver-
satile and can generate uniform fibres with a large range of diameters. 
The smallest nanofibres have cross- sections containing fewer than 10 
elongated molecules, and the largest diameters can be of hundreds of 
microns, similar to conventional textile fibres. The porosity of the fibre 
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mat may also be varied over a wide range through systematic changes to 
the experimental protocol.
In this chapter, we will discuss the key scientific concepts which 
underpin the electrospinning process, together with the different types 
of experiment that can be performed and the range of fibres that are 
produced.
2.2 A brief history of electrospinning
It is only in the last decade or so that researchers have begun to explore 
the use of electrospun nanofibres in drug delivery, but the EHD process 
has been studied for centuries. The physical phenomenon underpinning 
electrospinning was first noted in 1600 by William Gilbert, who described 
magnetic and electrostatic phenomena in which a droplet could be 
deformed into a cone shape and a spray of liquid jetted from the droplet 
when a piece of charged amber was placed close to it. The electric field 
exerted by the charged amber induced electrostatic charges on the sur-
face of the liquid droplet. When the built- up surface charges overcame the 
surface tension of the liquid, an aerosol of charged droplets was produced.
Similar observations were made in 1744, when George Mathias 
Bose reported aerosols produced by applying high electric potentials to 
liquid droplets at the end of a glass capillary tube. A quantitative explan-
ation emerged towards the end of the nineteenth century: in a series of 
essays published in 1879 and 1882, Lord Rayleigh calculated the max-
imum charge that a liquid droplet could carry and remain stable, known 
as the Rayleigh limit.
Cooley was the first to patent an electrospinning set- up in 1900.2 
This involved the use of auxiliary electrodes to direct fibre deposition on 
to a continuously rotating reel, similar to the spinning drum in conven-
tional fibre production. Several others have since investigated the phe-
nomenon:  in particular, Zeleny’s work in 1914– 1917 initiated efforts 
in academia to model mathematically and understand the physics of 
the EHD process.3 In the 1930s and 1940s, Formhals registered 11 
patents on the process of electrospinning. Many of Formhals’ designs 
laid the foundations for some of the most important contemporary 
electrospinning set- ups such as needleless spinning,4 multiple needle set- 
ups5 and using parallel electrodes to produce aligned fibres. At the same 
time, in Russia electrospun fibres were developed into filter materials 
known as Petryanov filters by Rozenblum and Petryanov- Sokolov. By 
1939, the Soviets had commercialised the technology to manufacture 
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electrospun smoke filter elements for gas masks, which found use during 
the Chernobyl disaster.6
Taylor’s work during the 1960s provided a mathematical model for 
the conical shape of the droplet under the influence of an electric field 
and experimentally confirmed the Rayleigh limit. Taylor’s work further 
underpinned the theoretical understanding of electrospinning, and the 
conical shape formed at the spinneret during a stable EHD process is 
often called the Taylor cone.7 
Furthermore, Simons filed a patent in 1966 describing non- woven 
patterned fibrous mats collected on metal grids, electrospun from 
thermoplastics such as polycarbonate and polyurethane.8 Simons iden-
tified key liquid parameters that must be controlled for electrospinning, 
including solvent properties such as volatility, viscosity, dielectric con-
stant and conductivity. He particularly highlighted the importance of 
solution viscosity in obtaining continuous fibres. 
In addition to solutions, Larrondo and Manley investigated polymer 
melts as materials for electrospinning. Melt electrospinning is a valuable 
approach when the polymer, such as many thermoplastics, does not 
dissolve in common solvents. However, melt spinning is difficult to set 
up due to the need to maintain a high temperature in the range of 200°C, 
and the requirement of a higher voltage (above 25 kV) compared to solu-
tion electrospinning (below 25 kV in most cases).9
Although the aforementioned studies laid the foundation for the 
electrospinning technique, it was not until the 1990s, with interest 
in nanoscience and nanotechnology increasing rapidly, that the EHD 
phenomena enjoyed resurgent attention from researchers, and the 
name ‘electrostatic spinning’ gave rise to the now widely used name 
‘electrospinning’.10 During this time, work was focused on furthering 
understanding of the interrelated electrospinning parameters, electro-
statics and fluid dynamics under a strong electric field.11 Since then, 
the number of publications on electrospinning has seen an exponential 
increase year on year.
2.3 EHD fundamentals
Electrospinning can be used to process a very wide range of materials, 
from liquids such as melts to solutions or suspensions of small molecules, 
biological materials, cells, bacteria and polymers (both natural and syn-
thetic).12 Here, we are most interested in the electrospinning of polymers, 
and thus our discussion will centre on the processing of polymers and 
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polymer/ drug mixtures. Since the solution approach is more common, 
the topics will be discussed from this perspective; analogous consider-
ations apply to the processing of emulsions or suspensions.
As explained earlier, electrospinning and electrospraying are 
‘sister’ EHD technologies for the production of polymer- based micro- and 
nanomaterials. The two are governed by identical theoretical principles 
and use the same basic equipment. The experimental set- up is illustrated 
in Figure 2.1.
There are four common components to the basic EHD apparatus: a 
high- voltage power supply, a precision syringe pump, a syringe fitted 
with a metal needle (the spinneret) and a collector. The power supply is 
connected to both the spinneret and the collector, with the former usu-
ally supplied with either a positive or a negative charge and the latter 
either grounded or having the opposite polarity to the spinneret. The 
syringe is filled with a spinnable liquid (e.g. a solution of a polymer, usu-
ally with a functional component such as a drug), often referred to as 
the working solution. The solution is extruded through the spinneret at 
a constant flow rate, controlled by the syringe pump. In conventional 
electrospinning using a benchtop set- up (described above), a voltage of 
5– 25 kV is usually applied to the spinneret with a distance of 5– 25 cm 
between the spinneret and the collector. It is worth noting here that, over 
0000
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V
I
Syringe pump
Syringe
Polymer soluon
High-voltage
power supply
Collector
plate
Spinneret
Figure 2.1  A schematic illustration of the apparatus required for 
electrohydrodynamic experiments.
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the last decade, numerous modifications to the electrospinning appar-
atus have been reported, allowing direct writing/printing of fibres in pre-
cise arrangements. One of the commonly studied variations, near- field 
electrospinning, can now deposit nanofibres with great precision under a 
voltage as low as 200 V over a distance of 0.5 mm.13
If a solution is dispensed from a capillary with no voltage applied, 
it will exit in the form of spherical droplets, in order to minimise sur-
face tension (an attractive force which acts to minimise surface area). 
In electrospinning, when a charge is applied to the spinneret, the solu-
tion inside acquires a charge, the magnitude of which is dependent on 
the applied charge, and the solution conductivity and dielectric con-
stant. Repulsive forces between the charges at the droplet surface and the 
strong potential difference between the charged solution and the collector 
cause its spherical shape to deform into a cone shape (the Taylor cone; 
Figures 2.2 and 2.3). In electrospinning, at the tip of the cone the polymer 
solution emits a jet, which rapidly elongates and reduces in diameter. 
The jet travels away from the spinneret, with the solvent evaporating as 
the charged solution moves towards the collector. When the jet reaches 
the grounded collector it discharges. Typically, by this time the solvent 
has been exhausted, and thus solid products are obtained. As mentioned 
in section 2.2, electrospinning is strongly dependent on the physical 
properties of the polymer solution as well as the processing parameters 
employed.14 These will be discussed in more detail in sections 2.4 and 2.5.
When the Taylor cone emits a polymer jet, electrospinning occurs 
to yield fibre products. However, it is also possible that the cone breaks 
up into droplets: this is electrospraying (Figure 2.2). Similarly to the 
Applied voltage
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Figure 2.2  A schematic illustration of the formation of the Taylor cone.
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electrospinning process, the droplets lose solvent and shrink as they 
move towards the collector, typically being deposited on it as spher-
ical particles. The explanation for the difference between spinning and 
spraying lies in the solution properties and processing parameters.
For both electrospinning and spraying, most reports in the literature 
apply a positive potential at the spinneret. However, it should be noted 
that the voltage is not constrained to positive polarity, although negative 
polarity has been reported to produce fibres with larger average diameter.15
2.4 Understanding the electrospinning process
Electrospinning involves a range of interlinked parameters broadly 
categorised into material (here we focus on solution) parameters and 
processing parameters. Electrospinning is in many ways similar to con-
ventional fibre spinning in textile production. The jet initiated during 
fibre spinning is generally subjected to tensile, rheological, gravitational, 
inertial and aerodynamic forces. The difference between electrospinning 
Taylor cone
Polymer jet
Spinneret
V1+ V2= V 
V2= 1/3 V
V1= 2/3 V
Surface
tension
Gravity
Normal electric
stress
Tangenal
electric
stress
Viscosity
Electric polarisaon
stress
Spinneret
nozzle exit
V2
V2 Cone
Jet
V1
Connected to high-voltage supply
Semivercal angle of
cone shape (θ)
(a) (b)
Figure 2.3  (a) A digital photograph of the Taylor cone and ejected 
polymer jet observed in a typical electrospinning experiment. (Modified 
with permission from Yu, D.- G.; Williams, G. R.; Gao, L.- D.; Bligh, 
S. W. A.; Yang, J.- H.; Wang, X. ‘Coaxial electrospinning with sodium 
dodecylbenzene sulfonate solution for high quality polyacrylonitrile 
nanofibers.’ Colloids Surf. A 396 (2012): 161– 168. Copyright Elsevier 
2012.) (b) A geometric diagram of a symmetric liquid cone with a thin 
jet at its apex, depicting forces acting on the cone jet. V is the volume of 
the conical frustum  (i.e. the shape left when the top part of the cone 
has been cut off), V1 is the jet volume and V2 is the space the jet is not 
occupying in the conical frustum.
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and conventional textile spinning lies in the origin of the tensile force ini-
tiating the fibre jet. In electrospinning, free charges carried by the liquid 
interact with the applied electric field and the tensile force inducing fibre 
jetting is due to the potential difference between the charged liquid in 
a spinneret and a grounded collector. On the other hand, conventional 
industrial fibre processing employs mechanical means (spindles and 
reels) to generate tensile force and initiate fibre formation.
Factors influencing electrospinning include rheology, electro-
statics, hydrodynamics and the transport of heat, mass and charge within 
the polymer jet. For simplicity, electrospinning can be divided into three 
stages: jet initiation, jet elongation and solidification of the jet to generate 
fibres. A detailed understanding of the underlying physics is not required 
for the purposes of this volume, but some insight into the processes 
underway is useful. For more in- depth discussions, the interested reader 
is invited to consult recent reviews.1b, 12, 16
2.4.1 Jet initiation
The charging of a droplet at the spinneret exit is usually the first step in 
electrospinning. When a polymer solution is supplied by a syringe pump 
to the spinneret without an applied voltage, droplets form at the exit and 
fall off under the influence of gravity. This dripping can continue even 
with the presence of an applied voltage, and ceases only when the elec-
tric field becomes sufficient to balance the surface tension of the liquid.
With the application of voltage, a charge is induced on the surface 
of the liquid droplet as it exits the spinneret. Repulsions between the like 
charges in the solution act to oppose the forces of surface tension, causing 
the droplet to change shape from spherical to conical (Figure  2.3(a)). 
Taylor supplied a mathematical model for the conical shape of the droplet 
under the influence of an electric field, showing that a conducting liquid 
can exist in the form of a cone under the action of an electric field when 
the semivertical angle θ (Figure  2.3(b)) is approximately 49.3°.7, 9a A 
critical voltage, Vk, is required to transform a spherical droplet to a cone 
shape at the end of a needle connected to one of the electrodes, and can 
be predicted based on the semivertical angle using Equation 2.17b:
V
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In Equation 2.1, H is the spinneret- to- collector distance (in cm), L is the 
length of the spinneret (cm), R is the inner radius of the spinneret exit 
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(cm) and T is the surface tension of the fluid (dyn cm– 1). All these factors 
will therefore have an effect on the voltage that needs to be applied to 
initiate the spinning process. Further, the semivertical angle can also 
vary with different polymer solutions and melts, and hence the critical 
voltage required to generate the cone shape droplet varies with different 
electrospun materials.17
Following the establishment of a conical- shaped droplet at the spin-
neret exit with a sufficiently high  applied voltage, additional surface area 
needs to be created by some means to accommodate the charge build- up 
on the conical surface. This occurs through the formation of a ‘cone jet’. 
The formation of the Taylor cone and ejection of the jet can be clearly 
seen by eye in electrospinning experiments (Figure 2.3(a)). A geometric 
model of a stable cone jet is given in Figure 2.3(b), and illustrates the 
forces at play during an electrospinning cone jet process.
It is important to be aware of the electric field gradient in the 
electrospinning experiment. The average gradient (V cm– 1) is often 
described as the potential difference divided by the spinneret- to- 
collector distance. The resultant value is a good approximation of the 
field near to the collector. However, the electric field close to the tip of 
a Taylor cone, just before jet emission, is much higher. After the point of 
jet emission, the electric field varies across the distance between spin-
neret and collector in a manner dependent on the surrounding environ-
ment. That said, in the interests of establishing functioning experimental 
parameters, the average field gradient is a sensible parameter to con-
sider when deciding on the voltage and spinneret- to- collector distance 
being used. In order to operate an efficient and reproducible production 
process, when varying applied voltage during process optimisation one 
should keep the collection distance constant to ensure meaningful and 
systematic optimisation of the field strength.
2.4.2 electrospinning vs. electrospraying
The distinction between electrospinning and electrospraying depends 
on the stability of the electrified liquid jet, governed by what is known 
as Rayleigh instability.18 The latter depends on the molecular entangle-
ments in the liquid (a frequently used analogy is to imagine polymer 
chains in a solution as snakes slithering over one another).
There are two key forces acting on the surface of the cone jet, 
and these oppose one another. Electrostatic repulsion of the charges 
in the solution promotes an increase in surface area to minimise these 
repulsions. This drives the charged polymer jet emitted from the Taylor 
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cone to become longer and narrower. Acting against this, the surface 
tension seeks to reduce the total surface area of the jet. Which of the two 
opposing forces prevails depends on the properties of the fluid being 
processed, particularly its viscosity and surface tension.
Viscosity is a reflection of the degree of molecular entangle-
ment in the liquid,19 and is fundamental in determining whether a 
material can be employed to form fibres or not. In electrospraying, the 
molecular entanglement of the liquid is insufficient to overcome the 
Rayleigh instability; thus, surface tension prevails and the electrified 
jet breaks up into small charged particles to minimise surface area.11a, 20 
Electrostatic repulsions between the charged droplets prevent them 
from coalescing, and as the solvent evaporates the particles shrink. This 
causes an increasing charge density at their surfaces, and so they break 
up into even smaller droplets (hence the name EHD atomisation). 
Electrospraying arises with low- viscosity solutions (i.e. those which 
flow easily; water has low viscosity, while honey is a high- viscosity 
fluid). In electrospinning the viscosity of the liquid is high and the 
molecular entanglements present are sufficient to overcome Rayleigh 
instability within the charged cone jet. Therefore, instead of capillary 
break- up the jet takes the form of a fibril undergoing a rapid whipping 
motion. The jet will elongate and its diameter will decrease until a dried 
fibre is deposited on the collector.
The molecular weight of the polymer strongly influences the 
degree of molecular entanglement of the polymer solution, and is thus 
very important in ensuring electrospinning rather than electrospraying 
is performed. The explanation for this lies in the manner in which the 
molecules in a solution interact. Small molecules can easily flow past one 
another, giving low- viscosity solutions. In contrast, long- chain polymer 
molecules are able effectively to become wrapped around one another, 
leading to entanglement. This is illustrated in Figure 2.4.
As a simple analogy, it can be helpful to think about the diffe-
rence between cooked rice and noodles. Grains of rice are small and 
exist as discrete units; it is thus very easy to remove a single grain of 
rice from a bowl. In contrast, noodles are long and narrow, and when 
placed in a bowl will become wrapped around one another. Extracting 
a single noodle from the bowl is rather difficult. The same is true for 
solutions, and a suitable degree of entanglement is critical for successful 
electrospinning because the tangling of the polymer molecules helps the 
jet elongation force to outweigh the surface tension. This ensures that 
the jet continues to the collector to form solid fibres, and does not break 
down into droplets. Entanglement can be promoted through the use of 
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higher- molecular- weight species and elevated concentrations. However, 
care must be taken because if the viscosity is too high then spinning will 
be unstable, resulting in heterogeneous fibre diameters or discontinuous 
fibres. Moreover, the solvent may deplete quickly at the spinneret exit, 
leading to blockage.
In addition, it is useful to describe here the ‘bead- on- string’ 
or necklace- like morphology of fibres sometimes observed during 
electrospinning. Bead- on- string arises from a situation intermediate 
between electrospraying and electrospinning, when charge repulsion 
and viscous forces are momentarily overcome by the surface tension 
of the charged liquid. This is often an intermittent occurrence during 
fibre elongation and considered a defect, resulting in a chain of droplets 
connected by fibrils. Careful control of the processing parameters 
during electrospinning can reduce this phenomenon. Methods to avert 
bead- on- string morphology include moderately increasing the viscosity 
of the solution either by increasing polymer molecular weight or con-
centration, or adding surfactants to decrease the surface tension of the 
solution.
(a) (b)
Figure 2.4  The concept of entanglement. (a) Small molecules 
and low- molecular- weight polymers cannot effectively overlap and 
entangle. Instead, they flow easily past one another. This leads to low- 
viscosity solutions which suffer from Rayleigh instability. (b) High- 
molecular- weight polymers undergo effective entanglement, meaning 
the force of elongation outweighs the surface tension and permitting 
electrospinning to be performed.
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2.4.3 Jet elongation: bending and whipping
As the charged liquid jet travels from the Taylor cone to the collector, 
it initially follows a linear trajectory (known as the straight jet), as it is 
attracted by the oppositely charged (or grounded) collector. During its 
journey, it is subjected to a variety of forces with opposing effects. The 
physical details are out of the scope of this volume and we do not need 
to consider them in detail here, but the result is that the linear jet does 
not continue all the way to the collector.21 Instead, it undergoes what is 
termed whipping instability (also known as bending mode instability or 
bending instability). This is a rapid elongation process that involves long- 
waveform perturbations of a liquid column driven by the lateral electric 
force (Figure 2.3(b)) and aerodynamic interactions, resulting in the jet 
bending or stretching. This is key in reducing the jet diameter to the 
nanometre scale to yield nanofibres.
The repulsive Coulombic forces between the charges carried within 
the polymer solution cause the jet to elongate and narrow continuously 
until it solidifies. Initially, this results in the emission of a straight jet, 
but as the jet grows longer the solvent evaporates and the diameter of 
the jet decreases. The surface charge density of the fibre concomitantly 
increases, which leads to a further increase in repulsive forces in the jet. 
Consequently, an increasing amount of time is required to distribute 
the repulsive charges along the jet length, and therefore it accelerates 
towards the collector. This produces an extremely high velocity at the 
leading end of the straight jet. As a result, at a certain point the jet 
bends and follows spiralling loops (Figure  2.5). Each subsequent loop 
grows larger in diameter as the jet grows longer and thinner.1a, 11c There 
are repulsions between each segment of the loop, since all parts of the 
jet bear the same charge, which means the jet follows a bending and 
whipping pattern before it solidifies on the collector.
The jet may also split into several smaller jets when electrospinning 
becomes unstable, a phenomenon termed splaying or branching.11c This 
occurs because of changes in the shape of the jet and/ or its charge per unit 
volume which can arise during the process of jet elongation and loss of 
solvent. Such changes shift the balance between the repulsive Coulombic 
forces and surface tension, such that the jet becomes unstable. To reduce 
the charge per unit surface area, a smaller jet is ejected from the sur-
face of the primary jet. This tends to be seen in highly concentrated and 
viscous solutions, as well as at very high field strengths.1a Splaying should 
ideally be avoided in the use of electrospinning to produce drug delivery 
systems, since it leads to inhomogeneities in the products, which can 
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preclude the robust and reproducible generation of materials with the 
desired properties.
2.4.4 Jet solidification
When all the solvent has been exhausted, the jet will become solid. This 
solidification results in the deposition of dry fibres on the collector.16 
Solvent evaporation begins as soon as the liquid jet is initiated, and 
increases as the jet undergoes whipping instability. As described in 
section 1.2, the fibres will collect as a non- woven mesh known as the fibre 
mat. The solidification rate is controlled by the concentration of the solu-
tion, the voltage, the spinneret- to- collector distance, the boiling point 
of the solvent system being used, the environmental temperature and 
humidity and the surrounding air movement. It is important to balance 
these to ensure that a dry fibre is produced and the electrospinning 
process can be undertaken continuously. If solidification happens too 
quickly (which can occur if the polymer concentration is very high, or 
the solvent very volatile), then the solution can solidify on the spinneret. 
This not only results in loss of material but also can block the spinneret. 
Figure 2.5  A digital photograph depicting bending instabilities during 
an electrospinning experiment. (Modified with permission from Yu, 
D. G.; Yu, J. H.; Chen, L.; Williams, G. R.; Wang, X. ‘Modified coaxial 
electrospinning for the preparation of high- quality ketoprofen- loaded 
cellulose acetate nanofibers.’ Carbohydr. Polym. 90 (2012): 1016– 1023, 
with permission from Elsevier. Copyright Elsevier 2012.)
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If the solvent is not all exhausted when the fibres reach the collector 
then the products are likely to have defects, and not comprise smooth 
cylindrical fibres. Residual solvent in the fibres may evaporate subse-
quently, leading to internal voids or porosity being developed and the 
fibres collapsing in on themselves. This causes their surfaces to wrinkle 
and/ or the fibres to become flattened (Figure  2.6). Alternatively, 
re- dissolution of the polymer in the solvent may occur, resulting in layers 
of fibres merging together.
(b)
(a)
(d)
(c)
Figure 2.6  Defects that may arise during fibre solidification, showing 
(a) smooth, cylindrical fibres resulting from a well- optimised process; 
(b) flattened fibres; (c) wrinkled fibres; and (d) merged fibres. (Images 
(a) and (b) are modified with permission from Yu, D. G.; Yu, J. H.; 
Chen, L.; Williams, G. R.; Wang, X. ‘Modified coaxial electrospinning 
for the preparation of high- quality ketoprofen- loaded cellulose acetate 
nanofibers.’ Carbohydr. Polym. 90 (2012): 1016– 1023, with permission 
from Elsevier. Copyright Elsevier 2012. Images (c) and (d) are 
modified with permission from Jia, D.; Gao, Y.; Williams, G. R. ‘Core/ 
shell poly(ethylene oxide)/ Eudragit fibers for site- specific release.’ 
Int. J. Pharm. 523 (2017): 376– 385, with permission from Elsevier. 
Copyright Elsevier 2017.)
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During the drying process, conglutination can also occur. This is a 
process by which partially solidified jets come into contact, resulting in 
fibres that are fused together at these points of contact. The attachments 
dictate the mechanical properties of the fibre mat, with more contact 
points making it more rigid.
2.5 The parameters affecting electrospinning
The electrospinning process is affected by many parameters, which can help-
fully be divided into solution, processing and environmental parameters. 
Solution parameters include the polymer molecular weight and struc-
tural conformation (these strongly influence the minimum concentration 
and viscosity required to form continuous fibres) and the choice of solvent 
or solvent mixtures (which strongly influences surface tension, rate of 
evaporation, dielectric constant and electrical conductivity). Processing 
parameters are dependent on the electrospinning apparatus design, but 
chiefly comprise the applied voltage, spinneret- to- collector distance and 
the solution flow rate. Each parameter will influence the morphology of the 
fibres obtained. Through their optimisation and control it is possible to tune 
the electrospinning process to yield nanofibres with the desired morphology 
and diameters. In addition, environmental parameters – the humidity, tem-
perature and air circulation speed of the surroundings in which the pro-
cess takes place – are also important to consider. These are described briefly 
below, and discussed in more detail in subsequent chapters.
2.5.1 solution parameters
The fibre formation process relies on the elongational stretching of 
the polymer solution exiting the spinneret. The dominant influence of 
the properties of the polymer solution on the electrospinning process 
and the resultant fibre morphology cannot be overstated. The prop-
erties of the polymer solution, such as viscosity, surface tension, con-
ductivity,  dielectric constant and volatility, change with the molecular 
characteristics of the polymer, the concentration of the polymer in solu-
tion, and the choice of solvents used. Understanding the polymer solution 
brings profound insight in achieving a successful electrospinning process.
Key solution parameters which need to be considered are as follows.
Concentration: The concentration of the polymer in solution is a deter-
mining factor for the formation as well as diameter and morphology 
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of the fibres from electrospinning. A  critical minimum concentra-
tion ce is needed to allow sufficient molecular chain entanglement to 
overcome surface tension and prevent the electrospinning jet from 
breaking up. Concentrations below ce will produce droplets when 
electrified (electrospraying). At concentrations above ce, electrospun 
fibre diameter increases with increasing polymer concentration 
and the frequency of bead- on- string defects decreases, eventually 
leading to the formation of beadless uniform nanofibres. The value 
of ce is dependent on the molecular chain length, macromolecular 
structure and the solvent(s) selected to dissolve the polymer.
Molecular weight and molecular chain length:  The polymer 
molecular weight inversely affects the value of ce required to enable 
electrospinning.22 A polymer molecule generally has a long chain- like 
geometry, but these chains may be branched and there may be crosslinks 
between chains. These characteristics depend on the polymer’s chem-
ical structure and the synthesis method. A linear polymer with a high 
molecular weight (above 3000 g mol– 1, preferably above 10,000 g mol– 1, 
and more preferably above 50,000 g mol– 1) leads to a lower ce for 
fibre formation in electrospinning than a branched polymer with low 
molecular weight when dissolved in the same solvent.
Solution viscosity: Viscosity reflects the degree of polymer molecular 
chain entanglement in a solution. The solution viscosity is influenced 
both by the molecular weight of the polymer and the properties of the 
solvent used. Hence, it can be adjusted by both varying polymer con-
centration in solution and/ or changing the solvent. The minimum 
solution viscosity required to enable electrospinning is that of a solu-
tion with polymer concentration higher than the relevant ce value.
If the viscosity is very low, then electrospraying will occur 
and the products will comprise particles. An intermediate vis-
cosity will lead to beaded fibres (a situation intermediate between 
electrospraying and spinning). The effect of viscosity on fibre 
morphology is depicted schematically in Figure 2.7.
It might therefore be thought that the higher the viscosity the 
better, but unfortunately the situation is not that simple. A greater 
viscosity will make it more difficult for the jet to become elongated 
and narrow, thus leading to thicker fibres. Helix- shaped fibres 
have also been observed when working with very- high- viscosity 
solutions,23 and incomplete drying of a high- viscosity jet can lead 
to the formation of flattened ribbon- like fibres.24 Finally, if the vis-
cosity is too high the polymer solution may solidify on the spinneret, 
leading to it becoming blocked.
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The range of viscosities that allows electrospinning is specific 
to the polymer and solvent system used. For example, Doshi and 
Reneker found that the optimum viscosity range for electrospinning 
poly(ethylene oxide) (PEO) nanofibres is 800– 4000 mPa s.21 On the 
other hand, in a comprehensive investigation on electrospinning 
poly(acrylonitrile) dissolved in dimethyl formamide (DMF), 
Baumgarten observed that smooth submicron fibres could be 
electrospun when the viscosity of the solution was 170– 21500 mPa s.25
Surface tension: Surface tension acts together with the viscosity 
of the polymer solution to oppose the electrical drawing force. To 
begin the electrospinning process, the surface tension must be over-
come by the repulsive forces between the charges in the polymer 
solution. In Equation 2.1, the critical voltage for cone formation Vk is 
proportional to surface tension T, and thus liquids of higher surface 
tension require higher Vk for electrostatic processing. However, a 
higher electric field also means greater potential leakage of the sur-
face charge on the jet into the surrounding air. This makes the cone 
jet unstable, leading to defects and non- uniformity in the fibres. 
Defects such as bead- on- string formation can arise when the surface 
tension of the solution briefly overcomes the elongational forces.
Solutions with very high surface tensions can thus be difficult 
to spin, as they require significantly stronger electric force to over-
come this. In addition, the higher the surface tension, the greater 
the forces opposing jet elongation, and thus the more likely it is that 
it will break up into droplets or form bead- on- string defects.
Increasing viscosity
Parcles Beaded
fibres
Fibres
Figure 2.7  The effect of solution viscosity on the products from 
electrohydrodynamic processing.
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At a fixed polymer concentration, reducing the surface tension 
has been reported to be an effective route to improve the morph-
ology of the electrospinning product from beaded fibres to smooth 
fibres.23 Most solvents used for electrospinning have relatively low 
to moderate surface tensions (20– 45 mN m– 1 at 20°C), but working 
with water, a high surface tension solvent (72.75 mN m– 1 at 20°C) 
with low volatility (boiling point at 100°C) can be problematic. 
Surfactants can be added to the working solution to reduce surface 
tension if required, but these will be carried through into the fibre 
products, which may be undesirable.
The surface tension of a polymer solution is temperature- 
dependent, but also varies with the choice of solvent(s), and the 
concentration and the chemical structure of the polymer. As the 
electrospinning jet travels towards the collector, solvent evaporation 
leads to an increasing polymer concentration in the jet. The surface 
tension of the jet is therefore likely to evolve upon exiting the spin-
neret and landing on the collector.
Electrical conductivity: The greater the electrical conductivity of the 
solution, the more easily charge can accumulate in it to build up suf-
ficient tangential stress for fibre elongation, and hence the lower the 
voltage required to initiate jet electrospinning. Fibres with thinner 
diameters also result from more conducting solutions. The addition 
of trace amounts of inorganic salts or ionic organic species to the 
solution offers a simple route to enhance electrical conductivity, 
if required. Solutions of zero conductivity cannot be electrospun. 
However, if the electrical conductivity of the liquid is too high, elec-
trical discharge into the surrounding air will occur, resulting in 
unstable jetting or halting the electrospinning process altogether. 
For instance, Morota et al. found that increasing the conductivity of 
aqueous solutions of PEO changed the stable cone jet to an unstable 
multijet, and solutions with conductivity above 0.5 S m– 1 could not 
be electrospun.26
Dielectric constant: A temperature- dependent property, the dielec-
tric constant ε (otherwise known as the relative permittivity) of 
a substance is a measure of the extent to which it concentrates 
the electrostatic lines of flux when placed in an electric field. It 
is defined as the ratio of the amount of stored electrical energy 
when a voltage is applied relative to the permittivity of a vacuum. 
Solvents of different dielectric constant values interact with the 
electric field differently during solution electrospinning. Solutions 
in solvents of an appropriately high range of dielectric constants 
(ε value above 30 at 20°C) allow a more even distribution of the 
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surface charge on the jet, and have been reported to be easier to 
electrospin and to produce fibres with smaller diameters.27
Volatility: Solvent evaporation has a significant effect on fibre morph-
ology and diameter. Selecting a relatively volatile solvent allows the 
fibre to dry completely upon reaching the grounded collector, avoiding 
defects such as fused wet fibres. However, solvent volatility also affects 
the kinetics of phase separation and hence the morphology of the 
electrospun fibres obtained. Highly volatile solvents can cause a hard 
solidified shell to form on the elongating fibre before complete drying 
can occur, trapping the solvent inside the fibre. As the residue solvent 
slowly diffuses out of the fibre shell, defects such as wrinkled or porous 
surface morphologies can occur. In addition, rapid solvent evapor-
ation from the jet can hinder the production of smaller fibre diameters, 
since there is less time for elongation before complete solidification 
occurs. Hence, volatile solvents such as acetone, dichloromethane and 
chloroform are often reported to generate fibres with a larger average 
diameter than solvents such as water and DMF (though other solvent 
properties such as water and DMF having moderately high dielectric 
constants can also contribute to such observations).
Solvent choice:  The choice of solvent or solvent mixture strongly 
influences the viscosity, surface tension, electrical conductivity, 
dielectric constant and volatility of the solution, and thus is of cru-
cial importance. The selected solvent must not only provide appro-
priate electrical conductivity, viscosity and surface tension, but also 
needs to be able to dissolve/ disperse the polymer and the functional 
component of interest at appropriate concentrations.
In general, it is useful to know that using a solvent of lower 
solubility for the polymer(s) of interest can enhance nanofibre for-
mation or dramatically change the value of the critical concentra-
tion, ce.28 For example, Shenoy et  al.22 found that poly(vinylidene 
fluoride) (PVDF:  molecular weight (Mw) 180 kDa) fibres can be 
electrospun at concentrations as low as 7.5% w/ w using acetone, 
whereas a concentration of 30% w/ w PVDF in DMF was necessary 
for successful electrospinning. In this case, acetone was a marginal 
solvent for PVDF whereas DMF was a good solvent. The addition of 
acetone to the PVDF solution in DMF significantly lowered the ce 
necessary for fibre formation.
2.5.2 Processing parameters
Process parameters include the operating parameters (such as applied 
voltage, flow rate, diameter of the spinneret inner orifice and collection 
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distance), the spinning environment (temperature and humidity) and the 
set- up design (e.g. the choice of material used as the collection substrate).
Voltage: A sufficient voltage must be applied to initiate jet formation, 
and as discussed above, this threshold voltage depends mainly on 
solution properties such as surface tension and viscosity. Increasing 
the voltage beyond the threshold for jet initiation increases the 
degree of whipping instability and hence the elongation of the 
fibre jet. However, on the other hand, it also reduces the flight time 
between the spinneret and the collector. Hence,  its effect on the fibre 
products is controversial. While numerous studies have observed 
decreasing fibre diameter with increasing applied voltage,29 many 
others have shown minimal effect or an increase in fibre diameter.30
This discrepancy in the literature is a result of the interrela-
tionship between applied voltage and other parameters such as 
flow rate and collection distance. If the voltage is too high and the 
flow rate is sufficient to maintain an increased rate of mass transfer, 
then multiple jets may be formed from the Taylor cone. This should 
be avoided, because it can lead to the products comprising several 
different subpopulations of polydisperse fibres. Voltage is therefore 
an important parameter, but no general statements can be made, 
other than to say it must be greater than Vk, the critical voltage 
needed to overcome the surface tension and emit a jet, and not so 
high as to lead to multiple jets forming or deplete the cone- shaped 
droplet at the nozzle exit.
In the majority of cases, a positive voltage is applied to the 
spinneret. Electrospinning with a negative voltage is also possible 
(as indeed is alternating current (AC) electrospinning, where the 
voltage alternates from positive to negative values), but both are 
much less explored than the positive polarity set- up. Studies have 
shown that AC current can cause non- uniform fibre diameters, and 
a negative polarity at the spinneret can result in fibres with larger 
average diameters.15, 31
Flow rate: Flow rate, also known as infusion rate or feed rate, is the 
rate at which the polymer solution is pumped into the spinneret to 
feed the spinning cone jet. The rate at which the solution is ejected 
from the spinneret collectively depends on the inner size of the spin-
neret orifice, the applied voltage (which provides the electrical force 
pulling the solution out of the needle) and the flow rate at which 
the solution is fed into the needle. As mentioned earlier, the voltage 
required for jet initiation is in turn dependent on the polymer solu-
tion properties. Therefore, at any given voltage, an optimum range 
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of flow rates exists for a polymer material, which varies with the 
inner diameter of the needle. Fibre diameter increases and uni-
formity decreases with flow rates higher than this optimum range; 
a higher than optimum flow rate may not provide enough time for 
the polymer solution to become sufficiently charged to generate the 
Taylor cone, and some droplets may form upon exiting the spinneret.
A faster flow rate will usually lead to thicker fibres at a given 
voltage, because more mass is dispensed in a given unit of time. It 
may also produce fibres with defects such as beads or wrinkles if the 
solvent does not have time to evaporate completely before reaching 
the collector. Multiple jets can additionally be initiated if the flow rate 
is too high. On the other hand, at flow rates lower than the optimum 
range, electrospinning becomes discontinuous as the cone at the tip 
of the nozzle becomes depleted and even recedes into the needle.
Reducing the flow rate, of course, also has the disadvantage 
of increasing the time required to produce the desired amount of 
material. Hence, balancing the flow rate and applied voltage is vital in 
obtaining and maintaining a stable cone jet during electrospinning. 
To ensure steady mass transfer and continuous fibre production, the 
mass of liquid supplied to the needle tip needs to be equivalent to the 
mass of the jet spinning out of the needle.32
Spinneret: Metal spinnerets are most commonly used. In general, 
these comprise needles with small inner orifice diameters to generate 
narrow fibres.33 The single- bore needles used for electrospinning 
monolithic fibres usually have diameters below 2 mm. A narrower- 
bore needle can be helpful in reducing the fibre diameter and also in 
preventing the formation of beaded fibres, but is also more prone to 
becoming blocked.
Spinneret- to- collector distance: The shorter this distance, the higher 
the electric field strength will be. However, the flight time will reduce 
with distance, and short distances can hence lead to incomplete solvent 
evaporation and the concomitant problems discussed in section 2.4.4. 
The optimum range for collection distance is most commonly 100– 
200 mm for conventional set- ups. Special apparatus such as near- field 
electrospinning, which requires a much lower collection distance, will 
be discussed in Chapter  6. Longer distances have been reported to 
lead to narrower fibres, because a greater period of elongation is pos-
sible. However, long distances beyond the optimum collection range 
will cause significant increases in the flight time, which can result in 
increased corona discharge and Rayleigh instability, leading to large 
fibre diameters and defects such as fused or beaded fibres.34 For 
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example, when increasing the collection distance from 10 to 30 cm, 
Kidoaki et  al. (2006) observed a steady increase in fibre diameter 
from electrospun polyurethane in tetrahydrofuran and DMF mixed 
solvents.34
Finally, it is important to note that the polymer jet will dis-
charge itself at the earliest opportunity, and thus using long 
distances can result in low yields and thinner fibre mats because 
the product is deposited over a larger surface of the collector, and in 
some cases not on the collector at all, but rather on the walls of the 
electrospinning chamber.
2.5.3 environmental parameters
Environmental parameters are in essence the temperature and humidity 
of the location in which electrospinning takes place. It is also worth 
noting the surrounding speed of air flow: the presence of fast movements 
or changes in the degree of ventilation in the laboratory could affect the 
stability of the cone jet and the rate of solvent evaporation, leading to 
changes in the products obtained. To ensure reproducibility, it is usually 
best to conduct electrospinning in a space enclosed with an electrically 
insulating material such as plastic sheets.
An increase in humidity from 20% to 40% can reduce the as- spun 
fibre diameter, depending on the particular solvent used. This is because 
the evaporation rate of a solvent from a free surface is proportional to 
the difference between the vapour pressure of the solvent and the vapour 
pressure in the surrounding air. Increasing humidity retards the rate of 
solvent evaporation, thereby allowing longer time for fibre elongation. 
However, high humidities (> 60%)35 can be problematic and often result 
in the formation of a film or poorly defined fused fibres on the collector, 
particularly with hygroscopic polymers such as poly(vinylpyrroli-done).35a 
This is because the absorption of water is favoured by a higher humidity 
and the concomitant greater partial pressure of water in the atmosphere; 
the presence of such high amounts of water in the air excessively retards 
the rate of solvent evaporation, allowing wet fibres to land on the collector 
and the possibility for this atmospheric water to interact with the products. 
If the polymer is insoluble in water it may precipitate in high- humidity 
environments, which can lead to blocking of the spinneret, thicker fibres, 
porosity or defects driven by phase separation in the products.
Higher temperatures will generate two opposing effects in 
electrospinning: on the one hand, it provides more energy to the molecules 
in solution, thereby increasing the electrical conductivity and reducing vis-
cosity and surface tension of the solution. This facilitates the formation of 
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finer fibre diameters as well as leading to higher polymer chain alignment 
(enhancing mechanical properties).36 However, an increase in tempera-
ture also provides additional energy to accelerate the rate of solvent 
evaporation, reducing the time available for fibre elongation before solidi-
fication. Increasing the temperature from the ambient temperature of ca. 
20°C to 40°C leads to reduced fibre diameter,35a, 37 indicating that the 
former effect dominates over this temperature range. Fibre diameter was 
found to increase at temperatures higher than 40°C, however, indicating 
that here the faster solvent evaporation factor has overtaken the effect on 
surface tension and viscosity. There is very limited literature on the effect 
of temperatures cooler than the ambient temperature of approximately 
20°C. However, Vrieze et al. observed reduced fibre diameters at 10°C and 
attributed this to a reduced rate of solvent evaporation.35a
2.5.4 solvent and polymer selection
Pillay et al. have published an excellent review including the typical par-
ameter ranges used for the electrospinning of a range of polymers for 
drug delivery purposes.38 A summary is given in Tables 2.1 and 2.2.
2.6 The experimental set- up
The equipment needed for electrospinning will be briefly introduced in 
this section. More detail will be presented in subsequent chapters where 
the different types of electrospinning are discussed.
2.6.1 Basics
As discussed in section 2.3, the basic electrospinning apparatus 
consists of a high- voltage power supply, syringe pump, syringe fitted 
with a spinneret and a collector. All of these can be purchased at rela-
tively low cost, and it is possible to construct a home- made set- up for 
a few thousand dollars (certainly less than $4000). Alternatively, a 
range of ready- made commercial apparatus exists, for instance from 
YFlow,39 SprayBase,40 or IME Technologies.41 These are more expen-
sive, ranging from around $15,000 to more than $100,000, but have 
advantages in terms of ease of getting the equipment up and running 
and access to specialist advice, of particular benefit to groups working 
on electrospinning for the first time.
There are two ways of setting up the orientation between the spin-
neret and the collector in electrospinning:  vertically or horizontally. 
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Table 2.1 The properties of some solvents commonly used in the preparation of electrospun drug delivery systems
Solvent Boiling point  (°C) Other properties Fibre morphology References
Dichloromethane 39.8 Low dielectric constant, 
high surface tension
Beaded, large diameter J. Biomater. Sci. 2006, 17, 9, 1039
J. Polym. Sci. B 2004, 42, 20, 3721
Chloroform 61.2 High intrinsic viscosity Beaded at very low polymer 
concentration, smooth at higher 
concentration
Polymer 2004, 45, 9, 2959
Methanol 64.7 High dielectric constant Small fibre diameter with 
dichloromethane/ methanol 
mixtures until the methanol 
concentration reached 50%, then 
rising fibre diameter
J. Biomater. Sci. 2006, 17, 9, 1039
Tetrahydrofuran 66 High dipole moment, good 
conductivity
Smooth and beaded, ribbon- like, 
high pore density
Polymer 220, 43, 16, 4403
Eur. Polym. J. 2005, 41, 3, 409
Ethyl acetate 77.1 High dielectric constant, 
fair conductivity
Smooth and beaded, ribbon- like Eur. Polym. J. 2005, 41, 3, 409
Ethanol 78.3 Low surface tension, high 
intrinsic viscosity
Smooth, large diameter Polymer 1999, 40, 16, 4585
J. Polym. Sci. B 2004, 42, 20, 3721
Polymer 2004, 45, 9, 2959
Methyl ethyl 
ketone
79.6 High dipole moment, good 
conductivity
Flat, ribbon- like, very few beads Eur. Polym. J. 2005, 41, 3, 409
new
genrtpdf
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Dichloroethane 83.5 High dipole moment, fair 
conductivity
Smooth and beaded, C- shaped Eur. Polym. J. 2005, 41, 3, 409
Water 100 Low intrinsic viscosity Beaded, small diameter Polymer 1999, 40, 16, 4585
Polymer 2004, 45, 9, 2959
Dimethyl 
formamide
153 High dipole moment, 
high conductivity, low 
intrinsic viscosity
Smooth and beaded, round Polymer 2004, 45, 9, 2959
Eur. Polym. J. 2005, 41, 3, 409
Adapted with permission from Pillay, V.; Dott, C.; Choonara, Y. E.; Tyagi, C.; Tomar, L.; Kumar, P.; du Toit, L. C.; Ndesendo, V. M. K. ‘A review of the effect of processing 
variables on the fabrication of electrospun nanofibers for drug delivery applications.’ J. Nanomater. 2013 (2013): 789289. This is an open access article distributed under 
the Creative Commons Attribution License. Copyright V. Pillay 2013.
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Table 2.2 Polymers and solvent types commonly used in the preparation of electrospun drug delivery systems, together with examples of the 
drugs which have been incorporated
Polymer Solvent Active ingredient(s) References
 Cellulose acetate  2:1 acetone/ 
dimethylacetamide  
Naproxen, indomethacin, 
ibuprofen, sulindac
Polymer 2007, 48, 17, 5030
Curcumin Polymer 2007, 48, 26, 7546
Vitamins A and E Eur. J. Pharm. Biopharm. 2007, 67, 2, 
387
Poly(ε- caprolactone) 7:3 dichloromethane/ 
methanol
Heparin Biomater. 2006, 27, 9, 2042
3:1 chloroform/ ethanol Resveratrol, gentamicin J. Biomed. Mater. Res. A 2006, 77, 1, 169
Poly(ethylene oxide)/poly(ε- 
caprolactone) blend
Chloroform Lysozyme Colloids Surf. A 2008, 313– 314, 183
Poly(vinyl alcohol) Deionised water Ketoprofen Mater. Sci. Eng. A 2007, 459, 1– 2, 390
Sodium salicylate, diclofenac, 
naproxen, indomethacin
Nanotechnol. 2006, 17, 9, 2317
Gelatin/poly(vinyl alcohol) 
blend
Gelatin in formic acid, 
poly(vinyl alcohol) in 
deionised water
Raspberry ketone Carbohydrate Polym. 2007, 69, 3, 538
Poly(lactic- co- glycolic acid) Dichloromethane/ 
dimethyl formamide
Paclitaxel Biomater. 2008, 29, 20, 2996
Dimethyl formamide Cefoxitin sodium J. Control. Release 2004, 98, 1, 47
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Polyurethane Dimethyl formamide Itraconazole J. Control. Release 2003, 92, 3, 349
Dimethylacetamide Ketanserin
Poly(l- lactic acid) 2:1 chloroform/ acetone Doxorubicin HCl J. Control. Release 2005, 105, 1– 2, 43
Tetracycline HCl J. Macromol. Sci. B 2006, 45, 4, 515
Chloroform Cytochrome c J. Control. Release 2008, 127, 2, 180
Dichloromethane Bovine serum albumin Biomacromol. 2006, 7, 8, 2327
Poly(ethylene- co- 
vinylacetate)
Chloroform Tetracycline HCl J. Control. Release 2002, 81, 1– 2, 57
Poly(ethylene glycol)– poly(l- 
lactic acid) copolymer
Chloroform Doxorubicin HCl Eur. J. Pharm. Biopharm. 2008, 
70, 1, 165
J. Control. Release 2005, 108, 1, 33
Poly(acrylic acid)/
poly(allylamine 
hydrochloride) blend
Deionised water Methylene blue Colloids Surf. B 2007, 58, 2, 172
Adapted with permission from Pillay, V.; Dott, C.; Choonara, Y. E.; Tyagi, C.; Tomar, L.; Kumar, P.; du Toit, L. C.; Ndesendo, V. M. K. ‘A review of the effect of 
processing variables on the fabrication of electrospun nanofibers for drug delivery applications.’ J. Nanomater. 2013 (2013): 789289. This is an open access article 
distributed under the Creative Commons Attribution License. Copyright V. Pillay 2013.
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The difference lies simply in the direction of liquid travel:  in the former 
approach, liquid is dispensed in a direction perpendicular to the floor 
and aided by gravity, while in the latter it travels parallel to it. Both have 
advantages and disadvantages. In the horizontal approach, the force of 
gravity on the fluid jet can become significant if the collection distance is 
greater than 10 cm, and the jet can be dragged downwards, away from the 
collecting area, as a result. This can cause fibres to build up at the bottom 
of the collector, or even below it, compromising the effective yield of the 
process. In the vertical approach, gravity is acting in the same direction 
as the electrostatic accelerating force. However, the downside of the ver-
tical approach is that, if any droplets are formed during the process (e.g. 
when pausing or restarting the process), these can potentially fall on to 
the collector, compromising the quality of the products. In the horizontal 
approach, the droplets will fall to the bottom of the experimental chamber 
and will not reach the collector, and thus the product can be of higher 
quality.
2.6.2 The power supply and syringe pump
These are commercial items which can be purchased from a large number 
of different suppliers. The major issues to consider when buying are the 
cost vs. the precision and stability of the power supply and pumps, and 
whether the apparatus meets the user’s needs in terms of the range of 
voltages which the supply will generate and the rates at which the pump 
will dispense. In general, a simple power supply capable of producing 
a positive voltage up to 25 kV should suffice (most electrospinning is 
performed between around 5 and 25 kV).
2.6.3 The spinneret
In the simplest electrospinning experiment, termed monoaxial 
electrospinning, a solution of a polymer and drug is dispensed through 
a single- bore blunt- end needle, most often made of a conductive and 
solvent- resistant metal such as stainless steel. This gives a monolithic 
product, with the drug and polymer typically evenly and homogeneously 
blended throughout the fibres. However, it is possible to process two, 
three or even more liquids as compound jets (co- flowing liquid jets) and a 
range of more complicated spinnerets such as concentric or multi- needle 
designs can be prepared to generate sophisticated nanostructures made 
of multiple polymers and/ or active pharmaceutical ingredients. A sum-
mary of the most important designs is given in Figure  2.8. To process 
multiple liquids, each is loaded into a separate syringe and dispensed 
independently using multiple syringe pumps.
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Coaxial electrospinning uses a coaxial needle that contains two 
capillary channels arranged in a concentric manner. Each channel is 
infused with a polymer solution at an individual flow rate. If the experi-
ment is well designed and optimised there will be minimal blending 
between the two solutions, and since the electrospinning process is 
very fast the concentric structure of the spinneret will result in core/ 
shell fibres with two distinct compartments (Figure  2.8). Similarly, if 
two needles are arranged side by side the fibres produced should have 
a Janus morphology, with two different sides. Moving up to three or 
four liquids can yield three- layer or even four- layer fibres if a triaxial 
or quad- axial concentric spinneret is used. There are a range of more 
complicated spinneret designs but the key types of electrospinning as 
far as this volume is concerned are monoaxial, coaxial, triaxial/ quad- 
axial, and side- by- side; they will be discussed in more detail in subse-
quent chapters.
2.6.4 The collector
The speed at which each layer of the produced nanofibres becomes 
discharged upon reaching the collector plays a significant role in 
Fibre morphology
Electrospinning type
3D view
End-on view
Monolithic Core/shell Janus Triaxial
Monoaxial Coaxial Side-by-side Triaxial
Figure 2.8  Spinneret designs for different types of electrospinning, and 
the structures of the fibres produced.
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controlling the spacing and density of the fibre mat. This discharging pro-
cess is affected by the dielectric properties, surface area and the collective 
conductivity of the collecting substrate. Various geometries of collectors 
have been designed to achieve better control of fibre deposition density 
and alignment. A  comprehensive review on collector designs has been 
undertaken by Teo and Ramakrishna.42
The simplest collector is a flat conducting collector plate, usually a 
metal plate coated in aluminium foil. This will give a mat of non- woven 
fibres which are randomly oriented. For most drug delivery applications, 
this is perfectly satisfactory. However, a problem can arise when spinning 
for long periods of time (> 2 h) to prepare larger amounts of product. 
As the layer of fibres on the collector builds up and becomes thicker, it 
acts as an insulating coating to the grounded collector. This reduces the 
electrical field gradient to new fibres being deposited, which can result 
in incomplete evaporation of solvent and defects forming at the top of 
the mat.
It can thus sometimes be useful to employ a rotating mandrel 
collector. This increases the area of fibres which can be collected, and 
is depicted in Figure  2.9. Here, the collector comprises a conducting 
cylinder which rotates along its long axis. To ensure even coverage of 
the collector, the spinneret is moved back and forth along the length 
(rastering). This generates a tubular structure. At the end of the experi-
ment, a scalpel can be used to cut through and remove the fibres as a 
flat mat. If the tube can be rolled off the mandrel without damaging it, 
the rotating mandrel set- up can be used to prepare tubular scaffolds for 
tissue engineering, for instance of veins or arteries.43
With the recent explosion of interest in electrospinning technology, 
a number of more sophisticated collecting systems have been reported. 
Mandrel
Spinneret
Electrospinning
Figure 2.9  A schematic showing the use of a rotating mandrel collector 
with a rastering spinneret.
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For instance, for tissue- engineering scaffolds it can often be desirable to 
obtain aligned fibres. This can be achieved by rotating a cylindrical man-
drel very quickly (at a rate of hundreds or thousands of revolutions per 
second). Alternatively, a collector comprising parallel electrodes can be 
used to achieve alignment. For the purposes of drug delivery systems, 
alignment is not generally necessary, however, and the majority of the 
examples discussed in this volume use simple flat-plate detectors. When 
scaling electrospinning up for industrial applications, conveyor belt- type 
collectors are required to allow continuous manufacturing; we will dis-
cuss these more in Chapter 7.
2.6.5 other considerations
Most commonly, research on electrospinning is carried out in laboratories 
on the benchtop. Care must be taken when doing this because many of 
the solvents used for preparing polymer solutions smell unpleasant, and 
some are harmful. A robust risk assessment is thus required, but because 
the volumes of solvents used are small and the dispensing rates low 
there are normally no problems spinning in a well- ventilated laboratory. 
However, because humidity, temperature and the surrounding speed 
of air flow have a major influence on the electrospinning process, the 
ambient conditions and the location of experiment need to be monitored 
and recorded throughout to ensure it can be reproduced. Equipment 
exists which can precisely control temperature and humidity, but this 
often costs more than $5000 and requires a large isolated space (around 
2 m3) to house the cumbersome and bulky apparatus. Both these factors 
are usually highly inconvenient for many research labs. A simpler alterna-
tive is to procure a simple temperature and humidity meter and monitor 
these quantities throughout experiments to ensure reproducibility.
When preparing polymer solutions for spinning it is necessary to 
ensure that the polymer fully dissolves in the solvent to yield a solution 
with appropriate properties (in terms of conductivity and viscosity). 
Achieving this can require extensive optimisation. Solution preparation, 
together with other important considerations for a successful experi-
ment, will be considered in detail in Chapters 3– 5 as they differ some-
what for the different spinning processes.
2.6.6 establishing and troubleshooting an electrospinning process
A more detailed discussion of how to set up and optimise fibre production 
will be provided in Chapters 3– 5 for single- fluid, coaxial and triaxial, and 
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side- by- side processes, respectively. An excellent overview of the steps to 
be followed can be found in an instructive video article by Leach et al.44
2.7 Fibre properties
The fibres produced by electrospinning can be made from a wide variety 
of polymers, with very different drug release properties. For instance, 
the use of a fast- dissolving polymer such as PEO can accelerate the rate 
at which a drug gets into solution. Alternatively, a slow- dissolving or 
water- insoluble polymer such as poly(lactic- co- glycolic acid) or poly(ε- 
caprolactone) will give extended release, while a pH- sensitive polymer 
such as poly(methacrylic acid- co- methyl methacrylate) can be employed 
to target release to the small intestine by exploiting the changes in pH in 
the different parts of the body. Complicated architectures can be prepared 
through multi- liquid processing, and the diameter, porosity and mechan-
ical properties of the fibre mat can all be tuned by systematic variation 
of material and processing parameters. These properties all lead to the 
products of electrospinning having a wide range of potential applications 
in the drug delivery field.
2.8 Characterisation
As described in detail in section 1.4, the first characterisation 
performed on an electrospun product is generally a simple visual 
inspection of a few fibres collected on a glass slide. If fibres can clearly 
be seen, then they can be inspected under a microscope to check if 
the process is optimised (are the fibres linear, or are beads present? 
Are there any particles or droplets present?). Once small quantities 
of good- quality fibres have been prepared, a larger batch can be 
produced. Typical characterisation for this would include scanning 
electron microscopy to check the fibre morphology, with transmission 
electron microscopy, focused ion beam microscopy and/ or confocal 
microscopy often also undertaken to check for internal structure, par-
ticularly in the case of fibres from coaxial or multi- axial spinning. The 
ImageJ software (freely available from https:// imagej.nih.gov/ ij/ ) 
can be employed to quantify the fibre diamaters. The physical form 
of the drug and polymer is usually investigated with X- ray diffraction 
and differential scanning calorimetry, and infrared spectroscopy 
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is used to study the functional groups present in the fibres and any 
interactions between components. Thermogravimetric analysis can 
be performed to check for the presence of any residual solvent in the 
fibres; if solvent does remain and this is problematic, then the fibres 
can be stored in a desiccator or vacuum oven to remove this.
Depending on the intended application, it may be necessary to 
evaluate the mechanical properties of the fibres, and in the majority of 
cases drug release will be quantified through dissolution experiments. 
Permeation studies and in vivo work may also be appropriate if all the 
previous assays give promising results.
2.9 Summary
In this chapter, the EHD process has been introduced and explained. 
A  brief discussion of the fundamental physics behind electrospinning 
has been presented, followed by a detailed discussion of the parameters 
which can affect the process and the nature of the influence they have. The 
requirements to establish a successful electrospinning experiment to gen-
erate defect- free fibres have been described. As a result, the reader should 
now have a good grasp of the overarching principles of electrospinning. 
Subsequent chapters will describe the different processes in more detail 
and explore the applications of the fibres produced.
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Monoaxial electrospinning
3.1 Introduction
Monoaxial (or uniaxial) electrospinning is the simplest route by which 
fibres can be made using the electrohydrodynamic technique. To employ 
this to generate drug delivery systems, a mixed liquid (solution, emulsion 
or suspension) of a polymer and a drug in a (typically volatile) solvent 
is first prepared. This is dispensed through a single- bore blunt- end 
needle (often made of a solvent- resistant metal such as stainless steel) 
towards a metal collector (such as a stainless steel plate or an aluminium 
sheet), with a high electrical potential difference (commonly 5– 20 kV for 
monoaxial single- liquid electrospinning) applied between the two. The 
fibres collected comprise monolithic systems, with the drug most usu-
ally evenly dispersed throughout the polymer, as depicted in Figure 3.1. 
Because the electrospinning process is very rapid, with the time between 
the solution exiting the spinneret and reaching the collector being 
well under a second, the arrangement of the molecules in the solution 
is propagated into the solid state. Thus, electrospun fibres typically 
take the form of amorphous solid dispersions (ASDs), as described in 
section 1.3.4.
The first report of electrospun fibres being used in the drug 
delivery context came from Kenawy et al.1 These researchers generated 
fibres loaded with tetracycline hydrochloride using poly(lactic acid) 
(PLA), poly(ethylene- co- vinyl acetate) (PEVA) or a blend of the two 
as the filament- forming polymer matrix. Since then, a vast number of 
studies have been reported in which fibres from electrospinning are 
explored for drug delivery: a Web of Science search for ‘electrospinning 
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AND drug delivery’ on 28 June 2017 gave 1547 hits. This interest has 
arisen because there are a number of advantages of using electrospun 
nanofibres in drug delivery. These include: (1) high drug loadings (up 
to 60%) and encapsulation efficiency (up to 100%);2 (2) a wide range 
of polymers (> 100) can be spun;3 (3) drug release can be modulated 
through the choice of polymer (hydrophilic or hydrophobic, molecular 
weight);4 (4) the fibres have high specific surface areas (10– 100 m2 g– 1);5 
and (5) the process is simple to perform and cost- effective, on the labora-
tory scale at least.6
In this chapter, we will review the major applications of fibres from 
monoaxial spinning in drug delivery.
3.2 Experimental considerations
As was discussed in section 2.5, a number of solution and processing 
parameters need to be controlled for successful electrospinning.
3.2.1 solution parameters
The molecular weight and concentration of the polymer(s) and the 
choice of solvent are important because they control the viscosity, sur-
face tension and conductivity of the spinning solution, and thus how it 
behaves in electrospinning. The spinnable viscosity range varies with 
the polymer and solvent, but should be at least around 120 cP. In very- 
low- viscosity solutions, there will be insufficient polymer chain entangle-
ments to produce fibres.7 In contrast, if the viscosity is too high then the 
surface tension cannot easily be overcome. In both cases, the result can 
be droplets or particles forming rather than fibres.
The solvent used must be capable of dissolving the polymer 
of interest at an appropriate concentration to form fibres, and must 
possess a suitable volatility. A  low- volatility solvent like water (boiling 
point (b.p.) 100ºC) may fail to evaporate completely over the distance 
Polymer filament
Drug molecules
Figure 3.1  A schematic illustration of an electrospun fibre from 
monoaxial spinning.
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between the spinneret and the collector. When the fibres form, they will 
hence contain residual water owing to this incomplete evaporation. The 
residue solvent will subsequently evaporate from the fibres upon storage, 
resulting in ribbon- like (flattened) fibres, wrinkles on the fibre surface 
or fused fibres. On the other hand, a high- volatility solvent may evap-
orate very quickly, leading to larger fibre diameters (less time for elong-
ation before solidification) and clogging of the spinneret (due to drying 
of the liquid at the spinneret before jetting, or drying of the Taylor cone 
during jetting). Solvents commonly used for electrospinning include 
ethanol (b.p.  78ºC), chloroform (61ºC), dichloromethane (40ºC) and 
hexafluoroisopropanol (58ºC).
Mixtures of miscible solvents can be used to ensure that sufficient 
polymer can be dissolved to give a solution of appropriate viscosity and 
volatility with a suitable dielectric constant range to allow fibre forma-
tion. For instance, less volatile solvents such as dimethyl  formamide 
(DMF:  b.p.  153ºC) and dimethylacetamide (b.p.  165ºC) are frequently 
used in combination with more volatile solvents like acetone (b.p. 56ºC), 
dichloromethane (b.p.  40ºC), tetrahydrofuran (b.p.  66ºC) or methanol 
(b.p.  64ºC). However, care must be taken because using a mixture of 
solvents with very different volatilities can result in porous fibre structures, 
as reported by Katsogiannis et  al. for organic solvent mixtures with 
dimethyl sulfoxide (DMSO).8 DMSO evaporates much more slowly than 
the organic solvents used, which results in its incorporation into the fibres. 
The remaining DMSO will eventually evaporate, yielding porous fibres.
It is also important to take into account the surface tension of the 
solution. Solvents with very high surface tensions (e.g. water) can result 
in instability arising during the spinning process, and a broad range of 
fibre diameters in the products and/ or the generation of electrosprayed 
particles rather than fibres. If necessary, a surfactant can be added to 
reduce the surface tension, but this will be incorporated into the fibres 
produced and may require post- spinning removal.
3.2.2 Processing parameters
The applied voltage needs to be sufficient to overcome the surface 
tension of the liquids being processed, giving a clear Taylor cone and 
emitting a polymer jet from the latter. The range of voltages suitable for 
monoaxial electrospinning in a conventional benchtop apparatus is typ-
ically between 5 and 25 kV.
The distance between the needle and collector, the temperature, 
the humidity and the surrounding air flow can exert a major influence on 
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the process, as discussed in section 2.5.3. It will be important to monitor 
both temperature and humidity during the experimental process to 
ensure reproducibility.
The distance between the spinneret and collector is usually in the 
range of 10– 20  cm. It is possible to place the collector further away, 
but problems arise because the charged polymer jet seeks the nearest 
grounded surface on which to discharge. Thus, higher distances can lead 
to much of the fibre product landing in places other than the collector. If 
the distance is too short, there will be insufficient time for solvent evap-
oration and the fibres may fuse or become wrinkled when the residual 
solvent in the fibre subsequently diffuses out on the collector.
Finally, we should note that these parameters are not mutually 
exclusive, and that varying one will inevitably have an effect on others 
(for instance, an increased temperature will result in reduced sur-
face tension and viscosity of the solution). This means that, although 
the electrospinning process is conceptually simple, its implementation 
requires some optimisation. A good understanding of the fundamentals 
of electrospinning (as described in Chapter 2) can significantly facilitate 
the optimisation process.
3.2.3 The spinneret
The spinneret for monoaxial spinning most commonly comprises 
a simple narrow- bore, blunt- end metal needle. The diameter of this 
needle can vary, but most commonly researchers work with internal 
diameters below 1 mm, with around 0.4– 0.8 mm probably being most 
usual. This translates to needles of gauge 18– 22. In general, this simple 
spinneret design can be used to achieve successful spinning. A blunt 
end rather than a tapered end for the needle exit is important as the 
size and size distribution of the products increase with an increase in 
needle tip angle. Blunt- ended needles can be procured commercially, 
or a disposable medical hypodermic needle can be adapted by cutting 
off the bevelled edge of the needle with a pair of scissors and using a 
filing paper to smooth the end. However, it should be noted that there 
will be some interactions between the solvent and polymer molecules 
in the solution and the metal surface of the spinneret. There will exist 
some attractive forces between these (e.g. between polar groups in the 
polymer and the electropositive metal surface), which can act counter 
to the drawing force of the electric field and can pull the polymer 
solution back into the spinneret. It has been found that coating the 
spinneret exterior in a non- conducting and non- stick polymer such as 
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Teflon can reduce these interactions.9 As a result, the electrical energy 
can be more efficiently used to elongate and narrow the polymer jet, 
and narrower fibres can be produced. In addition, strong attractive 
forces between the polymer jet and a metal spinneret can result in 
fibres or other solid material becoming attached to the needle, leading 
to lower yields and potentially to blocking of the exit orifice. This effect 
too can be ameliorated using a Teflon coating. An epoxy coating can 
also be used to similar ends.10
3.2.4 Polymer choice
The choice of polymer will be largely dependent on the intended 
application. For instance, if a fast- dissolving drug delivery system 
is required, then a rapidly dissolving hydrophilic polymer such as 
poly(vinyl pyrrolidone) (PVP) or poly(ethylene oxide) (PEO) should 
be selected. For extended release, a slow- dissolving polymer (e.g. 
poly(ε- caprolactone) (PCL) or poly(lactic- co- glycolic acid) (PLGA)) or 
a water- insoluble system (e.g. ethyl cellulose (EC)) can be employed. 
This will be discussed in more detail in subsequent sections of this 
chapter.
Consideration must also be given to compatibility between the 
polymer and the drug of interest. For instance, if a hydrophilic polymer is 
being used to form fibres but the drug is very hydrophobic, phase separ-
ation is likely to occur, to minimise any hydrophobic/ hydrophilic contacts. 
The fibres will thus be unstable, and their functional performance will 
change upon storage. Selecting a polymer which can form intermolecular 
interactions (such as hydrogen bonding, van der Waals forces) with the 
drug can help to prevent this. The literature refers often to component com-
patibility, by which it means the possibility of forming such interactions 
to prevent phase segregation and encourage long- term stability. Infrared 
spectroscopy can be helpful to identify intermolecular interactions, which 
are indicated by small shifts in peak positions (see section 1.4.4).
A solution of the polymer at an appropriate concentration will need 
to be prepared for spinning. The concentration range required will vary 
widely depending on the polymer and solvent (see description of the crit-
ical concentration ce in section 2.5). By way of example, PEOs with Mw 
≤ 300 kDa in chloroform or ethanol solvent can be spun from solutions 
of 3– 4% w/ v, while very- high- molecular- weight PVP solutions in ethanol 
(Mw  =  1300 kDa) are typically 6– 10% w/ v,11 and for the naturally 
occurring polymer shellac, very high concentrations of around 80% w/ 
v are needed.
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3.2.5 starting experimental work
When beginning a new electrospinning experiment, the literature will be 
an invaluable source of guidance as to suitable experimental parameters 
to use. Working from these precedents, the best place to start is to pre-
pare a range of polymer solutions in the solvent of interest (i.e. one that 
dissolves both the polymer and drug at appropriate concentrations). If 
the best solvent to use is not known, then a solvent screen to explore 
the solubility of the polymer in a range of solvents commonly used 
for electrospinning (e.g. acetone, ethanol, dichloromethane, DMF, 
chloroform, methanol) can be helpful. In the authors’ personal experi-
ence, we have found that very many materials dissolve in the solvent 
hexafluoroisopropanol. However, this solvent is both expensive and 
toxic; if it is to be used then care must be taken to ensure there is no 
residual solvent in the fibres produced.
If a single solvent does not prove satisfactory – for instance, because 
the volatility or dielectric constant is inappropriate  – then solvent 
mixtures may offer the opportunity to modulate the solution properties. 
If a solution can be prepared which is a viscous liquid but flows (that is, 
it is slightly sticky, like honey), then it is suitable for further study. If the 
polymer concentration is too high, then a gel will be obtained – this will 
not flow under gravity, and will not be spinnable.
Once a series of solutions has been prepared, electrospinning 
can begin. The solution should be loaded into a syringe, taking care 
to avoid any air bubbles. The spinneret is then fitted to the syringe, 
which is mounted on to the syringe pump. For viscous solutions, the 
experimenter may find it preferable to use a syringe with a Luer lock 
tip, which connects with the needle in a more secure fashion than slip 
tip syringes.
The solution should be dispensed slowly from the needle; 0.5– 6 mL 
h– 1 is a generally appropriate range. As an approximate guide to flow rate, 
when a droplet forms at the tip, wipe it away; if the droplet is immedi-
ately replaced then the flow rate is in an appropriate range for spinning. 
The high- voltage power supply should now be connected to the 
needle with the mains power remaining switched off for safety, and the 
collector grounded. Next, increase the voltage slowly from zero until 
the Taylor cone can be seen, and a long jet of polymer is ejected from it. 
The process should now be monitored for a few minutes to see if the cone 
jet remains stable and continuous. If so, then optimisation of the pro-
cessing parameters can begin in order to fine- tune the morphology and 
diameter of the fibres. If not, then the polymer concentration will need 
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to be adjusted. This procedure is depicted in a video article by Leach and 
co- workers.12
It is important to take care when increasing the voltage beyond 18 
kV. If the voltage is too high then the flow rate feeding the solution into 
the needle may not keep up with the electric field drawing the solution 
out of the needle, and the Taylor cone may disappear into the spinneret 
(see section 2.5.2 for a detailed description of the effect of processing 
parameters on the electrospun product).13
The next stage is to look at the fibres formed. To do this, we rec-
ommend collecting for around 5 s to 1 min on a glass slide or aluminium 
sheet, and then examining this under a microscope (see section 1.4.1 on 
nanofibre characterisation by microscopy). By systematically varying 
the voltage, flow rate and spinneret- to- collector distance from the ini-
tially identified parameters it should be possible to produce high- quality 
monodisperse fibres with a uniform morphology and diameter distribu-
tion and no beading or other defects (see sections 2.4 and 2.5).
3.3 Fibre properties
By varying the material and processing parameters, it is possible to 
obtain control of the surface morphology and porosity of the fibres 
generated. Their surface is generally smooth if the materials and pro-
cessing parameters are optimised. A high electrical potential or low con-
centration tends to result in beaded structures with considerably rougher 
surfaces, however.14 In very concentrated solutions, as well as the main 
population of fibres, a secondary population of smaller fibres is often 
seen.15 The fibre diameter can be controlled by tuning the solution and 
processing parameters (e.g. polymer concentration, flow rate, voltage), 
as described in section 2.5.
Two types of pores are possible with the fibre mats generated by 
electrospinning. Pores may form on or within the fibres themselves, and 
there will also be pores between the layers of fibres forming the mat (unless 
the fibres are electrospun with a very high degree of alignment such as by 
direct writing melt electrospinning; see Chapter 6 for more details).15b, 16 
A knowledge of pore size and porosity can be important, because in many 
cases it will affect the performance of the formulation. The pore size will 
control the size of substances which can pass through the fibre mat (indi-
vidual molecules will always be able to pass through, but cells require 
pores of tens of microns to permeate into the mat). The porosity will 
affect the diffusion rate across the fibre mat, governing for instance how 
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rapidly water can penetrate into the aggregate of fibres and interact with 
the polymer and drug molecules.15b All these properties will influence the 
drug release profiles observed. If it is necessary to increase the porosity of 
the fibre mat, porogens (e.g. salt and clay particles) can be added to the 
polymer solution, and then removed after electrospinning. This usually 
leads to micron- sized pores where the porogens were originally situated.17 
3.4 Some typical results
After electrospinning, the standard series of characterisations to be 
performed will comprise an assessment of the fibres using electron 
microscopy (to visualise morphology), together with X- ray diffraction 
(XRD) and differential scanning calorimetry (DSC) to observe physical 
form. Infrared spectroscopy will be employed to look for any interactions 
between the components of the fibres, and then functional performance 
studies will be undertaken (see sections 1.4 and 2.8). A  typical set of 
results from one of our studies is given in Figure 3.2. These data are for 
PVP fibres loaded with indomethacin.18 Materials were prepared with 
drug contents between 9.1% and 33.3% w/ w in the final fibres. Scanning 
electron microscopy showed the fibres to have smooth cylindrical morph-
ologies with the optimised parameters (Figure 3.2(a)).
DSC data (Figure 3.2(b)) show that the pure indomethacin powder 
is crystalline, because there is a large endothermic peak at 159ºC which 
corresponds to melting. Pure PVP has a broad endotherm below around 
125ºC. This is not a melting event (melting endotherms are sharp 
peaks), but arises due to the evaporation of water: PVP is a very hygro-
scopic polymer, and will absorb water from the air. The fibres show no 
sharp melting endotherms in their DSC traces, with only very shallow 
endotherms below 100ºC. The latter most likely occurs as a result of the 
fibres absorbing some water upon storage. Therefore, it can be concluded 
that the drug is amorphously distributed in the fibres. This should accel-
erate dissolution, since there will be no intermolecular interactions 
between indomethacin molecules.
The findings from DSC are confirmed by XRD (Figure  3.2(c)). 
The pattern for pure indomethacin contains many sharp peaks (Bragg 
reflections), because it is a crystalline material with the molecules 
arranged in a regular manner. In contrast, there are no sharp peaks in the 
patterns of either raw PVP or the drug- loaded fibres. This confirms them 
to be amorphous materials, with no long- range order. The XRD data thus 
agree well with the DSC findings.
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Infrared spectra for the formulations are shown in Figure 3.2(d). 
Indomethacin shows carboxylate vibrations at 1689 and 1712  cm– 1, 
while the C=O band for PVP can be observed at 1654  cm– 1. In the 
formulations with 9.1% and 23.1% w/ w drug contents, the carboxylate 
bands from the drug and PVP have merged into one broad band, at ca. 
1660 or 1664 cm– 1. This shift in peak positions can be attributed to inter-
molecular interactions between the two components of the fibres.
When the drug loading was raised to 33.3% w/ v, a shoulder on 
the main peak at 1664 cm– 1 could be seen at 1720 cm– 1. The observation 
5 μm
(a) (b)
(c) (d)
Figure 3.2  Exemplar data obtained on electrospun fibre formulations, 
as reported for poly(vinyl pyrrolidone) (PVP)/ indomethacin systems 
by Lopez et al. (a) Scanning electron microscopy image of fibres 
with a 9.1% w/ w drug content; (b) differential scanning calorimetry 
thermograms; (c) X- ray diffraction patterns; and (d) infrared spectra. 
IMC denotes pure indomethacin, and I5, I7 and I9 are fibres with 
9.1%, 23.1% and 33.3% w/ w drug loadings. (Adapted from Lopez, 
F. L.; Shearman, G. C.; Gaisford, S.; Williams, G. R. ‘Amorphous 
formulations of indomethacin and griseofulvin prepared by 
electrospinning.’ Mol. Pharm. 11 (2014): 4327– 4338. This is an open 
access article published under a Creative Commons Attribution  
(CC- BY) License.)
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of this additional peak can be attributed to the increased drug content. 
Again, it can be seen that the position is shifted from that in the raw 
material, indicative of intermolecular interactions. Overall, therefore, it 
can be concluded that the PVP/ indomethacin fibres exist as amorphous 
solid dispersions, stabilised by intermolecular interactions between the 
two constituents.
3.5 Fast- dissolving drug delivery systems
Fast- dissolving drug delivery systems (FD- DDSs) were initially developed 
in the late 1970s and have attracted a great deal of investment from the 
pharmaceutical industry.19 Rather than releasing their drug cargo in the 
stomach or small intestine like most oral formulations, FD- DDSs either 
dissolve or disintegrate in the mouth in a few seconds. Since their drug 
cargo is released directly and rapidly in the mouth, where there are large 
numbers of blood vessels, the drug can quickly reach the systemic cir-
culation. Thus, FD- DDSs can enhance bioavailability and give rapid 
onset of action.20 This can be very beneficial for a number of situations, 
for instance with children or the elderly (who might struggle to swallow 
large tablets), or where very rapid relief of symptoms is required. Unlike 
tablets, which can be difficult to swallow, FD- DDSs can be applied univer-
sally without requiring any water to aid in swallowing.
3.5.1 electrospun fast- dissolving drug delivery systems
Electrospun fibres have been widely explored as FD- DDSs. They have 
a number of properties which make them very suitable for this appli-
cation. First, the drug is typically amorphously dispersed in the fibre, 
usually as an ASD. This means that there is no lattice energy barrier 
to dissolution, because the drug molecules are randomly arranged in 
the polymer matrix with no drug– drug intermolecular interactions. 
The presence of long- chain polymer molecules in the fibre will provide 
steric hindrance to any recrystallisation occurring, and thus the ASDs 
can have long- term stability (see section 1.3.4). If the fibres are made 
of a water- soluble and fast- dissolving polymer, then they will dissolve 
very rapidly into an aqueous medium. They are aided in this by the high 
surface- area- to- volume ratio of electrospun fibre mats, coupled with 
their high porosity; a high specific surface area accelerates dissolution, 
and the high porosity makes water ingress into the centre of the fibre 
mat easy and rapid.
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One of the first reports of an electrospun FD- DDS came from Zhu’s 
group in 2009.21 Fibres loaded with the non- steroidal anti- inflammatory 
drug (NSAID) ibuprofen were prepared based on PVP with a molecular 
weight of 58 kDa. Using a polymer concentration of 30% w/ v, fibres could 
be electrospun with drug loadings of 20% and 33% w/ w in the dried 
products. The fibres had smooth cylindrical morphologies, although at 
the higher loading some drug particles could be seen at the fibre surface. 
Analysis by DSC and XRD proved the fibres to be amorphous materials, 
with no evidence of any crystalline drug being present. When added to 
water, the fibres disintegrated into small aggregates in less than 10 s, and 
all the drug loading was freed into solution within 1 min. Since the fibre 
mats had thicknesses of less than 1 mm, it was proposed that they have 
great potential for use as oral fast- dissolving films. The mats are also flex-
ible, and can be easily cut into different shapes suitable for sublingual 
(under the tongue) or buccal (to the cheek) delivery.
PVP is a particularly useful polymer for FD- DDSs, because it is very 
hydrophilic and dissolves rapidly into water. A range of drug- loaded PVP 
fibres have thus been reported, containing active ingredients as diverse 
as irbesartan (used for treating high blood pressure),22 ketoprofen (an 
NSAID),23 mebeverine hydrochloride (an antispasmodic drug also used 
for dental analgesia),24 vitamin D,25 isosorbide dinitrate (used for treating 
angina),26 borneol27 (a common ingredient in traditional Chinese medi-
cine) and curcumin28 (a natural product thought to have a range of 
health benefits). In all cases, the formulations behave similarly. Fibres 
are produced which are largely smooth and cylindrical, and contain the 
drug in the amorphous form (as demonstrated by XRD and DSC). The 
fibre mats disintegrate very rapidly (in a few seconds) and free all their 
drug loading into solution in a few minutes. Exemplar data for curcumin- 
loaded systems28 are given in Figure 3.3.
Other water- soluble polymers are also suitable for use in FD- DDSs, 
and poly(vinyl alcohol) (PVA) fibres loaded with caffeine or riboflavin 
have been reported by Li et al.29 As previously, the drug was found to be 
loaded in the fibres in the amorphous physical form, and the formulations 
released their drug cargo very rapidly (within 4 min). The fibres were 
found to perform much better than analogous cast films (made by pouring 
the drug/ polymer solution into a Petri dish and allowing the solvent to 
evaporate slowly), with significantly faster release from the former. This 
can be attributed both to the higher surface area and porosity of the fibres, 
and also to the rapid nature of electrospinning preventing any crystallisa-
tion of the active ingredients. Crystallisation is much more likely when 
cast films are made, because the solvent evaporation rate is slow and 
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therefore there is time for molecular reorganisation to take place. PEO 
has also been explored for accelerating drug release, for instance for the 
beta- blocker carvedilol.30
3.5.2 Caveats
It is important to note that simply electrospinning fibres containing a 
drug and hydrophilic polymer will not necessarily result in the very fast 
release discussed here. If the drug loading is too high (above its solubility 
limit in the polymer) then crystallisation may occur, meaning that for at 
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Figure 3.3 Experimental data for curcumin (CUR)- loaded poly(vinyl 
pyrrolidone) (PVP) fibres. Scanning electron microscopy images of 
(a) pure PVP and (b) PVP/ curcumin fibres show them to comprise smooth 
cylindrical entities; (c) X- ray diffraction (XRD) shows that, while the pure 
drug (blue) is crystalline with many Bragg reflections in its XRD pattern, 
the fibres (red and black) are amorphous systems; and (d) the fibres release 
their drug loading much more quickly than pure curcumin dissolves. 
(Reproduced with permission from Wang, C.; Ma, C.; Wu, Z.; Liang, H.; 
Yan, P.; Song, J.; Ma, N.; Zhao, Q. ‘Enhanced bioavailability and anticancer 
effect of curcumin- loaded electrospun nanofiber: In vitro and in vivo study.’ 
Nanoscale Res. Lett. 10 (2015): 439. This is an open access report published 
under the Creative Commons Attribution 4.0 International License.)
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least a portion of the drug there is an energy barrier to dissolution. This 
has been seen by Taepaiboon et al. when making PVA- based fibres.31 The 
presence of some crystalline drug in the fibres led to their performing 
similarly to cast films in terms of drug release.
The molecular weight of the polymer and the release environment 
are also important. For instance, Ahmad’s group prepared PVP fibres 
loaded with the NSAID indomethacin, using PVP with a molecular weight 
of 1.3 million Da.32 Although drug release was accelerated compared to 
the raw indomethacin, this occurred over around 30 min, much slower 
than the systems discussed above. This can be ascribed to the high 
molecular weight of PVP used, which results in its molecules being very 
long. There will be extensive entanglements between the PVP molecules 
in the fibre, which will take time to unravel. This will lead to slower dis-
solution than with the lower- molecular- weight PVPs used above. 
In another example, Baskakova et al. explored PVP- based fibres for 
drug delivery to the eye.33 In an in vitro model of the eye, release occurred 
over more than 100 h. This can be ascribed to the low volumes of fluid in 
the eye (< 5 mL, as opposed to the 1 L scale typically used for dissolution 
testing; see section 1.4.5.1).
3.5.3 Multicomponent formulations
It is possible to prepare systems more complex than a simple binary mix-
ture of drug and polymer. This can be helpful to overcome some of the 
problems associated with oral FD- DDSs. Since the drug is released in the 
mouth, it is important to consider the taste (palatability) of the formula-
tion. Many drugs are bitter-tasting, and if the formulation tastes unpleasant 
then there is a risk a patient will not take the required medication.
In one approach to solve this issue, Samprasit et al. reported three- 
component fibres made of PVP, meloxicam (an NSAID) and a cyclodextrin 
(CD).34 CDs are cup- like molecules with a hydrophilic exterior and hydro-
phobic interior. They can encapsulate hydrophobic molecules in their 
interior, thus hiding them from an external aqueous environment. CDs 
might hence be used to improve the solubility and mask the taste of hydro-
phobic active ingredients. Additional fibre formulations were prepared 
containing menthol and aspartate as taste- masking agents. While the CD 
alone was not sufficient to hide the bitter taste of meloxicam in palatability 
studies, the addition of menthol and aspartate was able to do so effectively.
Fibres may also be prepared containing combinations of drugs. 
For instance, Illangakoon et al. produced fibres of PVP loaded with para-
cetamol and caffeine (often used together to treat colds and influenza).19c 
 
 
 
 
 
 
 
 
 
 
73MonoAXiAL eLeCTRosPinninG
73
The fibre mats disintegrated within 300 ms (Figure  3.4), and both 
drugs were fully released within 200 s. A raspberry flavouring was also 
incorporated into the fibres to help with taste masking. Vrbata et al. have 
similarly reported fibres containing both sumatriptan succinate and 
naproxen, which might be used as oral FD- DDSs to treat migranes.35
Figure 3.4  Images taken with a high- speed camera depicting the 
rapid disintegration of paracetamol/ caffeine- loaded poly(vinyl 
pyrrolidone) (PVP) fibres prepared by Illangakoon et al. Stills from a 
video are given (a) 0; (b) 133; (c) 200; (d) 243; (e) 303; and (f) 408 
ms after the fibres were added to a Petri dish containing simulated 
saliva. (Reproduced with permission from Illangakoon, U. E.; Gill, 
H.; Shearman, G. C.; Parhizkar, M.; Mahalingam, S.; Chatterton, N. 
P.; Williams, G. R. ‘Fast dissolving paracetamol/ caffeine nanofibers 
prepared by electrospinning.’ Int. J. Pharm. 477 (2014): 369– 379. 
Copyright Elsevier 2014.19c)
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More complex systems can also be generated containing multiple 
excipients. One example of this comes from Yu et al.36 PVP fibres were 
prepared loaded with the antioxidant ferulic acid (FA), sodium dodecyl 
sulfate and sucralose. Sucralose was added to mask the taste of the very 
bitter FA. Sodium dodecyl sulfate acts as a permeation enhancer, aiding 
the drug to pass through the mucosa in the mouth to reach the systemic 
circulation. The fibres could increase the FA permeation rate by more 
than 13- fold.
3.5.4 stability
The stability of ASDs is a major concern for the pharmaceutical industry, 
because of the propensity for an amorphous system to convert to a crystal-
line material over time. It is vitally important that the medicine taken by 
a patient has the intended performance. This might well not be the case 
if there is recrystallisation during storage. The stability of electrospun 
FD- DDSs has been studied by several authors. Brettmann et al. prepared 
indomethacin/ PVP fibres and found that they remained amorphous after 
being stored for 6  months in a desiccator at 40ºC.37 Illangakoon and 
co- workers determined that PVP fibres containing mebeverine hydro-
chloride remained as ASDs over 12 months’ storage in a desiccator.24
Lopez and colleagues investigated in detail long- term stability for 
PVP- based fibres loaded with either indomethacin or griseofulvin (an 
antifungal agent).18 These active ingredients were chosen because of 
their very different glass- forming behaviour. Indomethacin can be made 
amorphous very easily and forms stable glasses, but amorphous griseo-
fulvin is known to convert rapidly to the crystalline state. Both drugs 
could be converted into ASDs with PVP, even with drug loadings of up 
to 33%. Drug release from all the composites was very rapid (< 10 min). 
In stability studies, there was some evidence for phase separation of the 
active ingredient and polymer after 8 months of storage in a desiccator, 
but no crystallisation was observed and the fibres remained amorphous 
after this time.
Nagy’s team have also looked in detail at stability, in their case for 
poly(vinylpyrrolidone/ vinyl acetate) (PVPVA) FD- DDSs loaded with 
itraconazole.38 The amorphous form was preserved over 1 year at 25ºC 
and 60% relative humidity (RH), but at 40ºC and 75% RH some recrys-
tallisation was observed over 3 months.
Overall, it appears that electrospun ASDs can retain their stability 
for a prolonged period of time. However, the hydroscopic nature of 
the polymers used for such systems can lead to recystallisation at high 
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humidities, since the fibres will be able to absorb moisture. This will 
enhance molecular mobility, allowing the drug molecules to reorient 
themselves into regular arrangements and form crystals. Packaging the 
formulations under nitrogen should prevent this instability from arising, 
however, and is an eminently affordable option for industry (crisps are 
packaged under nitrogen to keep them fresh).
3.6 Extended- release systems
The United States Pharmacopoeia (USP) defines a modified- release 
dosage form as one where ‘the drug release characteristics of time 
course and/ or location are chosen to accomplish therapeutic or con-
venience objectives not offered by conventional dosage forms such as 
solutions, ointments, or promptly dissolving dosage forms’.39 Extended- 
release systems (also known as controlled- release, prolonged- release, or 
sustained or slow- release) free their drug cargo over a prolonged period 
of time in the body. This can be beneficial to avoid there being an exces-
sively high drug loading in the systemic circulation, or for drugs which can 
be degraded in the blood. To achieve extended release with electrospun 
fibres, a polymer is chosen which dissolves or degrades slowly, or one 
which is insoluble. As for the FD- DDSs, it is usual that the fibres comprise 
ASDs, with the drug amorphously distributed in the fibres, but because 
the polymer itself is slow to dissolve or does not dissolve at all, drug 
release should be delayed.
Extended- release fibres may be prepared from non- biodegrad-
able or biodegradable polymers.40 The former do not degrade in the 
body, while the latter are broken down into small components over time. 
Biodegradable polyesters such as PCL, poly(glycolic acid) (PGA), PLA 
and PLGA have been widely studied.40 Suitable choices of non- degradable 
polymers might be polyurethane, polycarbonate or nylon- 6. Naturally 
occurring biopolymers (e.g. silk, collagen, chitosan, gelatin or alginate) 
are also appropriate. However, biopolymers are usually extracted 
from natural sources and invariably have batch- to- batch variations in 
molecular weight, purity, distribution of charged groups and crystal-
linity. This material inconsistency makes it difficult to generate repro-
ducible electrospun products from different batches of material, and 
complicates practical applications.41 In addition, owing to their strong 
inter- and intramolecular forces, many biopolymers only dissolve in a 
limited number of solvents that are unsuitable for electrospinning (e.g. 
polysaccharides such as cellulose and chitin, proteins such as collagen). 
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They may also form an ionic solution; when such solutions are electrified, 
the ionic groups generate high repulsive forces, disrupting continuous 
fibre formation and leading to defects (e.g. with chitosan and gelatin). 
Biopolymers are thus often mixed with a secondary polymer such as PEO 
or PVA to facilitate the electrospinning process.
3.6.1 Applications
Kenawy was the first to report an extended- release electrospun fibre 
system.1 PLA, PEVA and blend fibres were prepared loaded with the anti-
biotic tetracycline hydrochloride, and as a result release could be extended 
over more than 120 h. Such systems have a range of applications, most 
likely in the form of wound dressings or implantable formulations. One 
obvious indication in which they might be used is the treatment of cancer, 
and a number of studies have been reported looking at electrospun fibres 
in this regard. PLGA fibres loaded with the anticancer drug paclitaxel 
have been shown to give release extended over 60 days, and to inhibit 
the proliferation of glioma cancer cells effectively.42 Fibres made from a 
mixture of PLGA and PLA and loaded with cisplatin, another anticancer 
drug, also show promise for cancer treatments, with drug release 
occurring over at least 30 days, and reductions in cancer cell viability.43 
In addition, the inclusion of targeting molecules in the fibres can help 
target drug delivery to particular cell types; for instance, folic acid has 
been incorporated into fibres specifically to deliver viral vectors to cancer 
cells, while normal cells are unaffected.44
Other applications of extended- release fibres include in regenera-
tive medicine. Puppi et  al. electrospun PLGA fibres containing retinoic 
acid, with the aim of making scaffolds for tissue regeneration.45 Their 
materials were seen to retain their morphology over 12 weeks, with 
continuous drug release during this time. Cells were able to proliferate 
on the fibre mats. PCL fibres loaded with heparin have been reported 
to release around 50% of their drug loading over 14 days, and to have 
potential for delivering heparin to the site of vascular injury to prevent 
stenosis (narrowing of the arteries).46 More details on tissue- engineering 
applications are given in section 3.12.
The prevention of infection in wounds or after surgery is another area to 
have attracted attention. For instance, PCL fibres with potential applications 
in hernia repair have been produced containing antibiotics or antibacterial 
agents.47 Zhang et al. made blends of PLGA and poly(dioxanone) (PDO), 
poly(ethylene glycol)- b- poly(d,l- lactide- co- glycolide) (PELA) or PGA 
loaded with ciprofloxacin hydrochloride, moxifloxacin or moxifloxicin 
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hydrochloride.48 Selected data from this work are shown in Figure  3.5. 
The blend of polymers used permits control to be exercised on the release 
pattern, with some formulations able to give approximately linear drug 
release over more than 200 h.  The fibres could also effectively inhibit 
bacterial growth in vitro.48 These systems might effectively be used as an 
implant to prevent infection after abdominal surgery.
Other researchers have looked at wound healing. PCL and PLA 
fibres containing a vitamin D3 derivative have been electrospun and 
found to free their drug cargo over around 10– 15 days, potentially suit-
able for wound healing.49 Polyvinylidene fluoride fibres have also been 
explored in this setting, and release of the active ingredient observed 
over 45– 90 h.50 In other work, Zamani and co- workers explored metro-
nidazole benzoate- loaded PCL fibres for periodontal diseases (inflamma-
tion and degeneration of the gums).51 Drug release was prolonged over 
20 days.
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Figure 3.5  Data obtained by Zhang et al. for poly(lactic- co- glycolic 
acid) (PLGA) blend fibres loaded with ciprofloxacin hydrochloride 
(CiH). (a) Variation in the blend of polymers used leads to distinctly 
different release properties, with drug release occurring over more 
than 200 h in some cases. (b) The CiH- loaded fibres are able to inhibit 
bacterial growth effectively over at least 10 days. PDO: poly(dioxanone); 
PELA: poly(ethylene glycol)- b- poly(d,l- lactide- co- glycolide); 
PGA: poly(glycolic acid). (Reproduced with permission from Zhang, 
Z.; Tang, J.; Wang, H.; Xia, Q.; Xu, S.; Han, C. C. ‘Controlled antibiotics 
release system through simple blended electrospun fibers for sustained 
antibacterial effects.’ ACS Appl. Mater. Interfaces 7 (2015): 26400– 
26404. Copyright American Chemical Society 2015.)
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Extended release over shorter time periods than those discussed 
above can also be useful. For instance, it takes approximately 1 day for 
a formulation taken orally to pass through the gastrointestinal tract, and 
so a system able to extend release over the 10– 20- h time period could be 
beneficial for making once- daily medicines. Transdermal (through skin) 
delivery over this time period would also lead to potent formulations. 
Yu et al. have performed work in which poly(acrylonitrile) (PAN) fibres 
were loaded with acyclovir and explored as a potential transdermal 
drug delivery system.52 As for the fibres discussed above, the drug was 
amorphously distributed in the polymer matrix at lower loadings (10% w/ 
w), but at higher drug concentrations (up to 20% w/ w) some crystalline 
material was observed. Release was sustained over 12 h. In other work, 
indomethacin- loaded fibres prepared from EC and zein (water- insoluble 
polymers) have been found to extend drug release over more than 20 h.53 
This type of system might thus be useful for oral administration.
Vaginal applications have also been proposed for extended- release 
electrospun fibres, as reviewed by Blakney et al.3b
3.6.2 Drawbacks and release mechanisms
One key drawback encountered with using monolithic fibres from 
monoaxial spinning for extended release is that, in the majority of cases, 
there is a burst of release at the start of the process. This is because of 
the fibre mat’s very high surface- area- to- volume ratio, which results in 
a significant proportion of the drug molecules in the fibres being near 
to the surface. These can rapidly diffuse out into solution, even if the 
polymer matrix is slow- dissolving or insoluble. The burst is not a problem 
in the context of FD- DDSs where all the active ingredient is released very 
quickly, but with an extended- release formulation the rate of release 
(and thus the amount of drug reaching the bloodstream) will be much 
quicker immediately after the medicine has been taken than later on.
The burst release effect can be minimised with a low drug loading, 
but for clinical applications high doses (10– 100 mg of drug per dose) 
are often required. These necessitate high drug loadings in the fibres, 
and present additional challenges for sustaining drug release. Higher 
drug loadings lead to larger amounts of the active ingredient at or near 
the surface. Many studies have been performed with low loadings (< 
1% w/ w), and thus the formulations prepared have limited clinical 
applications. For instance, Ball et  al.3a made fibres from biodegrad-
able polymers and explored them for extended release, with antibac-
terial applications in mind. Maraviroc, azidothymidine, acyclovir and 
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glycerylmonolaurate- loaded fibres were generated successfully, and the 
formulations were found to be non- toxic. Although the fibres provided 
sustained release in some cases, the drug loading was only 1% w/ w, and 
so the formulations as they stand cannot directly be translated to the 
clinic.3a 
If the burst release is a major problem for a particular system, 
there are several possible solutions. One is coaxial or multi- axial 
electrospinning, as will be discussed in Chapter 4. Another option is to 
bond the active ingredient of interest covalently to the polymer and then 
spin this into fibres, a concept demonstrated by Jalvandi and co- workers 
in the case of levofloxacin and chitosan.54
Natu et al. have investigated the effect of drug location and phys-
ical form on the release rate from fibres electrospun from slow- dissolving 
polymers, using acetazolamide and timolol maleate as hydrophobic and 
hydrophilic model drugs, respectively.55 At low concentrations (below 
the drug solubility in the polymer: 1.16– 1.55% w/ w for acetazolamide; 
0.86– 0.88% w/ w for timolol), the drug was amorphously distributed in 
the fibres, but crystalline material was observed when the drug content 
was greater than its solubility in the polymer. With the low concentrations, 
where the drug was well encapsulated in the fibres, there was only a small 
initial burst of release. However, at high concentrations (above the drug 
solubility in the polymer: 12.67% w/ w for acetazolamide; 6.99– 7.6% w/ 
w for timolol) this burst was much greater, attributed to the presence of 
crystalline drug particles at the edge of the fibres.
The mechanism of drug release from extended- release fibres can 
be controlled by one or more of three processes: drug diffusion through 
the polymer, polymer degradation and drug dissolution into solution.2a 
This makes the details of the release process complex, and it can be dif-
ficult to predict how a particular system will behave. It would be intui-
tively expected that if drug release is controlled solely by the diffusion 
of the drug through the polymer, then larger- diameter fibres will release 
more slowly because there will be a longer path through which the drug 
must diffuse to reach solution. However, this is not always the case, and 
the diffusion distance is not the only factor which changes with fibre 
diameter. Verreck et al.56 posited that smaller- diameter fibres might be 
more tightly packed, inhibiting the swelling of the fibre matrix and the 
ingress of water. Fibre diameter is typically controlled through formu-
lation properties such as polymer concentration and solvent choice, but 
these can also affect the dispersion of drug in the fibre products (among 
other factors), which must be considered when developing monolithic 
extended- release fibres.2a
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There are several reports in the literature confirming the importance 
of considering formulations on a case- by- case basis. Studies performed 
with PLA (molecular weight = 75– 120 kDa) as the polymer matrix found 
that the rate of drug delivery for tetracycline became slower as the fibre 
diameter increased from 220 ± 60 nm to 360 ± 70 nm, and to 830 ± 
280 nm.57 However, when the fibres were loaded with chlorotetracycline 
the release rate became faster with an increase in fibre diameter from 
200 nm to 1.6 µm. The opposite release behaviours were thought to be 
because multiple factors, including the fibres’ swelling behaviour and 
the drug’s solubility in the polymer matrix and the release medium, 
influenced the release profile.57
A wide variety of active ingredients can be mixed with a polymer 
and electrospun into fibres, as has been described above. However, 
most examples of drug release extending beyond seven  days relate to 
macromolecules or hydrophobic small- molecule drugs.58 These active 
ingredients have at least one of the following characteristics: poor solubility 
in aqueous media, large molecular size and/ or favourable intermolecular 
interactions with the hydrophobic polymers typically used for extended- 
release formulations. All these characteristics help to retard the rate at 
which the drugs are freed from the polymer matrix. In contrast, hydrophilic 
small- molecule drugs are very difficult to formulate for extended release 
because they have high solubility in the release medium, and more favour-
able interactions with an aqueous environment than with the polymer in 
the fibres. These factors promote drug release from the fibres.
3.7 pH- controlled delivery
3.7.1 oral administration
When a medicine is given orally, the variations in pH occurring in the 
intestinal tract offer the potential to provide delayed release. The pH of 
the stomach is acidic, typically at around 1– 2, while that of the small 
intestine is close to neutral (with variations depending on the exact loca-
tion). Thus, if a fibre is made of a pH- sensitive polymer, which is insoluble 
at low pH but soluble at neutral pH, then it might be expected that its 
drug loading would be released only in the small intestine. This is poten-
tially very useful, because there are many drugs (such as the NSAIDs) 
which can cause serious irritation to the stomach, and others which are 
degraded by the acid or enzymes present.
A number of researchers have explored these possibilities. In 
2007, Wang et  al. produced erythromycin- loaded fibres made of 
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hydroxypropylmethylcellulose phthalate (HPMCP).59 Erythromycin 
(an antibiotic) is rendered inactive at low pH, and thus it is desirable to 
prevent it dissolving in the stomach. Since HPMCP is insoluble below 
pH 5.5, it was reasoned that fibres made of this polymer could have 
potential here. As expected, drug release was much slower at pH 1.2 
than at 6.8.
The Eudragit polymers, a family of materials based on 
methacrylates, have also received extensive attention for electrospun 
pH- sensitive drug delivery systems. For instance, Eudragit L100- 55 
dissolves at pH 5.5, L100 at pH 6.0 and S100 at 7.0; below these pH 
values, the polymers are insoluble. Thus, targeting to the small intes-
tine should be possible. The polymers can be successfully processed 
by electrospinning, with Shen et al. reporting Eudragit L100- 55 fibres 
loaded with diclofenac sodium in 2011.60 The formulations were sub-
ject to a dissolution test where the fibres were first placed in a pH 1.0 
solution (to mimic the stomach) and then transferred to a pH 6.8 buffer 
(representative of the small intestine). Less than 3% of the diclofenac 
content was released at pH 1.0, while at pH 6.8 extended release over 
up to 5 h was observed. These findings suggested that the fibres have 
potential for targeting release to the small intestine. Similar results have 
been found by Akhgari and co- workers for indomethacin- loaded fibres.61
The work of Shen and Akhgari used an acidic drug (one which can be 
ionised through loss of a proton). Such active ingredients have solubility 
which increases with pH, and thus will always have a lesser tendency to 
be released from a formulation at low pH than under neutral conditions. 
Illangakoon et al. prepared Eudragit L100- 55 fibres containing the basic 
drug mebeverine hydrochloride.24 This will be more soluble at low pH, 
and thus one might expect a greater amount of release in conditions rep-
resentative of the stomach than with an acidic drug. Smooth cylindrical 
fibres were obtained with drug loadings of 30% w/ w or below, but when 
the loading was increased to 55% w/ w the fibres were observed to break 
apart upon storage (Figure 3.6(a) and (b)). As for the FD- DDS materials 
discussed previously, the fibres comprise ASDs with no evidence for any 
crystalline drug being present.
After 2 h at pH 2 some 15– 25% of the mebeverine loading had 
been freed into solution, as would be expected given the basic nature of 
mebeverine. However, the fibres release much less drug at this pH than 
a Eudragit/ mebeverine physical mixture. At pH 6.8, extended release 
over ca. 8 hours was observed. Thus, using Eudragit- based fibres can be a 
suitable route to prepare delayed- release oral formulations even for basic 
drugs. However, it should be noted that the same burst release issue as  
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described in section 3.6.2 arises with these monolithic fibre systems. 
Further, some authors have observed significant amounts of release at 
low pH even with an acidic drug. Karthikeyan et al. reported fibres made 
from a blend of zein (a water- insoluble polymer) and Eudragit S100, 
loaded with aceclofenac (an acidic NSAID) and pantaprazole (a basic 
drug used to help prevent side effects when patients are taking NSAIDs 
for extended time periods).62 While the fibres were able to prevent 
pantaprazole release effectively at pH 1, some 25% of the aceclofenac 
(a)
(c) (d)
(b)
Figure 3.6  Experimental data on mebeverine chloride-loaded Eudragit 
fibres prepared by electrospinning. Scanning electron microscopy images 
of the fibres with (a) 30% and (b) 55% w/ w drug contents; (c) drug 
release at pH 2; and (d) the release profiles obtained at pH 6.8. Release 
data are shown for fibres containing 5 (■), 15 (●  ) and 30 (▲) % w/ w 
mebeverine hydrochloride contents, together with a physical mixture 
of drug and Eudragit as a control (▼). (Reproduced with permission 
from Illangakoon, U. E.; Nazir, T.; Williams, G. R.; Chatterton, N. 
P. ‘Mebeverine- loaded electrospun nanofibers: Physicochemical 
characterization and dissolution studies.’ J. Pharm. Sci. 103 
(2014): 283– 292. Copyright Elsevier 2014.)
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was freed into solution at this pH. This may be a result of the way in which 
the fibres were prepared from a mixture of pantaprazole/ Eudragit and 
aceclofenac/ zein solutions, but nevertheless shows that simple mono-
lithic fibres are not always effective for pH- targeted release.
3.7.2 Anticancer applications
Another route to impart pH sensitivity on electrospun fibres is to incorp-
orate a pH- sensitive agent other than the polymer. Cui’s group were able 
to prepare poly(l- lactic acid) fibres which released their drug cargo 
faster at lower pHs by the simple expedient of including sodium bicar-
bonate in the formulation.63 The fibres contained 5- fluorouracil (5- FU), 
an anticancer drug, and were found to be able to inhibit the growth of 
human osteosarcoma cancer cells while being harmless to fibroblast 
cells. This is because the tumour microenvironment is somewhat more 
acidic than normal physiological pH. At pH 5.0, sodium bicarbonate will 
react with the protons present, forming carbon dioxide gas. As the gas 
leaves the fibres, it creates channels in them. These channels make it 
easier for water to enter the fibres to dissolve the drug, and for the drug 
to diffuse into solution. Thus, in this particular instance 5- FU is freed 
more rapidly in the slightly acidic pH conditions of the cancer environ-
ment, and cancer cell proliferation is inhibited over a 4- day in vitro cul-
ture. At the normal physiological pH (7.4), the sodium bicarbonate in 
the fibres does not react, and thus no pores are created and drug release 
is slower. Similar results have been reported for ibuprofen- loaded PLGA 
fibres containing sodium bicarbonate.64
Interactions between the drug and polymer may also be used to pro-
vide pH sensitivity, if these change with pH. Salehi et al. have reported 
such a system built on poly(N- isopropylacrylamide- co- methacrylic acid- 
co- vinylpyrrolidone) and the anticancer drug doxorubicin.65 At pH 7.4, 
the polymer is ionised and favourable electrostatic interactions with the 
drug cause release to be slowed. At pH 5.4, representative of the cancer 
microenvironment, the polymer is uncharged, and thus these interactions 
are reduced and the drug releases more rapidly.
3.8 Pulsatile release
Pulsatile release refers to an on/ off pattern of release, with bursts of 
release separated by periods where no further drug is freed from a for-
mulation. This can be particularly beneficial for conditions which follow 
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the body’s natural circadian rhythms and are worse at particular times of 
day. Asthma attacks are more common late at night, for instance, while 
rheumatoid arthritis is worse in the morning. Electrospun fibres have not 
been much explored for pulsatile release, but there is one report of this 
modality being achieved.
Kaassis and co- workers made fibres from PEO, sodium alginate 
(a naturally occurring polysaccharide which is insoluble at low pH but 
freely soluble at pHs higher than around 5)  and sodium ibuprofen.66 
While the other fibre systems discussed in this chapter are obtained as 
flat mats, in this study the fibres were found to form a ‘mountain’ shape 
growing up from the collector (Figure 3.7(a)). Evidence for crystalline 
sodium ibuprofen was found in XRD and DSC. At pH 6.8 (representative 
of the small intestine), the fibres free their drug loading within around 
20 min (Figure 3.7(b)). However, at pH 3 (representative of the stomach 
in the fed state) clear pulsatile release is seen (Figure 3.7(c)), with two 
stages of release and a lag between them. The percentage of drug in the 
first stage can be controlled through the ibuprofen content of the fibres 
(Figure 3.7(c)), while the lag between them can be varied by altering the 
amount of alginate present (Figure 3.7(d)).
3.9 Multilayer materials
As discussed above, through variation of the polymer used to pre-
pare electrospun fibres, it is possible to provide a range of drug delivery 
patterns. It is also possible to produce a mat made of multiple layers of 
monolithic fibres, with each layer made of a different material, to provide 
more complex release profiles. Blagbrough’s team have used this approach 
extensively to prepare multilayer meshes for wound- healing purposes.
In the first such study, Alhusein et al. used solutions of either PCL or 
PEVA.67 By sequentially electrospinning layers of each polymer on to the 
collector, they could produce a three- layered formulation with alternating 
PCL/ PEVA/ PCL layers. The antibiotic tetracycline hydrochloride was either 
incorporated into all three layers, or just in the central PEVA layer. Simple 
two- component fibre mats of PCL/ tetracycline and PEVA/ tetracycline were 
also prepared. While the PCL/ tetracycline formulation released all its drug 
within 1  day, the PEVA/ tetracycline fibres were able to extend this over 
8  days. The three- layer PCL/ PEVA/ PCL system could extend tetracycline 
release over 14 days; when the drug was present in all three layers, a burst 
of 60% release was seen in the early stages of the experiment, but incorpor-
ating the drug only in the central layer reduced this to 10%, and permitted 
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an almost constant (zero- order) rate of release to be achieved. The PCL/ 
PEVA/ PCL system could also effectively inhibit bacterial growth.68 Similar 
results were reported using three- layer systems with tetracycline solely 
in the central layer when these were  fabricated from zein or zein/ PCL 
blends.69 The latter have been found to be potent in preventing biofilm for-
mation, and to be compatible with human skin cells.70
This idea of depositing multiple fibre layers was also explored by 
Huang et al.71 Using ketoprofen as a model drug, polymer/ drug solutions 
ca. 3 cm
(a) (b)
(c) (d)
30.3 % PEO; 9.1% SA; 60.6% SI
58.8 % PEO; 17.6% SA; 23.5% SI
66.7 % PEO; 20.0% SA; 13.3% SI
31.3 % PEO; 6.3% SA; 62.5% SI
30.3 % PEO; 9.1% SA; 60.6% SI
29.4 % PEO; 11.8% SA; 58.8% SI
28.6 % PEO; 14.3% SA; 57.1% SI
Legend as for (b)
Figure 3.7  Pulsatile release from electrospun fibres comprising 
poly(ethylene oxide) (PEO), sodium alginate (SA) and sodium ibuprofen 
(SI), as reported by Kaassis et al.66 (a) The mountain of fibres which was 
observed to form on the collector; (b) at pH 6.8 the fibres free their drug 
loading within 15 min; (c) at pH 3 pulsatile release is observed, with 
the amount of release in the first stage dictated by the ibuprofen content 
of the fibres; and (d) the lag between the two phases of release can be 
tuned by varying the sodium alginate content of the fibres.  (Reproduced 
with permission from Kaassis, A. Y. A.; Young, N.; Sano, N.; Merchant, 
H. A.; Yu, D.- G.; Chatterton, N. P.; Williams, G. R. ‘Pulsatile drug 
release from electrospun poly(ethylene oxide)– sodium alginate blend 
nanofibres.’ J. Mater. Chem. B 2 (2014): 1400– 1407. Copyright Royal 
Society of Chemistry 2014.)
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were prepared using PVP and EC. PVP/ EC/ PVP three- layer systems were 
produced, with ketoprofen present in each layer. Systems were generated 
with the different layers having varying thickness by varying the duration 
of time for which each was electrospun. The products comprised ASDs, 
and the three- layer system was found to give a two- phase (biphasic) drug 
release pattern. The PVP layers provided a burst of release at the start 
of the experiment, and then extended release ensued from the EC layer. 
Such formulations could be beneficial because the initial burst provides a 
loading dose, rapidly increasing the drug concentration in the plasma to 
therapeutic levels; the second, slow- release phase can then maintain the 
concentration in the effective range. Huang and colleagues were able to 
control the extent of the burst by varying the layer thickness.71
3.10 Thermoresponsive systems
A number of polymers are thermosensitive; that is, they change properties 
in response to temperature variation. Such polymers have been explored 
in electrospinning, with most attention paid to poly(N- isopropyl acryl-
amide) (PNIPAAm). This polymer is hydrophilic at room temperature, 
and can dissolve in water. However, at around 32ºC it undergoes a 
chain- to- globule transition and becomes hydrophobic. The temperature 
at which this arises is known as the lower critical solution temperature 
(LCST). Although PNIPAAm can be electrospun alone,72 it is more usually 
blended with carrier polymers such as PEO to facilitate the spinning pro-
cess.73 The thermosensitive properties of PNIPAAm are preserved after 
spinning, meaning that the fibres generated change their hydrophilicity 
in response to temperature.
Thermosensitive fibres have attracted some attention for drug 
delivery purposes. Fibres made from a blend of PNIPAAm and poly(2- 
acrylamido- 2- methylpropanesulfonic acid) release a nifedipine cargo 
more rapidly below the LCST than above.74 PNIPAAm/ PEO blend 
fibres containing vitamin B12 behave similarly,75 as do PNIPAAm/ EC 
formulations.76 Although the exact behaviour can be tuned by varying 
the composition of the fibres, the in vivo applications of these particular 
formulations are not clear: a system able to control release in response 
to small variations in body temperature would be useful, but PNIPAAm 
cannot deliver this because its LCST is well below the physiological 
temperature range.
Where systems based on LCST polymers might be very useful, how-
ever, is in the treatment of wounds. When a wound dressing is changed, it 
 
 
 
 
 
 
 
 
 
 
 
87MonoAXiAL eLeCTRosPinninG
87
is common for some tissue to be pulled away from the wound: this results 
in what are known as secondary injuries. Thermosensitive materials can 
be used to control cell adhesion, because interactions between cells and 
the polymer are much stronger above the LCST than below it. Thus, a 
thermosensitive wound dressing could be very beneficial if the LCST 
was a little below body temperature. A local low- temperature treatment 
would drop the temperature of the skin below the LCST, reduce the 
strength of interactions between the dressing and the cells around the 
wound, and hence prevent secondary injuries when the dressing is 
removed. Electrospun fibres have many properties making them suitable 
for wound dressings, since their high porosity allows them to absorb any 
fluids exuded from the wound, and their web structure helps to facilitate 
cell growth.
Thermoresponsive electrospun wound dressings have recently 
been reported by Li et  al. using either PNIPAAm77 or poly(di(ethylene 
glycol) methyl ether methacrylate)78 as the thermosensitive polymer 
in a blend with poly(l- lactic acid- co- ε- caprolactone) (PLCL). The anti-
bacterial drug ciprofloxacin was incorporated into the fibres to prevent 
infection. Ciprofloxacin was freed from the fibres over more than 200 
h, and the formulations could effectively prevent bacterial growth. The 
thermosensitive mats were able to accelerate wound healing over fibres 
prepared from PLCL and ciprofloxacin alone (Figure 3.8).
3.11 Emulsion and suspension electrospinning
The above discussion has focused on electrospinning a solution of a 
drug and polymer. In addition, it is possible to process emulsions and 
suspensions, and the resultant fibres can have a number of beneficial 
properties.
3.11.1 emulsions
A range of fibres have been prepared using monoaxial emulsion 
electrospinning. For instance, Jing’s group made a water- in- oil emulsion 
stabilised with the surfactant sodium dodecyl sulfate.79 The hydrophilic 
active pharmaceutical ingredient (API) doxorubicin hydrochloride was 
present in the water phase. A  block copolymer (poly(ethylene glycol)- 
poly(l- lactic acid)) dissolved in chloroform was used to form the fibres. 
This copolymer is amphiphilic and has both hydrophobic and hydro-
philic sections, which means that it should be able to interact with both 
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parts of the emulsion. After electrospinning, the fibres were found to 
have an aqueous core/ hydrophobic shell structure, despite having been 
produced from a monoaxial process. This was attributed to a separation 
of the hydrophobic and hydrophilic components of the fibres, with the 
surfactant at the interface. This spontaneous self- assembly of core/ shell 
Figure 3.8  Images showing the healing of wounds inflicted on rats and 
treated with electrospun dressings. The wounds were treated with (a) a 
commercial gauze; (b) poly(N- isopropyl acrylamide) (PNIPAAm)/ poly(l- 
lactide- co- ε- caprolactone) (PLCL)/ ciprofloxacin fibres with a 1:1 mass ratio 
of the polymers; (c) PNIPAAm/ PLCL/ ciprofloxacin fibres with polymer mass 
ratio 1:2; and (d) PLCL/ ciprofloxacin fibres. It is clear that the formulations 
containing PNIPAAm lead to faster wound healing. (Reproduced with 
permission from Li, H.; Williams, G. R.; Wu, J.; Wang, H.; Sun, X.; Zhu, L. 
M. ‘Poly(N- isopropylacrylamide)/ poly(l- lactic acid- co- caprolactone) fibers 
loaded with ciprofloxacin as wound dressing materials.’ Mater. Sci. Eng. C 79 
(2017): 245– 254.77 Copyright Elsevier 2017.)
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structures is very commonly seen in emulsion spinning. The mechanism 
underlying this is illustrated in Figure  3.9, and has been discussed in 
detail by Wang and Wang.80
The presence of a water- soluble active ingredient in the core of fibres 
spun from water- in- oil emulsions has the benefit of ameliorating any ini-
tial burst release. This was shown for the model drugs cefradine and 
5- FU: fibres prepared from emulsion spinning had reduced initial burst 
release and a slower release rate than analogous fibres made by standard 
monoaxial solution spinning.81 A  lack of burst release from emulsion 
spun fibres was also noted with doxorubicin hydrochloride by Xu et al.79  
Oil phase
Aqueous phase
(a)
(b)
Electrospinning
(c)
(d)
Figure 3.9  Schematic showing how a core/ shell fibre can be generated 
from emulsion electrospinning. (a) A water- in- oil emulsion, with 
droplets of water dispersed throughout a continuous oil phase; 
(b) a close- up of a single water droplet, showing how a surfactant (an 
amphiphilic molecule with a hydrophilic head and hydrophobic tail) is 
used to stabilise the emulsion. Surfactant molecules will be arranged 
around the edge of the water droplets, with their hydrophilic head 
groups touching the droplet and their hydrophobic tails dangling into 
the oil phase. (c) After electrospinning a core shell fibre is formed, with 
(d) the surfactant molecules collected along the oil/ water interface to 
minimise unfavourable interactions.
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Further, emulsion electrospinning has been demonstrated to modulate 
fibre properties, for instance reducing the fibre diameters in comparison 
with monoaxial solution electrospinning.82 Sy et  al. observed that the 
mixing of phases of different rheological properties in an emulsion 
caused electrospinning to occur at a much lower range of liquid viscosity 
than that for a conventional monoaxial solution system.82
The emulsion approach has attracted particular attention for the 
production of protein- loaded fibres. The therapeutic efficacy of protein 
drugs is highly dependent on their three- dimensional structure (known 
as the tertiary structure), and this is easily degraded by the organic 
solvents commonly used for electrospinning. Incorporating them into 
water droplets in an organic continuous phase could be an effective route 
to prevent protein denaturation and degradation.83 This was reported 
for the model protein bovine serum albumin (BSA) in 2008.84 Core/ shell 
fibres were obtained via emulsion electrospinning, and protein stability 
appeared to be preserved throughout the process.
Protein- loaded core/ shell fibres prepared through emulsion 
spinning have been explored for a range of applications. These include the 
delivery of growth factors to encourage tissue regeneration. For instance, 
PLCL fibres containing vascular endothelial growth factor have been 
shown to have potential for cardiac regeneration.85 Vascular endothelial 
growth factor was released over more than 28  days, and human bone 
marrow- derived mesenchymal stem cells could proliferate on the fibres 
over a 20- day culture period. Emulsion fibres carrying a protein payload 
have further been investigated in bone tissue engineering, inter alia.86
Another benefit of emulsion spinning is in incorporating APIs of 
opposing polarity to the polymer used. As discussed in section 3.2.4, if a 
hydrophobic drug is loaded in a hydrophilic polymer (or vice versa) there 
is a risk of phase separation occurring on storage. This can be a problem 
if the extended release of a hydrophilic drug is required, since most of 
the suitable polymers for this are hydrophobic. Similarly, since hydro-
philic polymers are used for fast- dissolving systems, it can be difficult to 
incorporate hydrophobic entities into these. Emulsion electrospinning 
was used to overcome the latter issue in the case of the lipophilic API 
celecoxib.87 Emulsion droplets could be seen in the fibres produced 
and the drug was amorphously distributed in the fibres, boding well 
for improved dissolution properties (although these were not tested). 
The situation of a hydrophilic drug in a hydrophobic polymer has been 
studied by Ramakrishna’s team.88 Emulsion and blend fibres of PCL or 
poly(3- hydroxybutyric acid- co- 3- hydroxyvaleric acid) (PHBV) loaded 
with metformin hydrochloride or metoprolol tartrate were generated, 
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and the initial burst and release rate were both reduced in the emulsion 
system (Figure 3.10).
It is not always the case that fibres made by emulsion 
electrospinning are superior to those from monoaxial solution spinning, 
however. A  study by Zhao et  al. fabricated PCL fibres loaded with l- 
ascorbic acid- 2- phosphate magnesium using standard blend spinning 
(using a co- dissolving solution of drug and polymer), as well as with 
emulsion and coaxial electrospinning.89 In this instance, the optimum 
fibres spun from solutions were found to have better mechanical prop-
erties and a reduced burst of release than the emulsion analogue.
3.11.2 suspensions
Suspensions of small (typically nanoscale) particles can be converted 
into fibres by electrospinning. For example, CaCO3 microparticles 
incorporating model drugs have been embedded in PLGA fibres by 
electrospinning.90 The fibres appeared beaded owing to the presence of 
particles. However, it is possible to prepare relatively smooth cylindrical 
fibres with minimal beading, if the experimental conditions are appro-
priately optimised.91
Figure 3.10  The release of metformin hydrochloride (MH) from 
blend and emulsion poly(ε- caprolactone) (PCL) and poly(3- 
hydroxybutyric acid- co- 3- hydroxyvaleric acid) (PHBV) fibres. Reduced 
burst release and slower rates are seen with the emulsion system. 
(Reproduced with permission from Hu, J.; Prabhakaran, M. P.; Tian, 
L.; Ding, X.; Ramakrishna, S. ‘Drug- loaded emulsion electrospun 
nanofibers: characterization, drug release and in vitro biocompatibility.’ 
RSC Adv. 5 (2015): 100256– 100267.88 Copyright Royal Society of 
Chemistry 2015.)
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Magnetic nanoparticles, such as those of Fe3O4, have attracted par-
ticular attention for inclusion into fibres, because of their potential in 
biosensing, imaging and cancer treatment (e.g. inducing magnetic hyper-
thermia to destroy cancer cells).92 Wang et al. produced systems made of 
cellulose derivatives and containing Fe3O4 nanoparticles as well as either 
indomethacin or aspirin.93 This resulted in magnetic fibres, but the inclu-
sion of nanoparticles did not affect drug release. Other inorganic materials 
to have been electrospun include hydroxyapatite (useful for bone repair 
applications),94 clays,95 drug- loaded metal hydroxide nanoparticles96 and 
silicas.97 Jalvandi et al. have shown that by covalently binding levofloxacin 
to mesoporous silica nanoparticles and then spinning these into PCL 
fibres, drug release can be slowed and the initial burst reduced, compared 
to PCL/ levofloxacin fibres with no nanoparticles present.98
Protein nanoparticles can also be prepared to help prevent degrad-
ation. This has been demonstrated by first encapsulating bone morpho-
genetic protein- 2 (BMP- 2) in BSA nanoparticles, and then electrospinning 
these into fibres based on poly(ε- caprolactone- co- poly(ethylene glycol)).99 
The rationale for this is that the BMP- 2 is fragile, and could become 
degraded during electrospinning if processed in solution. Incorporating 
it into the BSA particles can protect it from degradation. This approach 
was found to give formulations able to repair defects in the skull of rats.
Finally, although most commonly researchers work with mixed 
solutions of a drug and polymer to generate fibres in the form of ASDs, it 
is also possible to electrospin suspensions of API particles.100 This could 
be attractive for making extended- release systems, for instance.
3.12 Tissue- engineering applications
Electrospun fibres have attracted much attention for tissue- engineering 
applications, where they are explored as scaffolds to replace or heal bio-
logical tissue. The structure of the mat mimics the structural component 
of the extracellular matrix, a scaffold or network of nanofibrous proteins 
and gels of polysaccharides secreted by cells to give mechanical support 
to surrounding cells. This, coupled with the porosity of the mats (which 
means that nutrients and cellular waste can diffuse in and out, and it is 
possible for cells to infiltrate into the scaffold), can encourage cell growth. 
The fibres can be loaded with promoters of cell growth if required, and 
other functional ingredients (e.g. to prevent infection and modulate the 
inflammatory response toward regeneration rather than repair) may also 
be incorporated. Some examples of this are discussed above in the con-
text of drug delivery.
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For tissue engineering, the release from the fibres of a functional 
molecule may well be important, but the mechanical properties are 
also vital (they must mimic the relevant native tissue). Increasingly, 
researchers are seeking to make bioresorbable scaffolds, materials which 
degrade slowly over time in the body and are replaced by the body’s 
own tissue. There are myriad applications of such systems, including for 
instance in the treatment of congenital heart defects. For such resorbable 
scaffolds to be effective, the degradation time of the polymer and the rate 
at which it is replaced by native tissue will need to be carefully considered 
and controlled. A detailed discussion of electrospun fibres in tissue engin-
eering lies outside the scope of this volume, but there are a number of 
recent reviews which summarise elegantly the state of the art.101
3.13 Using fibres as sacrificial templates
As well as being used directly for drug delivery purposes, electrospun 
fibres can be used as sacrificial templates to generate higher- order 
materials. Electrospinning is regarded as a top- down fabrication tech-
nique, because the structure of the macroscale spinneret is propagated 
through into solid fibres (that is, a macroscopic object is used to prepare 
smaller ones). Another way to prepare nanoscale objects is bottom- up, in 
which smaller building blocks (often atoms and molecules) are brought 
together to form aggregates (e.g. in molecular self- assembly). This is a 
powerful approach, but unfortunately it is highly time- consuming, low- 
yield and more expensive than the top- down route. It is also very difficult 
to ensure that the building blocks assemble in the desired configuration. 
For example, self- assembled nanofibres often take the form of discon-
tinuous fragments of fibrils of different lengths.
Liposomes (artificial vesicles bounded by a lipid bilayer) are one 
type of nanoscale system typically prepared bottom- up. Liposomes 
have numerous applications, including the delivery of therapeutic and 
diagnostic agents. They self- assemble in aqueous media owing to their 
amphiphilic nature; the formation of liposomes minimises contact 
between hydrophobic and hydrophilic groups, and thus is thermodynam-
ically favourable. However, liposomes are unstable over time and have a 
tendency to aggregate. Controlling the size of the liposomes formed can 
also be challenging. Often, templates are used to direct the self- assembly 
processes and drive them towards the desired structure. Electrospun 
fibres can be used as such templates.
Yu et al. were the first to report this,102 making PVP fibres containing 
phosphatidyl choline (PC), an amphiphilic molecule with a polar head 
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Figure 3.11  The chemical structure of phosphatidyl choline. R and R′ 
are long- chain fatty acid groups.
(a)
Fibres 50 µm
Liposomes
(b)
0.1 µm
Figure 3.12 The self- assembly of phosphatidyl choline liposomes 
from poly(vinyl pyrrolidone)/ phosphatidyl choline fibres, as 
reported by Yu et al.102 (a) An optical microscopy image obtained 
during the self- assembly process, and (b) a transmission electron 
microscopy image of one of the resultant liposomes. (Reproduced 
with permission from Yu, D.- G.; Branford- White, C.; Williams, G. R.;  
Bligh, S. W. A.; White, K.; Zhu, L.- M.; Chatterton, N. P. ‘Self- 
assembled liposomes from amphiphilic electrospun nanofibers.’ 
Soft Matter 7 (2011): 8239– 8247. Copyright Royal Society of 
Chemistry 2011.)
group and hydrophobic hydrocarbon tail (Figure 3.11). Amorphous solid 
dispersions of PC in PVP were obtained from electrospinning. When 
the fibres were added to water, the PC molecules were observed to self- 
assemble into liposomes (Figure 3.12), the size of which could be tuned 
by varying the fibre composition. The authors attributed this to the PVP 
matrix confining the PC molecules in close proximity when the fibres are 
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added to water, driving them to aggregate into liposomes (Figure 3.13). 
This approach is potentially beneficial over other liposome production 
techniques, since it does not require any controlled heating, cooling or 
agitation steps. Furthermore, it can ameliorate some of the stability issues 
which are encountered during the storage of liposomes, because the fibres 
can act as proto- liposomes. These liposome precursors can be stored 
‘frozen’ in the solid- state nanofibres, endowing them with high stability, 
but can easily be converted to liquid suspensions in situ upon demand.102
This work was developed further by Song and co- workers, who 
developed magnetic liposomes via a similar route.103 Magnetic iron oxide 
nanoparticles were included in the fibres along with PVP and PC, and 
magnetic liposomes formed spontaneously when the fibres were added 
to water. The liposome size could be controlled by varying the iron oxide 
content of the fibres. The magnetic properties of the nanoparticles were 
unaffected by both the electrospinning and self- assembly processes, and 
thus these materials might find applications in targeted drug delivery.
Electrospinning
(top-down)
Preparing amphiphilic
composite nanofibers
composed of PVP and
PC
Self-assembly
(bottom-up)
PC molecules
co-aggregate into
vesicles templated
on the nanofibers
Phosphatidyl choline (PC) H2O
H2O
PVP Chloroform
Figure 3.13  The proposed mechanism for liposome assembly from 
poly(vinyl pyrrolidone) (PVP)/ phosphatidyl choline (PC) fibres. 
(Reproduced with permission from Yu, D.- G.; Branford- White, C.; 
Williams, G. R.; Bligh, S. W. A.; White, K.; Zhu, L.- M.; Chatterton, N. P. 
‘Self- assembled liposomes from amphiphilic electrospun nanofibers.’ 
Soft Matter 7 (2011): 8239– 8247. Copyright Royal Society of 
Chemistry 2011.)
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3.14 Conclusions
In this chapter, we have considered the uses of fibres prepared by 
monoaxial electrospinning in drug delivery. The experimental set- up 
required was first explained, and details given as to how to begin a new 
electrospinning process. The various different types of fibres that can be 
generated were then discussed. Fibres made by monoaxial electrospinning 
find applications as FD- DDSs able to provide very rapid release in the 
mouth, as extended- release systems to prolong release over time, and can 
be used to target drug delivery in response to particular temperature or pH 
conditions.
It is possible to prepare fibre mats made of multilayers of different 
drug- carrying polymers to give more complex or precisely controlled 
drug delivery patterns, and suspensions and emulsions can be processed 
in addition to solutions; this can be beneficial in preventing an initial 
burst release of drug and protecting proteins from degradation. Finally, 
the potential to use the fibres as templates to self- assemble higher- order 
objects was considered.
Monoaxial spinning is the simplest electrospinning technique and 
thus has received a great deal of attention in the literature, with many 
promising applications. However, there are some drawbacks  – in par-
ticular the burst of drug release which is often seen at the beginning of 
experiments – and therefore in some instances more complex approaches 
are required. We will discuss these in Chapters 4 and 5.
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Coaxial and multi- axial 
electrospinning
4.1 Introduction
As discussed in Chapter 2 (section 2.6.3), coaxial electrospinning (also 
known as co- electrospinning) involves the use of a two- needle spin-
neret, with one needle nested inside another in a concentric fashion. The 
rapid stretching and solvent evaporation in electrospinning mean that 
the structure of the spinneret is propagated into the fibre products: thus, 
where the single- liquid, monoaxial, electrospinning process gives mono-
lithic fibres, the arrangement of needles in coaxial spinning most com-
monly produces core/ shell materials. This is depicted in Figure 4.1.
The first report of coaxial electrospinning in the literature appeared 
in 2003.1 In this work Sun et al. described the spinning of systems where 
both the core and shell comprised poly(ethylene oxide) (PEO), in addition 
to materials comprising PEO (shell)/ poly(dodecylthiophene) (core), 
PEO/ polysulfone and poly(l- lactic acid) (PLLA)/ palladium acetate.1 
It was noted in this work that it is possible to use solutions which are 
non- electrospinnable for the core so long as the shell solution is amen-
able to processing by electrospinning, thereby significantly broadening 
the range of materials which can be handled. It was subsequently found 
that non- electrospinnable solutions can also be used as shell liquid when 
paired with an electrospinnable core solution, as elaborated in section 
4.9. Since the work by Sun et al., there has been an explosion of interest 
in using coaxial electrospinning to prepare drug delivery systems.
Coaxial systems have a number of potential benefits over the mono-
lithic fibres produced in single- liquid spinning. These include preventing 
the initial burst of release commonly seen with monolithic fibres, or 
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delivering more complicated release profiles. Release can also be targeted 
to different parts of the body or particular cell types, and multifunctional 
fibres loaded with multiple active ingredients can be prepared. Proteins, 
which often degrade in single- liquid spinning owing to their fragile three- 
dimensional structures, can be processed, as can cells. Each of these will 
be discussed in turn below. In addition, as mentioned in Chapter 2, the 
shape and morphology of an electrospun product also depend on the 
material properties. By varying the properties of the working material, 
the use of a coaxial spinneret also enables the formation of a variety of 
other structures, including bubbles, scaffolds and multilayered fibres and 
particles.2 Scientists have further sought to add additional liquids to the 
process, and we will finish the chapter with a discussion of three- liquid 
(triaxial) and four- liquid (quad- axial) processes.
4.2 Experimental considerations
The experimental set- up required for coaxial spinning was introduced 
in Chapter  2 (section 2.6). As for single- liquid spinning, to achieve a 
successful outcome it is necessary to consider carefully the properties of 
the solution and the processing parameters in the coaxial setting. The 
major considerations are the same as for single- liquid spinning (see 
section 3.2), but there are additional factors to take into account with 
coaxial spinning.
4.2.1 Handling two liquids
There are two fluid interfaces in the coaxial set- up: the liquid– gas inter-
face between the sheath solution and the surrounding air, and the 
liquid– liquid interface between the two working solutions. Optimisation 
of the fluid interfaces is key in the formation of a stable compound cone 
jet, which in turn is critical for achieving uniform and reproducible 
Monolithic
(b) Core/shell(d)(a) (c)
Figure 4.1  Schematic illustrations of the spinnerets used for, and 
products generated by, monoaxial and coaxial electrospinning. 
(a) A single- liquid spinneret for generating (b) monolithic fibres; (c) a 
coaxial spinneret, which results in (d) core/ shell products.
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core−shell products. The properties of the two solutions being processed 
cannot be considered in isolation. Although only one of the liquids (most 
commonly the sheath) needs to be electrospinnable, it is generally easier 
to achieve stable coflow if the two liquids have a relatively similar rate of 
solidification. If they do not, then there is a risk of one solution evapor-
ating much faster than the other. This can cause clogging of the needle, 
and/ or result in the separation of the two liquids. In turn, this leads to the 
properties of the fibres changing as a function of time during spinning, or 
separation of the core and shell fibre parts.
The charge distribution in a coaxial electrospinning jet is dependent 
on the properties of the core and sheath liquids. To form a cone shape as 
a compound droplet at the spinneret exit, at least one of the two liquids 
should enable a sufficient flow of charge. This is the driving liquid. In a 
typical monoaxial electrohydrodynamic process, the charge is localised 
at the interface between air and the charged liquid forming the Taylor 
cone. In a coaxial set- up, if the electrical relaxation time (time taken 
for an electron to travel in a material) of the sheath liquid is faster than 
or comparable to that of the core liquid, charges are localised at the 
outer interface between the sheath and the air, and the sheath liquid 
is the driving liquid. The core liquid can also act as the driving liquid if 
the outer is electrically insulating (a dielectric). In this case, when the 
driving interface is the inner one, the motion of the core liquid transmits 
to both the core and the sheath liquids via viscous force, setting the com-
pound liquid in motion to form a coaxial jet.3
When the outermost sheath polymer solution has sufficient visco-
elasticity, fibres with an encapsulated core are produced – this is coaxial 
electrospinning (or co- electrospinning). Hard- to- electrospin solutions or 
salts can be made into fibres by coaxial electrospinning, with a readily 
spinnable polymer serving as a template sheath for the core. If desired, 
the carrier polymer can be removed at a later stage. If the outermost 
sheath liquid does not allow sufficient molecular entanglement, coaxial 
electrospraying occurs, leading to core−shell particles.
As noted above, the integrity and reproducibility of the core−shell 
structure require simultaneous and concentric break- up of the com-
pound jet. The relative behaviours of the two liquids will hence signifi-
cantly impact the integrity of the core/ shell structure in the fibres. The 
miscibility of the two liquids must be considered, as must volatility:  a 
large difference between the boiling points of the solvents used can com-
promise the integrity of the core/ shell structure generated during product 
solidification. Defects such as porous structures or molecules from the 
core leaching into the shell layer can arise if the core and shell solvents are 
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miscible and evaporate at markedly different rates.4 Careful consideration 
of the solvents available and optimisation of the interfacial compatibility 
are required in order to ensure the desired fibre products are generated.
The importance of flow rate has already been discussed in section 
2.5.2; in coaxial spinning, the relative flow rates of the core and the shell 
liquids must also be considered. The faster the core flows with respect to 
the shell, the larger the core component of the fibres is expected to be. 
This tunability can be useful in varying the drug release profile, as will be 
discussed later. However, there is only a certain range of core- to- shell flow 
rate ratios over which the spinning process will be successful. At high core 
flow rates, there will not be a sufficiently fast rate of sheath solvent flow to 
encapsulate the core, leading to droplets with the two solutions mixed, or 
phase separation. The appropriate core- to- shell flow rate ratio is dependent 
on whether the core or the shell liquid is responsible for carrying the elec-
trical charge (the driving liquid). Most commonly, when the shell liquid is 
the driver, a core- to- shell flow rate ratio of between around 1:3 and 1:10 
is generally reported to give successful fibre formation, with lower ratios 
often (but not always) giving particles or mixtures of particles and fibres.5 
Higher ratios of 1:15 have also been reported to yield fibres successfully, 
however.6 The exact range of ratios suitable for a particular experiment is 
dependent on the nature of the solutions used for the core and sheath, and 
needs investigation for each formulation being developed. The flow rate 
of the driving liquid carrying the charge also strongly affects the range of 
applied voltages that maintain the cone jet mode: higher flow rates of the 
driving liquid allow more charge to be carried per unit time and require a 
higher applied voltage to maintain a stable cone jet.
4.2.2 The spinneret and electrodes
The coaxial spinneret is conceptually simple, comprising one (narrower) 
needle nested inside another (Figure 4.1(c)). The exact diameters of the 
needles used can be varied, but in the authors’ experience, we have had 
success using inner- needle internal diameters of 0.21– 0.35  mm and an 
outer needle of 0.84– 1.2 mm. Most researchers work with the ends of the 
two needles in line. However, the exact positions of the needles (does the 
inner needle protrude from the outer needle, and if so by how much, or 
vice versa?; Figure 4.2) can have an influence on the process, as illustrated 
by Sofokleous and co- workers.7 These researchers found that having the 
inner needle displaced inside the outer needle by a small amount (2 mm 
in their systems) led to more homogeneous products and better encapsu-
lation of the core inside the shell. Lee et al. have similarly developed what 
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they termed a ‘core cut’ nozzle where the terminus of the core needle is 
inside the shell needle, similar to Figure 4.2(c), and found that it reduced 
jet instability and gave more control over the spinning experiment.8
Most researchers use standard blunt- ended dispensing tips for 
electrospinning, but several studies suggest that covering the end of the 
needle with a plastic (e.g. Teflon or poly(vinyl chloride)) coating can 
be helpful. This is thought to reduce the attraction between the ejected 
polymer solution and the exterior of the needle, and can thereby reduce 
the formation of semi- solid substances on the syringe and the concomi-
tant clogging which often arises.9
In the most common coaxial experiment, the spinneret is connected 
to the positive electrode of the high- voltage supply and the collector is 
connected to the negative electrode or grounded. Under a high electric 
field, the inner and outer liquids in the coaxial jet may separate or break 
into indistinct layers. This arises due to flow instability during the evap-
oration of solvent as the jet travels towards the collector. Practically, it 
is often difficult to stabilise a compound cone jet when the interfacial 
liquid properties are less than optimal. In this situation, the stability 
of the coaxial cone jet can be improved by the addition of grounded or 
negatively charged ring electrodes placed at specific distances away from 
positive coaxial spinneret positive polarity.10 This approach has recently 
been proven powerful in coaxial electrospraying; since electrospraying 
and electrospinning differ only in the viscoelastic properties of the 
working liquids (see Chapter 2), improvements in the apparatus design 
and assembly for electrospray are usually applicable for electrospinning.
4.2.3 establishing a coaxial process
The best place to start with developing a new process is to find a literature 
precedent which uses a similar polymer system. There exists a wealth of 
(a) (b) (c)
Figure 4.2  Possible needle configurations in coaxial electrospinning, 
showing (a) the inner and outer needles inline; (b) the inner needle 
protruding from the outer; and (c) the inner needle nested inside the outer.
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information on single- liquid processes in particular, and thus a thorough 
review of the literature will likely reveal a protocol for a similar system 
to the one of interest. Using the closest possible literature parameters 
as a guide, we recommend initially spinning the two liquids singly and 
evaluating the fibres produced. If only one liquid in the process being 
developed is spinnable, then of course only this should be explored. The 
initial evaluation can be very crude, comprising simply collection of a few 
fibres (5– 20 s of spinning or so) on a glass slide (or across a piece of card-
board with a hole cut in the middle) and holding them up to the light. 
If fibres have formed, this will be immediately obvious unless the fibres 
are below 400 nm in diameter. A more detailed assessment can then be 
undertaken by optical microscopy (Figure 4.3(a)).
Once fibres have been formed, a systematic variation in the voltage, 
spinneret- to- collector distance and flow rate for the single- liquid process 
is desirable, to observe which values give the best fibres. The products 
can be assessed by optical microscopy, and ideally will comprise fibres 
only with no particles/ droplets. These fibres should possess uniform 
diameters, and no ‘bead- on- string’ morphologies should be visible. The 
optimisation process should be undertaken for each of the core and shell 
liquids. Coaxial electrospinning can then be commenced with the best set 
of parameters identified (or a compromise if very different parameters 
are found for the core and shell liquids).
In order to observe the behaviour of the liquids during initial 
coaxial experiments, it can be helpful to incorporate a small amount of 
(a) (b) (c)
Figure 4.3  Optimising the fibre production process. (a) Fibres collected 
on a glass slide. Clear fibres can be seen, with no evidence for beads- on- 
string morphology. Some of the fibres are rather curved, however, which 
might be resolved by additional optimisation. Using a dye in the core liquid 
can aid visualisation of a coaxial process, as shown in (b) and enlarged 
in (c); a distinct two- liquid Taylor cone can be seen here, with the dye 
confined to the core liquid and no obvious liquid mixing. ((a) Courtesy of 
Alexandra Baskakova; (b and c) courtesy of Ukrit Angkawinitwong.)
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a dye into the core liquid. This aids visualisation of the Taylor cone, and 
thus whether or not there is a compound cone with the core liquid nested 
neatly inside the shell can be established quickly (Figure 4.3(b) and (c)). 
Again, collection on to a glass slide or cardboard window will enable any 
fibres formed to be seen immediately, and can be followed by optical 
microscopy evaluations. If the dye is fluorescent, then in favourable 
instances (i.e. with large- diameter fibres) it will be possible to observe 
the core−shell structure using fluorescent light microscopy. Once the 
experimental parameters have been adjusted to obtain the best- quality 
fibres (see above) then the preparation of a larger- scale batch of fibres 
can commence. This should be followed by a detailed characterisation by 
scanning and transmission electron microscopy (SEM and TEM), X- ray 
diffraction, infrared spectroscopy, and so forth.
4.3 Extended- release systems
4.3.1 Preventing burst release
A standard approach to extending the time over which drug release 
from a polymer nanofibre occurs is to use a slow- dissolving or insoluble 
polymer in single- liquid spinning. However, a major problem which arises 
with single- liquid electrospinning is that, as a result of the very high sur-
face- area- to- volume ratio of the fibres, a relatively large amount of the 
incorporated drug is present at or near the fibre surface. This commonly 
results in a burst release, where a significant proportion of the drug con-
tent is freed rapidly into solution at the start of the process.4, 11 The initial 
burst is then usually followed by a tailing- off of the release rate. The burst 
release is not a problem when developing a fast- dissolving drug delivery 
system, because the aim is to release all the drug content into solution in 
a few seconds or minutes. It is, however, a major issue where modified- 
release systems are concerned.
The core/ shell structures which can be obtained through coaxial 
electrospinning offer one potential solution to this issue. By preparing a 
two- compartment fibre, where the shell comprises a blank polymer and 
the drug is in the core alone, the problem of significant amounts of drug 
being present at the surface should be resolved if the shell polymer is 
insoluble or slow- dissolving. One of the first studies to investigate this 
possibility came from He and co- workers, who prepared fibres with a 
PLLA shell and a core comprising the antibiotic tetracycline hydrochloride 
(TCH) mixed with a low quantity of PLLA.12 A small amount of a cross- 
linking agent was added to the shell solution to improve the mechanical 
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properties and overcome the brittleness inherent to PLLA fibres. PLLA is 
a slow- degrading polymer (with a complete degradation time of more 
than 1 year under physiological conditions), and was employed because 
the aim of this work was to prepare antibacterial fibres for suturing or 
wound- dressing applications. TEM data showed the fibres to have clear 
core/ shell structures (Figure  4.4(a)), and they were able to provide 
extended release over ca. 1 day. The production of core/ shell systems in 
this work12 additionally precluded the burst release previously reported 
from monolithic TCH-loaded fibres,13 as shown in Figure 4.4(b).
Similar poly(lactic- co- glycolic acid) (PLGA) core/ shell fibres, 
with both compartments made of PLGA and TCH in the core only, have 
been produced.14 PLGA is another relatively slow- dissolving polymer 
(complete degradation time usually ≥ 2  months under physiological 
conditions), but despite this the fibres prepared showed a considerable 
burst release. The extent of the latter could be tuned by varying the 
polymer concentrations in the respective compartments, but it is clear 
that simply making a fibre with a shell of a slow- dissolving polymer and 
a drug- containing core does not necessarily prevent a burst release. 
(a) (b)
Figure 4.4  (a) Transmission electron microscopy image of a poly(l- 
lactic acid) (PLLA)/ tetracycline hydrochloride (TCH) fibre prepared 
using a 10% w/ v PLLA solution as the shell and a 5% w/ v TCH/1% w/ v 
PLLA core solution, and (b) TCH release from core/ shell fibres prepared 
by He et al.12 with the same TCH/ PLLA core but varied concentrations 
of PLLA in the shell solution. (Adapted with permission from He, C. 
L.; Huang, Z. M.; Han, X. J.; Liu, L.; Zhang, H. S.; Chen, L. S. ‘Coaxial 
electrospun poly(l- lactic acid) ultrafine fibers for sustained drug 
delivery.’ J. Macromol. Sci. B 45 (2006): 515– 524. Copyright Taylor & 
Francis 2006.)
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Coaxial electrospinning to produce fibres with TCH in the core has add-
itionally been explored by Ramakrishna’s team,15 who prepared fibres 
with a PLGA (shell) and gum tragacanth (core). The core/ shell fibres 
were found to be able to prolong the release period compared to mono-
lithic fibres made from a blend of the two polymers, and also reduced the 
initial burst of release observed with the latter.
Analogous results have been seen for fibres comprising a poly(ε- 
caprolactone) (PCL) shell and a core of resveratrol (an antioxidant) or 
the antibiotic gentamicin sulfate, where drug release could be extended 
for more than 160 h.16 PCL dissolves very slowly (over around 3 years in 
vivo), and thus these results are as intuitively expected. However, such 
findings are not ubiquitous. Hollow fibres were prepared consisting of 
a PCL shell with PEO and dexamethasone (an anti- inflammatory gluco-
corticoid) in the core, and despite the shell comprising PCL, a significant 
amount of burst release was observed.17
The observation that making fibres with a slow- dissolving shell 
does not necessarily prevent a burst release is well established in the 
literature. Such findings have been seen for systems with a polymer 
shell and drug- only core, for instance poly(l- lactide- co- ε- caprolactone) 
(PLCL) (shell)/heparin (core) fibres18 and PLCL (shell)/paclitaxel (core) 
materials.19 In both cases, despite the fact the drug was only present in 
the core, a notable burst release was seen.
A number of other authors have observed this phenomenon when 
using a drug/ polymer matrix as the core solution rather than a simple 
drug solution, such as in the work of Zhu et al.20 In this study, the authors 
used poly(lactic acid) (PLA), PCL or PLGA as the shell and a flurbiprofen 
axetil (non- steroidal anti- inflammatory drug)/poly(vinyl pyrrolidone) 
(PVP) blend for the core. Again, a large burst release was seen. The 
reasons behind such burst release are not entirely clear, since all of PLA, 
PLGA and PCL are slow to dissolve/ degrade, but may arise as a result of 
some blending of the core and shell liquids, and/ or the loaded drug being 
able to diffuse through pores in the shell.
The problem of burst release is particularly acute when working 
with hydrophilic active ingredients and biodegradable matrices, and 
Venkatraman’s team have explored the use of coaxial spinning to 
ameliorate this issue.21 Metoclopramide hydrochloride (MtpH; used 
for the treatment of nausea and vomiting) was used as a model active 
ingredient, and fibres prepared with PCL, PLLA and PLGA shells and a 
poly(vinyl alcohol) (PVA)/ MtpH blend in the core. Significant amounts 
of burst release were observed with monolithic fibres spun from each 
of PCL, PLLA and PLGA. The coaxial PCL/ PVA system reduced this 
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burst somewhat, but a considerable amount of release was neverthe-
less observed in the first 6 h of dissolution testing. This was attributed 
to the presence of pores in the PCL shell. The coaxial PLLA/ PVA and 
monolithic PLLA fibres behaved very similarly, which was believed to be 
because diffusion through the PLLA was the rate- limiting step to release, 
and the PLLA shell was not porous. The greatest difference in behav-
iour was observed with the PLGA systems, where the burst release was 
much suppressed in the coaxial fibres. In this instance, the rate of MtpH 
movement from the PVA core to the shell was the rate- determining step 
to release, and diffusion through the PLGA phase was relatively fast.
The work of Venkatraman et al. is important because it shows that 
merely making a core/ shell fibre with drug located solely in the core 
and a slow- dissolving or insoluble shell is not sufficient to preclude 
burst release. It is important to consider the difference in hydrophil-
icity between the two polymers in the fibre; a moderate difference is 
required, because too great a difference may lead to a hollow core, as 
noted by Dror et  al. (this arises because a very sharp interface forms 
between core and shell).22 The drug itself needs to be more soluble in 
the core than the shell, and it is vital to control the electrospinning 
parameters to keep to a minimum the porosity of the shell (the ability 
of pores in a blank polymer shell to accelerate the rate of drug release 
from the core was also noted by Nguyen et  al.23). Finally, the rate of 
drug diffusion through the shell needs to be considered:  this should 
be relatively rapid, otherwise there is no benefit of using a core/ shell 
system and no improvement in performance will be seen over a mono-
lithic fibre of the shell polymer.
Zupančič et al. have built on these concepts, preparing fibres with 
an insoluble poly(methyl methacrylate) (PMMA) shell and a core of 
PVA or PVA/ PMMA blends.24 The core was loaded with the antibiotic 
ciprofloxacin, and the fibres proposed as advanced treatment modal-
ities for a range of bacterial infections. The release rate could be tuned 
by varying the shell and core liquid flow rates and through the variation 
of the PMMA:PVA ratio in the core. In the optimal formulations, a burst 
release can be completely avoided and nearly zero- order release over a 
few days can be achieved (Figure 4.5).
A number of other studies have investigated drug- loaded core−shell 
fibres for extended release. For instance, a mixture of cellulose acetate 
(CA) and gelatin has been used to form the shell of a coaxial fibre loaded 
with the antibiotic amoxicillin and poly(ethylene glycol) (PEG) in the 
core.25 Extended release over 1400 min was observed, with only a small 
burst release. However, it should be noted that the experiments were 
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conducted in a simulated gastric fluid at pH 1.2 throughout, not really 
representative of physiological conditions in the body.
In other work, Wang et  al. have made core/ shell PLLA/poly- (3- 
hydroxy butyrate) fibres with the enzyme inhibitor dimethyloxalylglycine 
in the core.26 Again, by doing so they could make significant strides 
towards ameliorating burst release by localising the drug away from the 
release milieu.26 Increasing the thickness of the fibre shell led to slower 
release in this work.
Further examples of coaxial electrospun core/ shell fibres being 
exploited to reduce or preclude a burst release include those loaded with 
epidermal induction factors for skin regeneration,27 the broad- spectrum 
antibiotic bacitracin,28 the antiviral drug acyclovir,29 silver nanoparticles 
(a)
(c) (d)
(b)
Figure 4.5  Tuning the rate of ciprofloxacin (CIP) release from 
core−shell poly(methyl methacrylate) (PMMA)/ poly(vinyl alcohol) 
(PVA) fibers. (a) and (b) show the influence of varying the ratio of the 
core:shell flow rate from 1:3 to 1:5 in the preparation of PMMA (shell)/
PVA (core) (csPVA) systems. (c) and (d) depict the release profiles of 
fibres prepared at a 1:4 core:shell flow rate and with a PMMA/ PVA blend 
core (percent values refer to the percentage of PVA in the core). (a) and 
(c) show the early stages of the release experiment, and (b) and (d) the 
full time period studied. (Adapted with permission from Zupančič, S.; 
Sinha- Ray, S.; Kristl, J.; Yarin, A. L. ‘Controlled release of ciprofloxacin 
from core–shell nanofibers with monolithic or blended core.’ Mol. Pharm. 
13 (2016): 1393– 1404. Copyright American Chemical Society 2016.)
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for antibacterial applications,30 dipyridamole to prevent platelet aggre-
gation and reduce stroke risk31 and tenofovir32 or maraviroc33 for anti- 
human immunodeficiency virus (HIV) treatment. The latter study 
employed ethyl cellulose (EC) as the shell and a PVP core, and found it 
was possible to tune the release rate by varying the shell thickness, with a 
thicker shell extending the release time. Similar results have been found 
with chitosan (shell)/PVA (core) fibres loaded with doxorubicin in the 
core,34 and zein (shell)/zein- allyltriphenylphosphonium bromide (core) 
materials.35
There also exist reports of more sophisticated systems designed 
to sustain release and prevent the initial burst release. For instance, 
fibres have been prepared in which levofloxacin (an antibiotic) was first 
loaded on to mesoporous silica nanoparticles, and these in turn spun 
into the core of PCL fibres (with PCL comprising both the core and shell 
polymer).36 A small reduction in burst release resulted from this system, 
and sustained release over more than 10 days was achieved. The use of 
the silica nanoparticles additionally extended the period of time over 
which the formulation was effective in preventing bacterial growth.
4.3.2 Biphasic release
Although it is commonly desirable to prevent a burst of release in the ini-
tial stages of dissolution, on occasion, and if it is properly controlled, such 
rapid release early on can be beneficial. This is because it can provide a 
loading dose, rapidly increasing the blood plasma concentration of drug 
into the therapeutic window. If a second, sustained, phase of release then 
ensues, a therapeutic concentration can be maintained over an extended 
period. This has been achieved on several occasions using core/ shell 
electrospun fibres, and involves using an insoluble or slowly dissolving 
polymer as the core, and a fast- dissolving polymer for the shell. The drug 
is present in both phases. This concept has been demonstrated using the 
non- steroidal anti- inflammatory agent ketoprofen as a model drug, PVP 
as the shell polymer and either zein37 or EC38 as the core. When the fibres 
are added to the dissolution medium, the shell rapidly dissolves and frees 
its drug content into solution for the loading dose. The drug in the core is 
then released over a prolonged period of time. By varying the drug con-
centration in the different phases or the flow rates of the core and sheath 
liquids38 it is possible to tune the amount of release in the first and second 
stages. Other work has used fibres with a CA shell and a core containing 
sodium hyaluronate and naproxen- loaded liposomes to achieve such a 
biphasic release profile.39
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The above studies use a single- fibre formulation to deliver biphasic 
release, but it is also possible to achieve this by combining two different 
sets of fibres. Ball et  al. have used this approach with core/ shell fibres 
comprising an EC shell and PVP/ maraviroc core.33 Different fibres were 
prepared with varied shell/ core thicknesses and then two formulations, 
one faster- releasing and one slow- releasing, physically mixed to pro-
vide a loading dose followed by sustained release of the remaining 
embedded drug.
4.4 Targeted drug delivery
Core/ shell fibres generated by coaxial electrospinning have attracted 
attention for targeting the location of drug release in the body. In 
its simplest embodiment, this has taken the form of preparing fibres 
with the shell made of a pH- sensitive polymer (e.g. a Eudragit) which 
is insoluble at low pH. Such systems are designed for oral adminis-
tration with the aim of preventing release in the stomach, where the 
shell is insoluble. Once the fibres enter the higher- pH lower parts of 
the intestine then the drug loading will be freed at a rate which can 
be controlled by judicious choice of the core polymer. For instance, 
fibres have been reported by Jin et  al. in which the shell comprised 
Eudragit S100 (which dissolves at pH > 7) and the core made of PEO 
loaded with either gadolinium (III) diethylenetriaminepentaacetate 
hydrate or rhodamine B (Figure  4.6(a)).40 The intention behind this 
work was to deliver an imaging agent locally to the colon for diagnosis 
of, for instance, irritable bowel syndrome. The authors found that the 
Eudragit coating successfully prevented almost all release in the pH 
conditions typical of the stomach, and upon an increase in pH to 7.4 
(typical of the small intestine) the embedded functional ingredient was 
released in a sustained manner (Figure  4.6(b)). The imaging agents 
were unaffected by the electrospinning process, and were thus capable 
of imaging the colon, as was demonstrated ex vivo (Figure 4.6(c)). This 
approach was further extended to fibres loaded with both a drug and 
imaging agent for simultaneous imaging and drug delivery (so- called 
theranostic applications).41
However, as was noted for fibres designed to preclude a burst 
release, simply making core/ shell materials with the exterior compart-
ment made of a pH- sensitive polymer such as Eudragit will not neces-
sarily result in the prevention of release in the stomach. Attempts to 
make such systems with 5- fluorouracil (5- FU; an anticancer drug) as 
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Figure 4.6  Data demonstrating the utility of core/ shell poly(ethylene 
oxide)/ Eudragit fibres loaded with rhodamine B in the core as colon- 
targeted imaging systems. (a) A transmission electron microscopy 
image of the fibres; (b) the rhodamine B release profile under varied 
pH conditions mimicking passage through the intestinal tract; 
(c) a photograph taken under ultraviolet light showing imaging of 
porcine colon by the fibres after they had been immersed in phosphate 
buffer to remove the Eudragit shell. The central column (control) is 
where a 50 ppm rhodamine B solution was added to the colon, while the 
left and right columns show results obtained after the fibres were placed 
in phosphate- buffered saline for 1 and 2 h, respectively, before being 
transferred to the colon sections. (Reproduced with permission from 
Jin, M.; Yu, D. G.; Wang, X.; Geraldes, C. F.; Williams, G. R.; Bligh, S. W. 
‘Electrospun contrast- agent- loaded fibers for colon- targeted MRI.’ Adv. 
Healthcare Mater. 5 (2016): 977– 985. Copyright John Wiley, 2016.)
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the active ingredient failed, for example.6 Fibres were generated with 
a blank Eudragit S100 shell and a drug- loaded core formed of PVP, EC, 
Eudragit S100 or drug alone. Clear core/ shell morphology could be 
seen by TEM, yet in all cases significant amounts of release were seen at 
pH 1.0. This arose even though the drug was only present in the core, 
and the Eudragit sheath is insoluble at pH 1.0. The authors ascribe 
this to the low molecular weight of 5- FU and its relatively high solu-
bility under acidic conditions, proposing that these drive it to diffuse 
through pores in the shell and escape into solution. The release profiles 
observed show an initial burst of release at pH 1.0, followed by a second 
burst when the pH is raised to 6.8. While these are potentially useful, 
they are not the colon- targeted profiles which the researchers hoped to 
achieve.
Similar results have been obtained by Yu and co- workers, although 
by design in this instance.42 A Teflon- coated spinneret was employed here 
to aid the electrospinning process (see section 4.2.3 above), and fibres 
prepared with a Eudragit L100- 55 (soluble at pH > 5.5) core and PVP 
sheath.42 Helicid, an extract from Chinese herbal medicine commonly 
used to treat headaches and insomnia, was present in both parts of the 
fibre. The materials were shown to give an initial burst release (loading 
dose) of the drug at pH 2 (representative of the stomach), followed by 
sustained release at pH 7, as illustrated in Figure 4.7. This arises because 
the PVP exterior dissolves very rapidly at all pH conditions, freeing the 
drug in the shell. Further release at pH 2 is prevented because the core is 
insoluble, but once the pH is raised the core too becomes soluble and the 
remainder of the drug is freed.
Other researchers have adopted innovative ways in which 
electrospun core/ shell systems can be used to target release. Zhou’s 
group performed an elegant study in which they first synthesised 
a folate- conjugated PCL–PEG copolymer, then assembled this into 
micelles with the anticancer drug doxorubicin, and finally spun the 
micelles into the core of PVA (core)/gelatin (shell) fibres.43 This was 
designed as an implantable device. The folate conjugation on the 
micelles enables them to target cancerous cells selectively, avoiding any 
damage to non- cancerous tissue. The systems were found to be able to 
release the doxorubicin incorporated over a prolonged period of time 
(> 100 h). During in vivo studies, application of the fibres directly to 
a tumour led to high local concentrations of the drug but low systemic 
levels, helpful in minimising side effects. Selective internalisation of the 
micelles to cancer cells was realised, ensuring low toxicity to normal 
tissue.
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4.5 Multifunctional materials
The core/ shell architecture of fibres from coaxial spinning naturally 
lends itself to the production of multifunctional materials, with different 
functional components loaded in the two compartments of the concen-
tric structure. One of the earliest reports of this came from Ramakrishna’s 
group, and explored the co- delivery of two model drugs, rhodamine B 
and bovine serum albumin (BSA) from PLCL fibres.44 Electrospinning 
was performed using PLCL as the shell and a drug solution in the core, 
and the location of the two active ingredients was varied systematically. 
Unsurprisingly, the drug in the shell was released much more quickly 
than when incorporated in the core. An initial burst of release was seen 
in all cases, but this was reduced when the drug was loaded in the core of 
the matrix. Dual drug release systems have also been prepared in which 
vitamin C and E derivatives were encapsulated in the core of fibres with a 
poly(acrylonitrile) shell, with potential applications in the protection of 
skin from ultraviolet light.45
Another possibility is to incorporate additional excipients into the 
fibres. A flavour enhancer can be incorporated to mask the taste of bitter 
(b)(a)
Figure 4.7  Using core/ shell fibres to give targeted biphasic release. 
(a) Transmission electron microscopy image showing the two- 
compartment structure of poly(vinyl pyrrolidone) (PVP) (shell)/Eudragit 
L100- 55 (core) systems with helicid loaded in both compartments. 
(b) Dissolution data for monolithic PVP/helicid (black) and Eudragit/
helicid (green) fibres, together with the core/ shell systems (blue). 
(Reproduced with permission from Yu, D.- G.; Liu, F.; Cui, L.; Liu, Z.- P.; 
Wang, X.; Bligh, S. W. A. ‘Coaxial electrospinning using a concentric Teflon 
spinneret to prepare biphasic- release nanofibers of helicid.’ RSC Adv. 3 
(2013): 17775– 17783. Copyright Royal Society of Chemistry, 2013.)
 
 
 
 
 
 
 
nAnofiBRes in DRuG DeL iveRy122
12
drugs, for example. Alternatively, surfactants could be added to solubilise 
poorly soluble active ingredients and/ or enhance permeation through 
biomembranes. In one example of such work, fibres were prepared 
consisting of a PVP/acyclovir core and a PVP/sucralose/sodium dodecyl 
sulfate (DDS) shell.46 Acyclovir is a potent systemic antiviral active ingre-
dient, but suffers from poor solubility. In the fibres generated, it is present 
in the amorphous form, which leads to much faster dissolution than the 
pure drug powder. Sucralose is added as a sweetener to hide the metallic 
taste of the drug, and DDS acts as a permeation enhancer. As a result of 
the latter, increased permeation through the porcine sublingual mucosa 
(cf. the drug alone) was observed. The same approach of a PVP/sucralose 
shell and PVP/drug core has also successfully been implemented with 
helicid.47 Similarly, PVP–quercetin/PVP–DDS core/shell fibres have been 
prepared.48
Multifunctional materials are of particular importance in tissue 
regeneration, and electrospun fibres have attracted some attention in this 
regard. Tang et al. prepared fibres with a core of PLGA/hydroxyapatite 
and a shell of collagen and amoxicillin.49 The latter (an antibiotic) was 
intended to prevent infections occurring in wounds, and the core to pro-
mote bone growth. The drug release rate could be tuned by varying the 
collagen concentration in the shell liquid, and it was found that the core 
could effectively prevent the ingress of fibroblast cells, which is often an 
obstacle to successful bone regrowth.
For drugs which are acidic or basic (i.e. those which can donate 
or accept a proton), the pH at which dissolution happens will have a 
profound effect on solubility. Yan et  al. have used core/ shell fibres to 
enhance the solubility of quercetin, an acidic drug which is more sol-
uble at elevated pHs.50 Fibres were prepared with a PVP core containing 
quercetin and sodium hydroxide, and a shell of PVP and citric acid 
(Figure  4.8(a) and (b)). The components were all amorphously 
distributed in the polymer matrix, which exhibited much accelerated 
dissolution over the pure drug (Figure 4.8(c)). Inclusion of the NaOH 
in the core was believed to increase the solubility and dissolution rate 
of the drug since it would be ionised upon being freed from the fibres. 
This, combined with the amorphous nature of the drug in the formu-
lation, raised the dissolution rate. Without the presence of the citric 
acid, the base in the core could have led to an increase in the pH of the 
dissolution medium (which in vivo would cause irritation or other side 
effects). The fact that an acid/ base pair existed in the material, how-
ever, led to improved functional performance but no change to the pH 
of the medium.
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Figure 4.8  The preparation of acid– base pair solid dispersions 
using coaxial electrospinning. (a) A schematic of the approach 
used; (b) a transmission electron microscopy image of the core/ 
shell poly(vinyl pyrrolidone) (PVP)–quercetin–NaOH/PVP–citric 
acid fibres; and (c) drug release data (F3 and F4 contain different 
amounts of quercetin). (Reproduced with permission from Yan, J.; 
Wu, Y.- H.; Yu, D.- G.; Williams, G. R.; Huang, S.- M.; Tao, W.; Sun, J.- 
Y. ‘Electrospun acid– base pair solid dispersions of quercetin.’ RSC Adv. 
4 (2014): 58265– 58271. Copyright Royal Society of Chemistry, 2014.)
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4.6 Other applications
The above sections have all considered small- molecule drugs, and 
represent the major challenges to which coaxial electrospinning has been 
applied in this regard. There are additionally a few further applications 
which have been explored. As has been discussed previously (section 
3.1), it is generally the case that electrospun fibres contain their func-
tional components in the amorphous physical form. This is because the 
very fast solvent evaporation in the process causes the random molecular 
arrangement present in the starting solution to be propagated into the 
solid state, and because the polymer matrices in the fibres hinder recrys-
tallisation. Dong’s team have specifically looked at using core/ shell fibres 
to prevent recrystallisation of the potent antimalarial drug artemisinin.51 
Conversion of the drug from the amorphous solid dispersion formed 
immediately after electrospinning to a crystalline material was found to 
be more rapid in monolithic blend fibres of PVP/ CA/ artemisinin than in 
coaxial systems with a PVP shell and CA/ artemisinin core.
Core/ shell fibres have been prepared with liposomes loaded in the 
core, in an attempt to ameliorate the stability issues which often plague 
liposomal formulations.52 Emulsions have also been incorporated into 
the fibre core.53 In the latter work by Viry et al., the highly soluble drug 
levetiracetam (used for the treatment of epilepsy) was loaded into fibres 
with a PLGA solution acting as the shell liquid, and the core liquid com-
prising either a drug/ PLGA solution or a water- in- oil emulsion with the 
drug in the dispersed aqueous droplets and the oil phase comprising a 
PLGA solution in dichloromethane. The emulsion fibres were able to 
extend the release time and reduce the amount of burst release seen at 
the early stages of the experiment.
Core/ shell fibres have further been exploited for the self- 
assembly of magnetic chitosan nanoparticles with potential biomedical 
applications.54 From fibres with a shell comprising PVP/ chitosan and a 
core of PVP/ Fe3O4 nanoparticles, Wang et al. were able to generate com-
posite chitosan/ Fe3O4 nanoparticles following addition of the fibres to 
acetone and drying.
4.7 Protein delivery systems
The small- molecule drugs discussed above can generally be processed 
by single- liquid electrospinning without problems, but it can be more 
desirable to prepare core/ shell systems to deliver enhanced functional 
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performance. In the case of proteins, however, coaxial electrospinning 
is often a requirement. This is because the activity of proteins is very 
dependent on their tertiary structure (a three- dimensional structure 
involving different parts of these large molecules being folded together 
and anchored by intermolecular forces such as hydrogen bonding). This 
tertiary structure is easily disrupted, leading to a loss of activity (denatur-
ation), and once it is lost often cannot be regained. Given the need to 
use volatile solvents in single- liquid electrospinning and the propensity 
of these to denature proteins, the single- liquid process often cannot be 
used to prepare protein- loaded fibres with acceptable activity.55 Further, 
the low solubility of many proteins in the non- aqueous solvents used in 
typical electrospinning processes means that only very low doses can be 
loaded.55
To resolve these problems, researchers have adopted two principal 
approaches. One is emulsion electrospinning, with protein- containing 
aqueous droplets distributed in a continuous phase, as discussed in section 
3.11.1. The second is preparing core/ shell systems by coaxial spinning. In 
such materials the core comprises a protein solution in a buffer designed 
to preserve the tertiary structure, possibly also containing stabilising 
excipients such as trehalose. The shell is a polymer solution in a volatile 
solvent.55 The potency of this approach was first demonstrated by Jiang 
et al., who used a PCL shell and a core of BSA or lysozyme and PEG.56 PEG 
was included because it is known to help stabilise proteins. The proteins 
were found to be unaffected by the electrospinning process, and through 
variation of the flow rate of the core solution the protein release profile 
could be tuned. Similar results have been seen from an analogous system 
but with dextran used instead of PEG in the core.57 Other proteins to have 
been explored in coaxial spinning include the enzyme lactose dehydro-
genase58 and gelatin.59
Romano et  al. recently reported an elegant study in which they 
used the E- green fluorescent protein to investigate the electrospinning 
and release of a biological active ingredient from core/ shell PEO/ PCL 
fibres.60 The photoluminescence spectrum of the fibres was virtually iden-
tical to the raw protein, indicating that the electrospinning process did 
not affect E- green fluorescent protein functionality (Figure 4.9). Release 
was observed to occur over an extended time period of more than 200 h.
The pH of the core protein solution has been proposed to be 
important in maintaining protein stability. Angkawinitwong et  al. 
explored the effect of varying the pH of the core solution on the stability 
for bevacizumab (an antibody potent for the treatment of cancer and 
age- related degeneration in the eye).61 Fibres were prepared with PCL as 
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the shell and a core solution buffered either to the isoelectric point (pI) 
of the protein (the pH at which it is neutral) or a pH below this. At the 
latter pH, the protein bore a net charge during electrospinning, which led 
to degradation. In contrast, the fibres fabricated at the pI ensured that 
the bevacizumab remained intact. They also permitted a constant rate of 
release to be maintained over 60 days.
A number of researchers have compared fibres from monoaxial 
and coaxial spinning. One such study produced fibres with a PCL shell 
and a core containing a fluorescently labelled BSA and compared these 
with those prepared in a blend electrospinning process.62 The core/ shell 
system was found able to reduce the initial burst release during in vitro 
dissolution experiments, as also observed for small- molecule- loaded 
core/ shell fibres (see section 4.3.1). Also working with PCL, Jansen’s 
team investigated the differences between single- liquid and coaxial 
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Figure 4.9  Data for core/ shell PEO/ PCL fibres loaded with E- green 
fluorescent protein (E- GFP). (a) Scanning electron microscopy image 
(scale bar: 100 μm) with enlargement of a single fibre in the inset (scale 
bar: 1 μm); (b) photoluminescence spectra of raw E- GFP in solution 
(red) and in the fibres (blue), with an inset showing the release of 
protein from the fibres; (c– h) confocal microscopy images (scale bars: 5 
µm) of the fibres showing the transmission (c, f), fluorescence (d, g) 
and merged (e, h) images. (Reproduced with permission from Romano, 
L.; Camposeo, A.; Manco, R.; Moffa, M.; Pisignano, D. ‘Core–shell 
electrospun fibers encapsulating chromophores or luminescent proteins 
for microscopically controlled molecular release.’ Mol. Pharm. 13 
(2016): 729– 736. Copyright American Chemical Society 2016.)
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spinning of BSA and alkaline phosphatase.63 The core/ shell systems both 
extended release for longer periods of time and proved better able to 
maintain the biological activity of the protein.
A similar study compared these two processes in the preparation 
of PLGA fibres loaded with fibroblast growth factor- 2 (FGF- 2), known to 
be important in tissue repair and stem cell proliferation and differenti-
ation.64 The protein encapsulation efficiency and release profiles were 
similar for both types of fibres, with the monolithic fibres from single- 
liquid spinning releasing the protein somewhat more rapidly, as would 
be expected. Bone marrow stem cells were cultured on the fibres, but no 
clear conclusions could be drawn as to the relative efficacy of the two 
spinning methodologies in this regard.
Chitosan has also been explored as a filament- forming matrix for 
FGF- 2, with both emulsion and coaxial emulsion (i.e. either the core or 
shell liquid is an emulsion) spinning compared as delivery systems.65 No 
intact growth factor could be found in the monolithic emulsion fibres. In 
the core/ shell case, inclusion of FGF- 2 into the core rather than the shell 
of the fibres led to the presence of more intact protein in the formula-
tion, in addition to improved cell adhesion and spreading. FGF- 2 has fur-
ther been incorporated into PCL (shell)/PEO (core) fibres.66 Sustained 
release of the active ingredient over more than 9 days was observed.
There are a number of additional studies investigating core/ shell 
fibres for the delivery of growth factors. For instance, Kong’s group 
prepared materials with a PLCL shell and a core comprising dextran and 
platelet- derived growth factor- BB.67 Smooth- muscle cells were cultured 
with the fibres, which were found to promote cell attachment and 
increase cellular activity.
In other work, nerve growth factor (NGF) has been incorporated 
into the core of PLCL shell fibres.68 These materials were explored in 
vivo in rats, and found to have potential in promoting nerve regrowth.68a 
Similar fibres have been produced with PLA shells and silk fibroin cores 
loaded with NGF, and reported to aid the growth of the elongated neurite 
cells required for nerve growth.69 Some authors have sought to prepare 
more sophisticated systems, in which the concentration of the NGF was 
varied through the thickness of the fibre mat.70 The shell of the fibres 
comprised PCL, with a PEG/ BSA/ NGF core (BSA was added as a carrier 
protein and to help stabilise the NGF). A peristaltic pump was used to 
vary the NGF concentration in the solution used for spinning, such that 
the initial fibres collected contained a different NGF content to those 
collected at the end of the experiment. The side of the mat formed of 
fibres with the higher NGF concentration led to a higher percentage of 
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cells having neurite outgrowths. Sustained release of both NGF and BSA 
was seen.
Core-shell fibres with PLGA shells and PVA/ transforming growth 
factor- β (TGF- β) cores have been produced and compared with mono-
lithic blend PLGA/ PVA/ TGF- β fibres.71 The core/ shell fibres had potential 
in directing stem cell differentiation for the treatment of spinal injuries, 
and led to slower release of the loaded growth factor than the monolithic 
fibres. However, over the timescale studied they were less effective in 
promoting differentiation than the monolithic analogues.
Vascular endothelial growth factor (VEGF) has also been 
incorporated into fibres with a PLGA shell and a dextran/ BSA/ heparin/ 
VEGF core.72 VEGF was freed from the fibres over more than 25  days, 
with only a small burst release noted. Cells could spread effectively on 
the fibres, which additionally did not cause any undesirable immune 
response. Seyednejad et al. have further explored a mixture of the poly-
ester poly(hydroxymethylglycolide- co- ε- caprolactone) and PCL as the 
shell and VEGF/ BSA as the core.73 The addition of the polyester helped 
to accelerate protein release, which is likely to be desirable since PCL 
degrades very slowly in the body (over 2– 4 years). Again, the VEGF was 
found to retain its biological activity post- electrospinning.
Multiple bioactive factors may be incorporated into a single fibre, 
as demonstrated by Chen’s group for TGF- β and stem cell affinity peptide 
E7.74 TGF- β was loaded in the core of PCL (shell)/PVP- BSA (core) fibres, 
and the peptide subsequently covalently bound to the exterior. The 
presence of the peptide promoted the initial adhesion of stem cells, while 
the TGF- β was freed from the matrices over around 20 days, maintaining 
its bioactivity throughout this time and promoting the differentiation 
of stem cells into cartilage cells. Such scaffolds hence have significant 
potential for connective tissue engineering.
Shalumon and co- workers have developed multifunctional growth 
factor- loaded fibres for bone regrowth.75 Their materials consisted of a silk 
fibroin/ chitosan shell loaded with nanosized hydroxyapatite particles, 
and bone morphogenetic protein- 2 in the core. The release of protein 
from the core aided the differentiation of stem cells into osteoblasts and 
the presence of hydroxyapatite in the shell helped to direct bone growth. 
PLGA (shell)/collagen (core) fibres co- loaded with fibronectin and 
cadherin 11 – biomolecules known to be important in bone growth and 
cell adhesion – have additionally been reported.76
Other types of biomolecules which have been processed using 
coaxial electrospinning include a model virus,77 which was incorporated 
into the core of PCL (shell)/PEG (core) fibres. These were found to release 
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the virus over more than 2 weeks, and the released virus was determined 
to be less immunogenic than the unprocessed virus. These materials could 
have great potential in the development of viral gene delivery systems for 
a range of applications where defective DNA needs to be corrected, for 
instance in cystic fibrosis or severe combined immune deficiency. Non- 
viral genes can also be delivered through the coaxial electrospinning 
technology. For instance, plasmid DNA has been incorporated into the 
core of coaxial electrospun fibres.78 A  gene delivery vector was loaded 
into the shell of the fibres, which were shown to act as extended- release 
systems potent in cell transfection over a prolonged period of time.
4.8 Cell electrospinning
Beyond proteins and other small biomolecules, researchers have also found 
it is possible to process living cells through coaxial electrospinning. This 
field of research has been pioneered by Jayasinghe, with the first report in 
2006.79 A suspension of human 1321N1 astrocytoma (brain tumour) cells 
in culture medium at a concentration of 106 cells mL– 1 was used as the core 
liquid, with a poly(dimethylsiloxane) solution as the sheath. No statistical 
differences were observed between cell viability post- electrospinning and 
of control cells passed through a needle but without any potential diffe-
rence applied. Follow- on work demonstrated that it is possible to process 
cells at very high concentrations of up to 107 per mL.80
Cell- loaded fibre mats have successfully been grafted into mice, and 
the ability of the cells to proliferate in vivo was found to be unaffected by 
the electrospinning process.81 A range of cell types has been electrospun, 
with a number of resultant applications. For instance, cardiac myocytes 
have been spun into fibres with potential application in cardiac tissue 
engineering.82
In order to ensure that the cells remain viable post- spinning, the 
collector used for cell electrospinning needs to be considered carefully, 
and differs from the metal plates or cylinders most commonly employed. 
Collection is usually into a Petri dish or other container filled with a cell 
culture medium, with a grounded ring electrode placed above or below 
this. If required, a wire mesh can be inserted into the medium to provide 
a structure on which a scaffold can be constructed. Experiments are also 
usually performed in a laminar flow hood to ensure sterility. The appar-
atus commonly used is depicted in Figure 4.10, together with an image 
of electrospun cardiac cells.82 It should also be noted that the polymers 
used for cell electrospinning must be highly biocompatible in order to 
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Figure 4.10  Cell electrospinning. (a) The experimental set- up; (b) a 
photograph taken during the spinning process; and (c) a combined 
bright- field and fluorescence image of the cell- loaded electrospun 
scaffold. The cells can be seen in green and the fibre meshes in black. 
(Reproduced with permission from Ehler, E.; Jayasinghe, S. N. ‘Cell 
electrospinning cardiac patches for tissue engineering the heart.’ Analyst 
139 (2014): 4449– 4452. Copyright Royal Society of Chemistry 2014.)
maximise viability. This, and other, detailed experimental considerations 
are discussed in some recent reviews.83
4.9 Modified coaxial spinning
As discussed above, it was initially thought that for successful coaxial 
electrospinning a spinnable shell solution was required, while the core 
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liquid did not necessarily need to be processable alone by electrospinning. 
However, this is not always the case, and it turns out that a wide variety of 
non- spinnable shell solutions can be processed too. This can be achieved 
if the core liquid is a spinnable polymer solution,84 or even a common 
solvent without a carrier polymer.85 Working with an unspinnable shell 
solution has been termed modified coaxial electrospinning in the litera-
ture. It was first reported by Han and Steckl in 2009,84 with the first 
application of the technique in drug delivery following in 2010.86 The 
latter employed a pure solvent or solvent mixture as the sheath liquid, 
and very concentrated solutions of the PVP or Eudragit L100 polymers 
as the core, yielding monolithic fibres from a two- liquid process. Coaxial 
electrospinning was successful even when the core polymer solution was 
too concentrated to be electrospun in the standard single- liquid set- up.
This work was built upon to explore the influence of the shell 
solvent on the fibre properties (morphology, diameter, etc.), and the 
modified coaxial products were found to have reduced diameters 
and greater diameter homogeneity compared to analogous materials 
from single- liquid spinning.87 A shell liquid comprising LiCl in N,N- 
dimethylacetamide (DMAc) has also been shown to be able to reduce 
the diameter of poly(acrylonitrile) (PAN) fibres, giving materials with 
smoother surfaces and reduced polydispersity.88 The presence of a blank 
solvent or solvent blend outside the polymer core is believed to perform 
a number of functions, including reducing surface tension at the exit 
to the spinneret and slowing down the evaporation of the core solvent 
(by replacing the air/ polymer solution interface with a solvent/ solution 
interface).89 This in turn can be helpful in preventing the formation of 
solid substances on the spinneret and subsequent blocking of the working 
liquid flow,90 and hence it is possible to run spinning processes for much 
longer without manual intervention. Surfactant solutions can be used to 
similar ends.91
Such processes are of interest for drug delivery applications, 
because they offer new ways to tailor the arrangement of components 
in the fibres, and in particular the possibility of preparing in one step a 
polymer fibre with a functionalised exterior. For instance, using a solu-
tion of AgNO3 as the sheath liquid and a PAN core solution, PAN fibres 
with AgNO3 at the surface can be prepared.92 Exposing these to ultra-
violet light reduces the AgNO3 to Ag nanoparticles, resulting in highly 
effective antibacterial materials. The benefit of the modified coaxial 
approach over the single- liquid monoaxial process is that it allows a 
functional ingredient to be localised at the surface; in this particular 
example, such localisation is very useful because any Ag trapped inside 
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the fibres would have no efficacy. By ensuring the Ag nanoparticles are 
only at the surface, there is no wasted material, which is beneficial in 
both cost and environmental terms. It is also possible to use a solution 
of a hydrophobic molecule such as stearic acid as the sheath, resulting 
in polymer fibres with a hydrophobic coating; this has been reported 
to improve the stability to humidity of PVP fibres, which usually are 
extremely hygroscopic.93
A direct comparison of ketoprofen- loaded CA fibres prepared by 
single- liquid electrospinning and those generated in a modified coaxial 
process with a mixture of DMAc, acetone and ethanol as the sheath 
liquid has been undertaken.94 The modified coaxial fibres were found 
to be narrower and less polydisperse in their diameters than those from 
the single- liquid experiment, as shown in Figure 4.11(a)– (f). Both sets 
of fibres contained the drug in the amorphous physical form, and the 
dissolution profiles were similar (Figure  4.11(g)). However, the modi-
fied coaxial fibres showed more linear release between 8 and 144 h, and 
reached a higher overall release percentage. This indicates that the use 
of the sheath solvent has promise in preparing high- quality drug delivery 
systems.
Similar observations have been reported for zein/ ibuprofen 
fibres,95 and for Eudragit L100/ sodium diclofenac materials using both 
blank solvent96 and a salt solution as the shell.97 A further study explored 
the preparation of fibres comprising CA and ferulic acid (an antioxidant 
commonly found in Chinese traditional herbal medicine), with PVP as 
an additional component.98 The use of a blank sheath solvent reduced 
fibre diameter and improved polydispersity as before, and the inclusion 
of PVP helped to control the rate of drug release and ameliorate the 
problem of ‘tailing off’ (a slowing down in the release rate) which often 
arises with monolithic formulations. Analogous results were reported 
for systems comprising PAN/ PVP and ibuprofen prepared using the 
modified set- up.99
Fibres prepared through the modified coaxial route have been 
explored as a template for self- assembly of solid lipid nanoparticles.100 
Materials were produced using PVP, tristearin and naproxen. Increasing 
the flow rate of the ethanol solvent used as the sheath liquid caused a 
reduction in the diameter of the composite fibres. When the fibres were 
added to water, the tristearin and naproxen spontaneously self- assembled 
into nanoparticles (see section 3.13), with narrower fibres resulting in 
smaller particles. These could play an important role in enhancing per-
meation through biomembranes, although no drug release or perme-
ation studies of the self- assembled particles were reported.
 
 
 
 
 
 
 
 
 
133CoAXiAL AnD MuLTi-AXiAL eLeCTRosPinninG
13
Figure 4.11  A comparison of ketoprofen- loaded cellulose acetate 
fibres prepared by single- liquid and modified coaxial electrospinning. 
(a– c)  Surface morphologies and diameter distribution of single- 
liquid fibres; (d– f) surface morphologies and diameter distribution 
of modified coaxial fibres; (g) dissolution profiles of the two sets of 
fibres. The scale bars in the insets of (b) and (e) represent 500 nm. 
(Reproduced from Yu, D. G.; Yu, J. H.; Chen, L.; Williams, G. R.; Wang, 
X. ‘Modified coaxial electrospinning for the preparation of high- quality 
ketoprofen- loaded cellulose acetate nanofibers.’ Carbohydr. Polym. 
90 (2012): 1016– 1023, with permission from Elsevier. Copyright 
Elsevier 2012.)
Biphasic release formulations have additionally been prepared 
from modified coaxial spinning. Here, the sheath solution is not a 
blank solvent or salt solution, but rather an unspinnable polymer solu-
tion. In one example of such work, Li et  al. generated fibres using a 
spinnable EC/quercetin solution as the core and an unspinnable PVP/ 
quercetin shell.9b They also used a poly(vinyl chloride) coating for the 
spinneret to aid the spinning process (see section 4.2.3 above). The 
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products comprised core/ shell fibres (Figure 4.12(a)). The PVP shell 
dissolved very rapidly to release a loading dose of drug, while the EC 
core then gave sustained release. The amount of release in the first 
phase could be controlled by varying the drug content in the shell 
(Figure 4.12(b)). Similar findings have been noted with paracetamol 
as the active ingredient.101
Formulations with close to zero- order release have been prepared 
from modified coaxial spinning.102 Experiments were undertaken with 
an unspinnable low- concentration CA shell  solution and a spinnable 
higher- concentration CA/ ketoprofen core. This led to fibres with a drug- 
loaded core and a shell of CA alone. The CA shell was able to ameliorate 
the burst release observed from analogous monolithic CA/ ketoprofen 
materials, and thus provide a release profile close to being zero- order 
over 96 h. This approach has additionally been demonstrated for zein/ 
ketoprofen systems.103
(a) (b)
Figure 4.12  Core/ shell ethyl cellulose (EC)/ poly(vinyl pyrrolidone) 
(PVP) fibres loaded with quercetin prepared by modified coaxial 
electrospinning. A series of fibres was prepared; formulation F2 
comprises EC/ quercetin fibres from single- liquid spinning, while  
F4– F6 are core/ shell EC/ PVP systems generated through the modified 
coaxial experiment, with increasing amounts of quercetin in the shell. 
(a) Transmission electron microscopy image of F5, showing the two- 
component architecture. (b) The results of dissolution testing, showing 
that increasing the amount of drug in the fibres leads to an increase in the 
percentage of release in the initial burst phase. (Adapted with permission 
from Li, C.; Wang, Z.- H.; Yu, D.- G.; Williams, G. R. ‘Tunable biphasic drug 
release from ethyl cellulose nanofibers fabricated using a modified coaxial 
electrospinning process.’ Nanoscale Res. Lett. 9 (2014): 258. Copyright 
Springer Ltd, 2014. This is an open access article.9b)
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4.10 Triaxial and quad- axial systems
To produce high- quality multi- compartment fibres, it is necessary 
to ensure that there is no merging between the spinning solutions. 
This means either the compartmentalised solutions need to be immis-
cible or all the solutions need to lose solvent at similar rates:  if one of 
the liquids dries faster than the others, then separation of the different 
compartments may arise. The first reports of triaxial electrospinning 
emerged from Lallave and co- workers104 in 2007 and Kalra et  al. in 
2009.105 The former report is concerned with using the resultant fibres 
to generate carbon nanotubes. The latter authors used silica in the core 
and outer layers. The middle layer comprised a block copolymer mixed 
with either magnetite nanoparticles or a second polymer, with the aim 
of making self- assembled structures in the confined space between the 
silica layers. Triaxial spinning has also been used to tune and optimise the 
mechanical properties of polystyrene/ polyurethane- containing fibres.106
The earliest example of a triaxial drug delivery system emerged 
from the work of Han and Steckl, who made fibres containing PVP and 
PCL loaded with two dyes as model drug molecules (Figure  4.13).107 
The authors were aiming to overcome the problem of burst release that 
can arise with core/ shell fibres if the shell is made of a hygroscopic (and 
therefore fast- dissolving) material. A hygroscopic shell is often desirable, 
however, in order to impart the fibres with good biocompatibility proper-
ties. A three- layer system with a drug- loaded core, hydrophobic middle 
layer and hygroscopic outer layer can combine both of these benefits 
(Figure 4.13).
In Han and Steckl’s work, they made some progress towards their 
goal by developing triaxial electrospinning and preparing materials with 
a hydrophobic exterior. Fibres were made with a core comprising PVP, 
and the middle and outer layers consisting of PCL.107 Two different dyes 
were incorporated, one in the core and one in the outer layer. The latter 
dye was released very rapidly, while sustained release from the core was 
seen. By varying the dimensions of the inner, middle and outer needles in 
the spinneret, it was possible to modulate the rate of release from the PVP 
core, while the dye in the shell was freed similarly rapidly in all cases.
Yu and co- workers, mindful of the need for the liquids being 
processed in triaxial spinning to have similar properties, have generated 
three- layer fibres from three solutions of EC containing varying 
concentrations of ketoprofen, a non- steroidal anti- inflammatory 
drug.108 The different concentrations of ketoprofen in each of the three 
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solutions resulted in fibres with a gradient distribution of the drug. The 
concentration of drug increased moving from the shell of the systems 
inwards. TEM images show that the fibres have a clear trilayer struc-
ture (Figure  4.14(a)), with all the components having the amorphous 
physical form.
Figure 4.13  Schematic showing the benefits of using triaxial 
electrospinning to prepare fibres which have a hygroscopic shell while 
preventing burst release of the incorporated drug. (a) A coaxial fibre 
with a hydrophobic shell will show sustained release, but may have 
poor biocompatibility, while (b) such a fibre with a hygroscopic shell 
will lead to rapid drug release, often obviating any benefits of the core/ 
shell structure. (c) A triaxial system with a hygroscopic sheath can both 
give sustained release and ensure biocompatibility. (d) Drug could 
also be loaded into the outer layer of the fibres to deliver a loading 
dose. (Reproduced with permission from Han, D.; Steckl, A. J. ‘Triaxial 
electrospun nanofiber membranes for controlled dual release of 
functional molecules.’ ACS Appl. Mater. Interfaces 5 (2013): 8241– 8245. 
Copyright American Chemical Society 2013.)
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(a) (b) (c)
Figure 4.14  Data on the three- layer ethyl cellulose/ ketoprofen (KET) 
fibres prepared by Yu et al. (a) A transmission electron microscopy 
image showing the internal structure of the systems; (b) the KET release 
profiles from monolithic fibres generated from each of the individual 
spinning solutions with different drug loadings; (c) the zero- order KET 
release profile of the three- layer fibres. (Reproduced with permission 
from Yu, D. G.; Li, X. Y.; Wang, X.; Yang, J. H.; Bligh, S. W.; Williams, 
G. R. ‘Nanofibers fabricated using triaxial electrospinning as zero order 
drug delivery systems.’ ACS Appl. Mater. Interfaces 7 (2015): 18891– 
18897. Copyright American Chemical Society 2015.)
As has been discussed previously, a major drawback with monolithic 
fibres is the initial burst of drug release which is typically seen. When 
monolithic fibres were prepared from the individual EC/ ketoprofen 
solutions with different drug concentrations, such burst release was 
indeed observed (Figure 4.14(b)). The release profiles are virtually iden-
tical, regardless of the drug loading in the fibres. However, the three- 
layer fibres from triaxial spinning were found to give zero- order release 
over around 20 h, with a constant rate of drug release throughout this 
time (Figure 4.14(c)).
This release profile was realised by balancing three key factors. 
EC is insoluble in water, and thus drug release from this system will be 
controlled by the rate at which the ketoprofen molecules can diffuse 
out of the polymer matrix. Drug molecules in the shell of the fibre are 
very close to the dissolution medium and thus do not have to diffuse far 
to reach the solution. The shell also has the largest surface area of the 
three compartments. The ketoprofen molecules in the middle layer have 
to diffuse further to reach the outside of the fibres, and this layer also 
has a smaller surface area. If the drug concentration were the same in 
both the shell and middle layers, there would be more rapid drug release 
from the former. However, the increase in drug concentration going 
from the shell to the middle compartment compensates both for the 
increased diffusion distance and reduced surface area, leading to both 
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compartments having the same release rate. The same considerations 
apply to the core: again, the increased drug concentration compensates 
for the greater distance the ketoprofen molecules must travel to escape 
from the fibres and the further reduced surface area.
One of the major benefits of multi- axial electrospinning is that non- 
spinnable solutions can be processed so long as at least one of the liquids 
being processed is spinnable on its own. This has been well documented for 
coaxial electrospinning, and although less explored, initial reports suggest 
it is equally true for triaxial spinning.109 Yang et al. successfully prepared 
fibres using a modified triaxial process in which the outer liquid was pure 
ethanol, the middle liquid a solution of Eudragit S100 and the core liquid 
a solution of lecithin and diclofenac sodium. Only the middle liquid here is 
individually spinnable, and the authors hence propose that a triaxial pro-
cess can be undertaken with only one spinnable liquid so long as the two 
non- spinnable ones are not in contact.109 The Eudragit/ lecithin/ diclofenac 
fibres were found to act as pH- sensitive drug delivery systems, with the 
Eudragit precluding release at acidic pH. At neutral pH, diclofenac was 
released in a novel two- stage process. Some drug was freed directly into 
solution upon dissolution of the Eudragit, but the majority of the drug 
and lecithin initially combined to form hydrophobic nanoparticles. These 
subsequently freed the embedded diclofenac, leading to both sustained 
release and increased permeation through the intestinal mucosa.
The modified triaxial approach has further been applied to prepare 
nanoscale drug depot fibres.110 A  solvent sheath liquid was employed 
to surround a CA middle layer, which in turn encompassed a core com-
prising a ferulic acid solution. This led to a system where partially crys-
talline ferulic acid was trapped inside a CA- based fibre. The release 
rate of the drug was controlled by its rate of diffusion through the CA, 
which resulted in close to zero- order release over around 36 h.  These 
fibres showed reduced initial burst and tailing- off effects compared to 
monolithic CA/ ferulic acid materials prepared from modified coaxial 
spinning. The drug depot fibres could not be prepared directly in coaxial 
electrospinning, because rapid solidification of the shell CA led to 
blocking of the spinneret.
Given the paucity of reports on three- liquid electrospinning, it is not 
surprising that relatively little work has been done to explore the effect of 
the processing parameters on the success of the process. However, some 
detail is known on the effect of solvent volatility and polymer molecular 
weight for systems of PCL and CA.111 Fibres were prepared with a CA 
shell, PCL intermediate layer and a mineral oil core. The latter was then 
removed by dissolution in octanol to produce hollow materials. It was 
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found that for successful electrospinning it was important to have the 
outer working liquid composed of a more volatile solvent system than the 
middle liquid, and also for the molecular weight of the outer polymer to 
be greater than or equal to that of the middle polymer.
There are only a few reports of triaxial spinning in the literature so 
far. This is most likely due to the difficulty in equilibrating the multiple 
liquid interfaces and the rate of solvent evaporation in a concentric jetting 
process with three or more coflowing liquids. On the other hand, there 
has been much effort in generating multilayered particles via triaxial and 
multi- axial electrospraying, the sister technique of electrospinning. As 
described in Chapter 2, electrospraying and electrospinning use the same 
set- up and differ only in the viscoelastic properties of the working liquids, 
which are primarily determined by the polymer concentrations and 
molecular chain length. The solvent choices that are optimal for coaxial 
and multi-axial electrospray could be helpful for optimising solvent 
choices and the handling of multiple liquids in coaxial and multi- axial 
electrospinning. Interested readers are directed to Chapter 6, section 6.8, 
for discussions on electrospraying.
It is possible in principle to process four, five or even more liquids: the 
complexity of such processes increases rapidly with the number of liquids 
being processed, however, which explains why only one report of a four- 
fluid electrospinning process could be found in the literature.112 In this work, 
Labbaf et  al. used a four- needle (quad- axial) spinneret and electrospun 
four- layer core/ shell fibres made of different biocompatible polymers: 
PEG, PLGA, PCL and poly(methylsilsesquioxane). The multilayered four- 
liquid electrospinning technique has significant potential in drug delivery 
applications, however, as it offers the advantages of achieving in one formu-
lation the delivery of multiple active pharmaceutical ingredients in a time- 
dependent fashion as demanded by the course of treatment.
4.11 Conclusions
This chapter has introduced the concept of coaxial electrospinning, 
and provided some details on how to implement the experiment. We 
have then discussed the various ways in which the approach has been 
applied to drug delivery, including the prevention or reduction of 
burst release, giving biphasic or targeted release and preparing multi-
functional materials. Its utility in processing more complex active 
biomolecules such as proteins, and even cells, has been considered, as 
has the modified coaxial electrospinning process where only the core is 
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spinnable. Finally, the possibilities of triaxial and quad- axial spinning 
and the layered materials it can produce have been enumerated. 
Overall, it is clear that multi- axial electrospinning offers the ability to 
generate increasingly complicated nano- and micro- scale architectures, 
with concomitantly enhanced functional performance. The caveat is 
that the experiment becomes increasingly complex as the number of 
liquids being processed increases; this is particularly important when 
consideration is given to scaling up the process. We will return to this 
topic in Chapter 7.
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Side- by- side electrospinning
5.1 Introduction
Side- by- side electrospinning is a two- liquid process, and in many ways 
can be regarded as a companion technique to coaxial spinning. Rather 
than the two liquids being nested inside one another as in the coaxial pro-
cess, however, they are placed adjacent to one another (Figure 5.1(a)). 
As for coaxial spinning, the structure of the spinneret is propagated into 
the solid products, and this should result in so- called Janus fibres with 
the two sides different (Figure 5.1(b)).
Janus fibres differ from core/ shell fibres in that both parts of the 
fibre are in contact with the surrounding milieu, while in a core/ shell 
fibre the shell protects the core. Thus, while for core/ shell fibres drug 
release from the shell will occur prior to release from the core, release 
from the two sides of the Janus fibres can occur concomitantly. This is 
potentially very useful. For instance, fibres with the two sides made from 
different polymers could be prepared with a different drug loaded in 
each, to release the two individual active ingredients at the same time 
but with different rates. This delivery modality might also be delivered 
with a mixture of two different types of monolithic fibre, but with such 
a mixture there is a risk of the two fibre populations separating during 
the release process. This might result in the two drugs being released in 
different parts of the body. With the Janus materials, each individual fibre 
has two sides and contains both drugs, so even if the fibre mat breaks up 
the two drugs will still be delivered concomitantly.
The first report of side- by- side spinning came from Gupta and 
Wilkes in 2003.1 These authors prepared fibres where one side comprised 
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poly(vinyl chloride) (PVC) and polyurethane (PU), and the other PVC/ 
poly(vinylidene fluoride) (PVDF). Since then there have been a few more 
reports of Janus fibres, but despite its great potential this area of work 
has received much less attention than coaxial electrospinning.
5.2 Experimental considerations
5.2.1 Challenges in side- by- side spinning
The main reason for the paucity of reports of Janus fibres from side- by- 
side electrospinning arises from the difficulty in generating integrated 
and homogeneous products when a standard spinneret is used. In the 
coaxial (or indeed triaxial) modality, the liquids are nested one inside 
another, and the charge imparted at the spinneret is spread across the 
liquid jet as it is emitted. This means that the liquids travel together from 
the Taylor cone towards the collector, and in general core/ shell- type 
architectures are obtained. However, with the side- by- side spinneret the 
two liquids emerge from adjacent needles, with both bearing the same 
charge polarity and only a small interfacial contact area. This will lead to 
extensive Coulombic repulsions between the two jets at the Taylor cone 
and beyond, and tends to cause separation of the two liquids.
The properties of the two liquids being processed also need to 
be carefully considered: for successful production of a Janus fibre, it is 
important for them to behave in a similar fashion under the influence 
of the electrical field. If one liquid charges or dries much faster than the 
other, this is likely to lead to phase separation and clogging of the needle.
Because of this difficulty, the majority of electrospun Janus 
fibres prepared to date use the same polymer for both working liquids. 
For instance, Liu’s group have prepared Janus fibres with magnetic– 
fluorescent properties using poly(methyl methacrylate) for both sides.2 
In other work, Lv et  al. have generated Janus CeO2/ SiO2 fibres by first 
spinning two poly(vinyl pyrrolidone) (PVP) solutions containing inor-
ganic precursors and then calcining the product.3 Liu and co- workers 
(a) Janus fibres(b)
Figure 5.1  The use of side- by- side electrospinning to prepare Janus 
fibres. (a) The side- by- side spinneret, and (b) the resultant Janus fibres.
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have similarly used Janus fibres with both sides based on PVP as sacrifi-
cial templates to yield inorganic materials.4
5.2.2 spinneret design
The simplest design one can envisage for side- by- side spinning 
comprises two metal capillaries aligned in a parallel manner, as shown in 
Figure 5.1(a). Although there are a number of issues with this, as iden-
tified above, some researchers have successfully used such a spinneret 
to generate Janus products.4, 5 It has been shown by Chen et al. that the 
angle between the two capillaries can be varied to adjust the width of 
the two sides of the Janus fibres produced.6 In this work, solutions of 
Eudragit L100 and PVP were electrospun through a side- by- side spin-
neret with the angle between the two capillaries varied between 40 and 
70º (Figure  5.2). An increasing angle led to narrower fibres, and the 
central interface between the two sides of the fibre became less distinct 
(Figure 5.3). The flow rates of the two sides could also be varied to tune 
the composition of the electrospun products. In this specific case, the 
Figure 5.2  Varying the angle between the capillaries in a side- by- side 
electrospinning experiment, showing (a) the spinneret design with the 
angle θ marked; (b) a photograph of the spinneret; (c) the experimental 
set- up; and (d) the compound Taylor cone. (Reproduced with 
permission from Chen, G.; Xu, Y.; Yu, D. G.; Zhang, D. F.; Chatterton, 
N. P.; White, K. N. ‘Structure- tunable Janus fibers fabricated using 
spinnerets with varying port angles.’ Chem. Commun. 51 (2015): 4623– 
4626. Copyright Royal Society of Chemistry 2015.)
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PVP side of the fibres was loaded with rhodamine B (a pink dye) and the 
Eudragit side with 8- anilino- 1- naphthalenesulfonic acid ammonium salt 
(a fluorescent probe), and altering the flow rates of the two sides allowed 
the colour of the fibres under ultraviolet light to be varied.
To overcome the issues identified above using a spinneret simply 
comprising two parallel needles, a number of different approaches have 
been explored. These focus on preventing the two liquids from separ-
ating when they leave the spinneret. One approach, used by Ma et al., is 
to feed the liquids into a plastic nozzle after they exit the parallel metal 
(a) (b)
(c)
(e)
(d)
Figure 5.3 Fibres produced with angles of (a) 40; (b) 50; (c) 60; and 
(d) 70º between the spinneret ports. (e) The relationship between the 
fibre diameter and angle. (Reproduced with permission from Chen, G.; 
Xu, Y.; Yu, D. G.; Zhang, D. F.; Chatterton, N. P.; White, K. N. ‘Structure- 
tunable Janus fibers fabricated using spinnerets with varying port 
angles.’ Chem. Commun. 51 (2015): 4623– 4626. Copyright Royal Society 
of Chemistry 2015.)
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capillaries.7 This is depicted schematically in Figure 5.4. The nozzle holds 
the two liquids together as they exit the spinneret, increasing the contact 
area between them, spreading the charge around the exterior of the two 
liquids and helping to ensure homogeneous Janus products.
Yu et  al. have employed a similar spinneret design, using a short 
length of Teflon tube to coat the parallel capillaries (Figure  5.5).8 The 
coating performs the same role as the plastic nozzle used by Ma. It was 
Metal capillaries
Plasc nozzle
Figure 5.4  The spinneret developed by Ma et al.7
(a) (b)
(c) (d)
Figure 5.5  A Teflon- coated side- by- side spinneret. Schematics are 
shown of (a) the experimental set- up and (b) the charge localisation 
around the spinnerets during electrospinning. Pictures of the (c) side- 
by- side and (d) Teflon- coated spinneret are also shown. (Reproduced 
with permission from Yu, D. G.; Yang, C.; Jin, M.; Williams, G. R.; Zou, 
H.; Wang, X.; Annie Bligh, S. W. ‘Medicated Janus fibers fabricated 
using a Teflon- coated side- by- side spinneret.’ Colloids Surf. B 138 
(2016): 110– 116. Copyright Elsevier 2016.)
 
 
 
 
 
 
 
 
nAnofiBRes in DRuG DeL iveRy154
154
found that a smooth and continuous spinning process could be performed 
using the Teflon coating, leading to homogeneous fibres with clear Janus 
structure. The use of a dye in each of the liquids allowed the authors to see 
a clear compound Taylor cone (Figure 5.6). However, when the experi-
ment was undertaken without the coating, the two liquids were observed 
to separate upon exiting the spinneret, resulting in a fibre mat which was 
visibly inhomogeneous (Figure 5.6). The addition of the Teflon coating 
is thus crucial for a successful experimental set- up. A microfluidic device 
has been employed as the spinneret to similar ends by Lin et al.9 In this 
approach, the two liquids flow adjacent to one another and in contact for 
some time before exiting the device.
An alternative route to ensure high- quality Janus structures was 
reported in some recent work.10 Rather than placing the two capillaries 
(a) (b) (c)
(f) (e) (d)
Figure 5.6  The side- by- side electrospinning process using a Teflon coated 
spinneret explored by Yu et al.8 (a) The experimental set- up; (b) a digital 
photgraph of the electrospinning process with the Teflon- coated spinneret; 
(c) use of the Teflon- coated spinneret leads to a compound Taylor cone with 
two distinct sides; (d) the fibre mat generated with the uncoated spinneret is 
clearly inhomogeneous, as a result of the two solutions separating on exiting 
the spinneret, as shown in (e); (f) a schematic of the influence of the Teflon 
coating: (A) an uncoated spinneret leads to the separation of the working 
liquids because of repulsive forces Ft (between the two Taylor cones), Fs 
(between the two straight liquid jets) and Fc (between the two coils), while 
in (B) the Teflon coating encourages formation of an integrated Janus 
Taylor cone. (Reproduced with permission from Yu, D. G.; Yang, C.; Jin, 
M.; Williams, G. R.; Zou, H.; Wang, X.; Annie Bligh, S. W. ‘Medicated Janus 
fibers fabricated using a Teflon- coated side- by- side spinneret.’ Colloids Surf. 
B 138 (2016): 110– 116. Copyright Elsevier 2016.)
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of the spinneret adjacent to one another, Yu et  al. took a different 
approach of nesting one capillary inside another (a so- called ‘acentric 
spinneret’; Figure 5.7). When working with PVP and shellac solutions, 
this led to a reduced tendency for the two polymer solutions to separate 
upon leaving the spinneret and the observation of more integrated Janus 
structures. The quality of the fibres produced was improved again if the 
acentric spinneret was incorporated in the centre of a larger needle and 
a pure solvent flowed around the outside of the two polymer solutions.
Figure 5.7  Different spinnerets explored for side- by- side 
electrospinning by Yu et al.10 The standard side- by- side spinneret is 
shown in (a); this leads to a small contact area between the two liquids 
(b), and as a result (c) the polymer solutions tend to separate when 
leaving the spinneret. Using a nested ‘acentric’ spinneret (d) spreads 
the charge around the exterior of the two liquids (e), leading to much 
less separation, as depicted in (f). The addition of a shell compartment 
(g) improves the situation still further, (h) spreading the charge over the 
shell compartment and (i) resulting in smooth electrospinning processes 
with no separation of the two polymer components. (Reproduced with 
permission from Yu, D. G.;  Li, J. J.; Zhang, M.; Williams, G. R.  ‘High 
quality Janus nanofibers prepared using three- fluid electrospinning,’ 
Chem. Commun. 53 (2017): 4542– 4545. Copyright Royal Society of 
Chemistry 2017.)
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5.2.3 other considerations
In order to establish a successful electrospinning process to generate 
Janus fibres, in addition to the spinneret design the same solution and 
processing parameters as have been discussed previously (see sections 
2.5, 3.2 and 4.2) must be considered. The voltage, solvent, polymer con-
centration, flow rate and spinneret- to- collector distance all need to be 
optimised. The considerations are essentially the same as for the coaxial 
process, and so they will not be discussed in detail here again. The rate 
at which the two liquids charge and dry under the electrical field will 
be particularly important for side- by- side spinning, and careful choice 
of the polymer concentrations and solvent/additive combinations such 
that both liquids can be successfully processed with the same voltage and 
spinneret- to- collector distance will be required.
As for the coaxial experiment, we recommend that the starting 
point for a side- by- side process is to understand and optimise the 
spinning of the two liquids individually before moving on to two- liquid 
work. The use of one or more dyes in the liquids, at least in initial side- 
by- side experiments, can be very beneficial to visualise the Taylor cone 
to ensure there are two clear compartments with no blending of the 
liquids.
5.3 Janus fibres in drug delivery
At the time of writing, there are only three reports of the use of Janus 
fibres in drug delivery. The first comes from Yu and co- workers, who 
used a Teflon- coated spinneret to facilitate the production of high- quality 
Janus fibres.8 One side of the fibres was made of PVP, and the other of 
ethyl cellulose (EC) with small amounts of PVP doped in it. Ketoprofen 
(KET) was used as a model drug, and incorporated into both sides of the 
fibres. The intention was to produce biphasic drug delivery systems, with 
the PVP compartment dissolving rapidly to release a loading dose of KET 
and rapidly raise the plasma concentration into the therapeutic window. 
The EC side then provides extended drug release, ensuring a thera-
peutic concentration of the drug is maintained for a sustained period of 
time. Clear Janus structures were produced, as shown in Figure 5.8(a). 
Varying the amount of PVP doped into the EC side of the fibres permitted 
the second (sustained) phase of release to be tuned, with greater PVP 
contents resulting in both more rapid release and also in a larger overall 
release percentage (Figure 5.8(b)).
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Similar biphasic release has been reported for fibres prepared using 
poly(acrylonitrile) (PAN) and PVP for the two sides.11 Most recently, Yu’s 
team used an acentric spinneret (see section 5.2.2) to prepare Janus 
fibres with both sides comprising PVP.12 One spinning solution was made 
from a high- molecular- weight and electrospinnable PVP (molecular 
weight (Mw)  =  360 kDa) and contained helicid as a model drug. The 
second comprised an unspinnable solution of PVP (Mw  =  8 kDa) and 
sodium dodecyl sulfate (SDS; a permeation enhancer). It proved pos-
sible to generate Janus fibres from these two solutions, showing that, 
just as with coaxial electrospinning, only one fluid need be individually 
electrospinnable to yield fibres. The fibres led to rapid release of helicid, 
and the presence of SDS accelerated the permeation of the drug through 
porcine sublingual mucosae ex vivo.
Figure 5.8  Biphasic release from electrospun Janus fibres. (a) Fibres 
prepared with one side comprising poly(vinyl pyrrolidone) (PVP)/ 
ketoprofen (KET) and the other ethyl cellulose (EC)/ KET doped with a 
small amount of PVP; (b) the effect of changing the PVP content in the EC 
side of the fibres on the release profile. F1 and F2 are control fibres made 
of PVP/ KET and EC/ KET, respectively, and F3– F6 are Janus fibres with 
increasing amounts of PVP in the EC side (F3: 0% w/w PVP; F4: 3.7%; 
F5: 7.1%; F6: 16.1%). The pure PVP fibres (F1) lead to very rapid release, 
while the pure EC fibres (F2) free the drug into solution only very slowly. 
The Janus fibres combine both these release modalities, to provide an 
initial burst of release followed by sustained release. Increasing amounts 
of PVP in the EC side of the fibres lead both to more rapid release in the 
sustained phase, and also to a greater extent of release being reached 
overall. (Reproduced with permission from Yu, D. G.; Yang, C.; Jin, M.; 
Williams, G. R.; Zou, H.; Wang, X.; Annie Bligh, S. W. ‘Medicated Janus 
fibers fabricated using a Teflon- coated side- by- side spinneret.’ Colloids 
Surf. B 138 (2016): 110– 116. Copyright Elsevier 2016.)
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5.4 Conclusions
This chapter has considered the possibility of preparing Janus fibres 
from side- by- side electrospinning. These structures are companion 
structures to the core/ shell architecture resulting from coaxial spinning. 
The side- by- side experiment is much more technically challenging to 
implement than coaxial spinning, however, because of the tendency of 
the two liquids to separate upon exiting the spinneret. As a result, there 
is very little work reporting Janus fibres for drug delivery. However, the 
results reported to date do suggest that they have potential in this field. 
Encouragingly, a number of significant improvements to the experi-
mental protocol have recently been developed, leading to much higher- 
quality Janus products being generated. It is expected that these will 
permit researchers to accelerate progress in this field over the coming 
years, such that the true potential of Janus nanofibres in drug delivery 
can be realised.
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6
Alternative nanofibre fabrication 
approaches
6.1 Introduction
The previous chapters have all focused on electrospinning as the means 
of fibre formation, since this is the technique which has to date received 
by far the most research attention. There exists a range of other, less 
explored, technologies for fibre production, however, and these will 
all be discussed briefly in the context of drug delivery in this chapter. 
Further details on the principles of many of these techniques can be 
found in recent reviews by Luo et al.1 and Qi and Craig.2
6.2 Alternating current electrospinning
Electricity comprises a flow of electrons (negatively charged sub-
atomic particles). In direct current (DC; used for the vast majority of 
electrospinning work) the electrons flow in one direction continually. It 
is also possible to have alternating current (AC), which is used to power 
most electrical devices in the home. AC involves a periodic change in the 
direction of current flow: that is, the electrons first flow in one direction 
and then switch to flow in the reverse direction. The switch between 
directions is repeated many times per second and is known as the fre-
quency of the AC. Using an AC power supply rather than the conven-
tional DC supply was first shown to generate polymer- based nanofibres 
in 2004.3
The experimental set- up for AC electrospinning is similar to that 
for the DC process, but it does not require a grounded collector. Because 
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the current alternates, the fibres produced at one instant in time carry a 
positive charge, while those generated shortly thereafter have a negative 
charge. The positive and negative fibres thus discharge on each other, 
which results in an aerogel plume of fibres, as depicted in Figure 6.1(a). 
The frequency of the AC current determines whether charge carriers 
of one polarity have sufficient time to charge the solution and result in 
spinning. The optimal AC frequency is material- dependent and typically 
in the range of 50 Hz– 1 kHz.4
The AC approach has been explored for the fabrication of drug- 
loaded fibres in a few recent studies. In one, Balogh et al. undertook a 
direct comparison of fibres prepared by DC and AC spinning.5 They used 
the beta- blocker carvedilol as a model drug, and fibres were generated 
using three different polymers: Eudragit EPO, a cationic copolymer sol-
uble below pH 5.0; Eudragit L100- 55, an anionic polymer soluble above 
pH 5.5; and the neutral polymer poly(vinyl pyrrolidone) (PVP). It was 
found that fibres could be generated with all three polymers from both 
types of spinning (Figure 6.1(b)), but that it was possible to use much 
faster flow rates in the AC process. With DC spinning, a maximum 
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Figure 6.1  Alternating current electrospinning for fibre production. 
(a) The plume of fibres produced; (b) fibres produced from direct 
current electrospinning (DCES) and alternating current electrospinning 
(ACES) (E: Eudragit; CAR: carvedilol); (c) dissolution profiles for the 
fibres. (Adapted with permission from Balogh, A.; Cselko, R.; Demuth, 
B.; Verreck, G.; Mensch, J.; Marosi, G.; Nagy, Z. K. ‘Alternating current 
electrospinning for preparation of fibrous drug delivery systems.’ Int. 
J. Pharm. 495 (2015): 75– 80. Copyright Elsevier 2015.)
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flow rate of 5 ml h– 1 could be achieved, whereas with AC this could be 
increased to up to 40 ml h– 1. All fibres, from both processes and made 
from all polymers, existed as amorphous solid dispersions. The drug 
release profiles were studied, and the AC and DC fibres were found to be 
indistinguishable in their performance (Figure 6.1(c)).
The same team have also compared AC and DC electrospinning 
of blends of hydroxypropylmethylcellulose (HPMC) and poly(ethylene 
oxide) (PEO) with the poorly water- soluble diuretic spironolactone.6 
Both HPMC and PEO alone could be processed by the DC approach. In 
contrast, AC electrospinning of HPMC led to a mixture of droplets and 
fibres, and high- molecular- weight PEOs did not yield any solid products 
at all in the AC method. Selecting appropriate blends of the two polymers, 
however, permitted high- quality fibres to be formed via AC spinning.
AC processing of HPMC or PEO with spironolactone also proved to 
be problematic, but again with the right mix of HPMC and PEO drug- 
loaded fibres could be generated. These were able to accelerate the 
dissolution rate of the drug, even at loadings of up to 40% w/ w. The AC- 
generated fibres were found to be several orders of magnitude thinner 
than the DC electrospun fibres despite the flow rate being three times 
faster in the AC process.
Similar observations have been reported using HPMC acetate suc-
cinate (HPMCAS) and spironolactone.7 HPMCAS could not be processed 
by either DC or AC electrospinning; the addition of PEO permitted fibres 
to be produced with the DC approach, but not using AC, and the addition 
of an ionic surfactant or salt was required to produce high- quality fibres 
with AC spinning. As with HPMC, the HPMCAS fibres led to a significant 
enhancement in the dissolution rate.
It is thus clear that AC electrospinning is similarly effective to the 
DC approach in producing drug delivery systems. Although its use in this 
regard is in its infancy, given the fact it allows higher throughput than the 
DC technique, it seems certain that this is an approach which is likely to 
receive much more attention in the coming years.
6.3 Melt electrospinning
Another variant of electrospinning which has attracted some attention 
in the drug delivery sphere is the melt process. This is discussed in 
detail in a recent review.8 In brief, the process is analogous to the solu-
tion electrospinning discussed in previous chapters, but in place of a 
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polymer solution a melt is used. This adds some complexity to the pro-
cess, because the syringe and spinneret must be heated to maintain the 
polymer in its liquid state. Further, the elevated temperature can poten-
tially lead to drug degradation, since many drugs are thermally labile. 
The fibres produced in melt spinning are typically found to have larger 
diameters than those from the solution route due to the significantly 
higher viscosity of a polymer melt than its solution form. The apparatus 
used is depicted in Figure 6.2.
Despite these apparent disadvantages, there are a number of 
attractive aspects of the melt spinning process, not least the fact that it 
obviates the need to handle large volumes of volatile solvents. This both 
renders the process safer, particularly if it is to be performed on the larger 
scale, and precludes any solvent contamination in the products.
The first report of a melt electrospun drug delivery system came 
from Nagy and co- workers, who prepared melt- spun fibres of Eudragit 
Figure 6.2  The apparatus used for melt electrospinning. (Reproduced 
with permission from Brown, T. D.; Dalton, P. D.; Hutmacher, D. 
W. ‘Melt electrospinning today: An opportune time for an emerging 
polymer process.’ Prog. Polym. Sci. 56 (2016): 116– 166. Copyright 
Elsevier 2016.)
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EPO loaded with carvedilol.9 The drug and polymer were melted and 
mixed to form a homogeneous solid mixture prior to spinning, and then 
processed as in a solution experiment but with both the syringe and spin-
neret heated. The melt fibres were much wider than analogous systems 
processed through solution spinning, with those from melt processing 
having diameters of 5– 30 µm, as compared to 300– 1000 nm for the solu-
tion- spun fibres (Figure  6.3). The drug was completely amorphously 
dispersed in the fibres regardless of the processing route. This is as 
expected for solution spinning, and in the melt case was thought to 
be because the experiment was carried out above the melting point of 
carvedilol. The melt fibres freed their drug loading faster than the solu-
tion- spun analogues, despite the much larger surface area of the latter. 
The authors ascribed this to the fact that the melt fibres had a loose non- 
woven structure, whereas those prepared by solution spinning were 
more tightly packed (Figure 6.3).
This work has been built on to blend plasticisers with the polymer 
Eudragit E and carvedilol active ingredient.10 The plasticisers triacetin, 
Tween 80 and polyethylene glycol were all investigated with the goal of 
reducing the melting point of the polymer/ drug blend and thereby per-
mitting lower temperatures to be used for spinning. This should reduce 
the likelihood of any degradation occurring. High- performance liquid 
chromatography data obtained on dissolved fibres revealed that the add-
ition of plasticisers clearly reduced the amounts of carvedilol degrad-
ation products present after melt spinning.
(a) (b)
Figure 6.3  Scanning electron microscopy images of Eudragit E / 
carvedilol fibres prepared by (a) solution and (b) melt electrospinning. 
(Reproduced with permission from Nagy, Z. K.; Balogh, A.; Dravavolgyi, 
G.; Ferguson, J.; Pataki, H.; Vajna, B.; Marosi, G. ‘Solvent- free melt 
electrospinning for preparation of fast dissolving drug delivery system 
and comparison with solvent- based electrospun and melt extruded 
systems.’ J. Pharm. Sci. 102 (2013): 508– 517. Copyright Elsevier 2013.)
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A direct comparison of poly(ε- caprolactone) (PCL) fibres generated 
by the melt and solution- spinning approaches has been reported by Lian 
and Meng.11 These authors prepared curcumin- loaded fibres of around 
4 µm in diameter using both techniques. They found that there was a 
greater tendency for the curcumin to crystallise using the solution route 
(a result of its low solubility in the solvent used for spinning). The melt 
fibres led to a reduced burst release and a slower release rate. These 
findings were attributed to the solution- spun fibres having a porous struc-
ture, which permitted both water ingress and the incorporated curcumin 
to diffuse out of the polymer matrix.
Melt electrospinning typically generates micron- size fibres. In a 
recent effort, however, highly uniform and precise deposition of PCL 
nanofibres (817 ± 165 nm) was achieved using a method known as melt 
electrospinning writing.12 This combines melt electrospinning with addi-
tive manufacturing (three- dimensional (3D) printing) technology, using 
a computer- controlled extruder moving on a translational stage to build a 
3D structure layer by layer. The 3D fibrous architecture produced allowed 
efficient in vitro proliferation of primary human mesenchymal stromal 
cells. The melt electrospinning writing technology can produce regular 
3D morphologies in a highly controllable and reproducible fashion, and 
is currently being explored for a range of tissue- engineering applications.
Although melt electrospinning has received much less research 
interest than the solution process, it appears to be equally as flexible in 
terms of handling multiple fluids, and coaxial melt spinning has been 
reported.13 The initial melt spinning experiment is perhaps harder to 
establish than the solution route, but it is clear that this approach has a 
great deal of unexplored potential in the development of drug delivery 
systems.
6.4 Centrifugal spinning
Centrifugal spinning employs a rotating polymer source to generate fibres. 
Several centrifugal methods can generate nanofibres. These include 
Forcespinning, which employs rotary speed of above 2000 revolutions 
per minute (rpm),14 electrocentrifugal spinning,15 which combines a 
strong electric potential (as in electrospinning) with centrifugal force, 
and pressurised gyration, which adds high pressure (> 10 kPa) to centri-
fugal spinning to enhance fibre formation (see section 6.8).16
These approaches can be applied to polymer solutions and 
emulsions, and if the source can be heated also to a polymer melt 
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(Figure 6.4).17 This technique has received some attention in the context 
of drug delivery. For instance, Zander prepared PCL fibres using both the 
solution and melt variants of the centrifugal technique.18 This author 
employed spinning speeds in the range of 3000– 18,000 rpm, yielding 
fibres of ca. 10 μm in diameter. PC12 neuron cells could be successfully 
grown on the fibres, demonstrating that they have potential in nerve 
tissue engineering.
In other work, centrifugally spun PCL/PVP fibres containing the 
antibiotic tetracycline have been produced from a methanol/ chloroform 
solution at 2000 rpm.19 These were sub- micron in their diameters, and 
highly aligned. The rate of drug release could be tuned by varying the 
PCL/ PVP ratio in the fibres, and the fibres were found to be effective in 
inhibiting bacterial growth. Core/ shell fibres for the delivery of growth 
factors have further been reported from centrifugal spinning of a water- 
in- oil emulsion, with PCL dissolved in the oil phase.20
Fibres have also been made using a melt process with sucrose (a 
sugar dimer) loaded with a range of poorly water- soluble drugs, including 
olanzapine (an antipsychotic medicine) and piroxicam (a non- steroidal 
anti- inflammatory).21 The fibres were 10– 15 μm in diameter, and the dis-
solution rate of the drugs enhanced after fibre formation.
Since the centrifugal spinning approach is a simple one which 
allows relatively large- scale production of fibres,22 it appears to have 
much promise in the drug delivery field. It can also be coupled to 
electrospinning, with both centrifugal and electrical forces applied 
Top heater
Boom 
heater
Spinneret
Fibres collect here
Figure 6.4  A schematic diagram of the apparatus used for centrifugal 
spinning. (Adapted from Zander, N. E. ‘Formation of melt and solution 
spun polycaprolactone fibers by centrifugal spinning.’ J. Appl. Polym. Sci. 
132 (2015): 4126918.)
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simultaneously to drive solvent evaporation.15 Such centrifugal 
electrospinning uses the same equipment as the standard centrifugal 
process but additionally applies a high voltage between the rotating 
spinneret and the collector. It has been reported to lead to significantly 
higher throughput than standard electrospinning,23 and to produce 
highly aligned fibres.23b, 24 Centrifugal electrospinning has further been 
demonstrated to have potential in the production of drug delivery 
systems, with a recent report of PVP fibres loaded with the antibiotic 
tetracycline hydrochloride.25 Production rates of up to 120 g h– 1 could 
be realised.
6.5 Solution blowing and melt blowing
A pressurised gas can be exploited to produce nanoscale fibres, starting 
either with a polymer solution in a technique known as solution blowing 
or from a molten polymer source (melt blowing). The experimental 
apparatus used is similar to electrospinning, in that a polymer solution 
(or melt) is expelled through a needle (spinneret) at a controlled rate. 
The spinneret is surrounded by an outer nozzle which applies pressured 
gas to the fluid being expelled, as illustrated in Figure 6.5.26
A few studies have explored solution blowing in drug delivery, 
with the first such work being from Oliveira et  al. in 2013.27 These 
authors prepared poly(lactic acid) (PLA) fibres loaded with the hor-
mone progesterone, which can be used to regulate the reproductive 
cycle in livestock. Fibres were produced from solutions with 6% w/ v 
PLA and between 0 and 8% w/ v progesterone (Figure 6.6(a)). The PLA 
is semi- crystalline both before and after processing, while the drug is 
amorphous post- spinning. The fibres behave very similarly in terms 
of their release behaviour, regardless of the amount of drug loaded 
(Figure 6.6(b)).
Polymer 
soluon
Gas
Gas
Cone of ejected 
soluon
Figure 6.5  The apparatus used for solution blow spinning or melt 
blowing. (Adapted from Souza, M. A.; Sakamoto, K. Y.; Mattoso, 
L. H. C. ‘Release of the diclofenac sodium by nanofibers of poly(3- 
hydroxybutyrate- co- 3- hydroxyvalerate) obtained from electrospinning 
and solution blow spinning.’ J. Nanomater. 2014 (2014): 129035.)
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A study comparing electrospun and solution- blown fibres of poly(3- 
hydroxybutyrate- co- 3- hydroxyvalerate) loaded with sodium diclofenac 
has also been reported.26 The drug- loaded fibres were slightly larger in 
diameter when generated by electrospinning, and the size uniformity 
was higher through solution blowing. In general there was a greater 
amount of burst release seen with the electrospun fibres, but otherwise 
there were no clear trends in the drug release data.
Solution- blown fibres have additionally been created loaded with 
oil extracted from the medicinal plant Copaifera sp., which is often 
explored for antimicrobial purposes.28 These materials were constructed 
from a blend of the polymers PLA and PVP, and were around 1 µm in 
diameter. An increased PVP content was found to result in increased anti-
bacterial activity after 24 h.
The melt blowing process has also  received some attention in the 
pharmaceutical setting, and the fibres produced compared with those 
from both solution and melt electrospinning.29 Marosi’s team generated 
formulations from a vinylpyrrolidone– vinyl acetate copolymer, employing 
poly(ethylene glycol) (PEG) as a plasticiser and carvedilol as a model 
drug. All three methods led to fibres, with the solution electrospun fibres 
narrowest (at ca. 2 µm in diameter), followed by the melt- blown (10 
µm) and melt- spun (50 µm) products. Carvedilol was rendered into the 
(a) (b)
Figure 6.6  Progesterone- loaded poly(lactic acid) (PLA) fibres prepared 
by solution blowing. (a) A scanning electron microscopy image of fibres 
prepared with 6% w/ v PLA and 4% w/ v progesterone; (b) drug release 
profiles for fibres prepared from solutions of 6% w/ v PLA and 2, 4 or 8% 
progesterone (P4). (Reproduced with permission from Oliveira, J. E.; 
Medeiros, E. S.; Cardozo, L.; Voll, F.; Madureira, E. H.; Mattoso, L. H.; 
Assis, O. B. ‘Development of poly(lactic acid) nanostructured membranes 
for the controlled delivery of progesterone to livestock animals.’ Mater. 
Sci. Eng. C 33 (2013): 844– 849. Copyright Elsevier 2014.)
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amorphous physical form by all three processing techniques, and all the 
formulations were able to accelerate the drug dissolution process. The 
melt- blown and melt electrospun systems led to the fastest release, with 
almost identical release profiles, while the solution- electrospun fibres 
freed their drug cargo somewhat more slowly.
A variant of the solution- blowing technique has been applied to 
the processing of living cells (in this setting it has been referred to as 
biothreading).30 Using a pressurised coaxial needle with the exterior 
fluid comprising a viscous polydimethylsiloxane solution and an aqueous 
cell suspension in the core, cells can be processed into scaffolds with no 
noticeable loss in viability.
6.6 Electroblowing
Electrospinning and melt/ solution blowing can be combined in a process 
known as electroblowing. This employs both electricity and a gas flow to 
aid fibre elongation and solidification. The experimental apparatus uses 
a similar spinneret to that in Figure 6.5, and in addition to the gas flow 
a potential difference is applied between the spinneret and the collector. 
This technique has been shown to have significant potential in medical 
applications: in 2014, Jiang et al. applied electroblowing in vitro and in 
vivo to deliver a homogeneous and continuous layer of a medical glue to 
stop bleeding during liver resection.31
More recently, Balogh et  al. prepared fibres of 2- hydroxypropyl- 
β- cyclodextrin loaded with sodium diclofenac.32 They found that when 
electrospinning this system, very frequent clogging of the spinneret 
occurred. Electroblowing overcame this issue and additionally allowed 
faster flow rates to be used, increasing the amount of material that 
could be produced. However, the uniformity of the fibre products was 
compromised, with more ‘beads- on- string’ type morphology seen with 
the blown products. In both cases, the fibres comprised amorphous solid 
dispersions with no crystalline drug evident. The electroblown fibres 
dissolved a little more slowly than those from electrospinning, but still 
much more rapidly than a physical mixture of drug and cyclodextrin.
A subsequent study using Eudragit E and itraconazole (an 
antifungal active pharmaceutical ingredient) also found that a faster 
flow rate could be used in blowing, but that the fibre products from the 
latter had less regular morphologies.33 Again, the drug was amorphously 
dispersed in the fibres, and the dissolution profiles of the electrospun and 
electroblown systems were very similar.
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6.7 Pressurised gyration
Pressurised gyration can be regarded as a combination of the centrifugal 
and blowing approaches. First reported by Mahalingam and Edirisinghe 
in 2013, it involves a pressurised solution of a polymer being rapidly 
rotated.16 The experimental set- up is depicted in Figure 6.7. In essence, it 
comprises a cylinder with a number of small orifices on its surface. This 
cylinder is loaded with a polymer solution, which is then pressurised by 
an inert gas (with pressures up to around 0.3 MPa). The cylinder sits 
inside a static collector and is rotated at speeds of up to 36,000 rpm. The 
centrifugal forces and pressure drive the polymer solution out through 
the orifices, and the solvent rapidly evaporates to produce fibres. The 
technique has the potential to be very easily scalable, with lab set- ups 
able to produce up to 6 kg of fibres per hour.16
In the initial development of this technique, the polymer PEO was 
dissolved in water and a range of processing parameters investigated.16 
Through a judicious choice of polymer concentration, applied pressure 
and rotation rate, the fibre diameter could be varied between around 
60 and 1000  nm. The technique has since been extended to a range 
of polymers,34 including PVP35 and blends of carboxymethylcellulose, 
sodium alginate or polyacrylic acid with PEO.36 The latter were found to 
have significant potential as vaginal mucoadhesive formulations.
Pressurised gyration can also be employed to yield drug- loaded 
fibres.37 A  detailed study of PVP/ ibuprofen fibres prepared in this way 
was performed by Raimi- Abraham et al. in 2015.37 Pure PVP fibres from 
pressurised hydration had nanoscale diameters, but after inclusion of 
ibuprofen the fibres were found to become wider, with diameters on 
the micron scale. Scanning electron microscopy images of the fibres 
Pressurised gas
CollectorCollector
Figure 6.7  A schematic illustration of the experimental apparatus used 
for centrifugal spinning.
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are depicted in Figure  6.8(a) and (b). They comprised amorphous 
composites of the drug and polymer, and accelerated the dissolution 
rate of the drug (Figure 6.8(c)). In non- sink conditions, super- saturation 
could be achieved (Figure 6.8(d)).
Protein active ingredients may also be formulated into fibres using 
the pressurised gyration route, as has been demonstrated for the gold- 
binding dodecapeptide Au- BP2.38 This confirms that the approach is 
not simply confined to polymers and small molecules, and that complex 
biomolecules with fragile 3D structures can also be processed.
1 µm 
3 µm 
(a)
(b)
Pure ibuprofen
Fibres with varied PVP loadings(c)
9% ibuprofen fibres
Pure ibuprofen and 
fibres with higher 
drug loadings
(d)
Figure 6.8  Poly(vinyl pyrrolidone) (PVP)–ibuprofen fibres prepared by 
pressurised gyration. Scanning electron microscopy images of (a) pure 
PVP fibres and (b) PVP– ibuprofen fibres with a drug loading of 9% 
w/ w, together with drug release profiles under (c) sink and (d) non- 
sink conditions. In (d), the red line denotes the saturation solubility 
for ibuprofen, and it is clear that the 9% (w/ w) ibuprofen fibres lead 
to concentrations higher than this in the early stages of the release 
experiment. (Adapted with permission from Raimi- Abraham, B. T.; 
Mahalingam, S.; Davies, P. J.; Edirisinghe, M.; Craig, D. Q. ‘Development 
and characterization of amorphous nanofiber drug dispersions prepared 
using pressurized gyration.’ Mol. Pharm. 12 (2015): 3851– 3861. 
Copyright American Chemical Society 2015. This is an open access 
article published under a Creative Commons Attribution (CC- BY) 
License.)
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Protein- loaded fibres generated by pressurised gyration have been 
proposed to have applications in biomineralisation.39 Fibres have also 
been prepared incorporating metal nanoparticles, with the aim of pro-
ducing antibacterial formulations.40 Most pressurised gyration work has 
been performed using polymer solutions, but recently it has been shown 
that the technique can similarly be applied to polymer melts.41 In the 
latter study, PCL fibres were prepared loaded with silver nanoparticles, 
and demonstrated to have antibacterial activity.
6.8 Electrospraying
It would be remiss not to mention the process of electrospraying 
in the  context of this volume. Electrospraying is analogous to the 
electrospinning process, and uses the same equipment. Rather than pro-
ducing fibres, however, it yields nano- to micron- sized particles. This is 
because, rather than ejecting a jet of polymer, the Taylor cone instead 
emits small droplets in electrospraying (see Chapter 2). As these travel 
towards the collector the solvent evaporates under the electrical field.
Electrospraying arises when, for instance, the polymer 
molecular weight is too low and/ or the solution too dilute to 
 provide a sufficiently large number of polymer chain entanglements 
to produce fibres (Figure  6.9). Other than their morphology, the 
particles from electrospraying are rather similar to the fibres produced 
in electrospinning. They commonly comprise amorphous solid 
dispersions, and if made of a fast- dissolving polymer this leads to con-
comitant enhancement of dissolution rate and solubility. Core/ shell 
and multilayered particles can be prepared by using coaxial and multi- 
axial spinnerets,42 as can Janus particles.
As mentioned in section 4.10, there are relatively few reports on 
parameter optimisation for multi- axial electrospinning. However, there 
are several informative studies mapping the material and processing 
parameters for coaxial and multi- axial electrospraying.43 Given the fact 
that electrospraying and electrospinning are analogous technologies, the 
reader may find these reports insightful for guiding material and pro-
cessing parameter optimisation during multi- axial electrospinning.
An elaborate discussion of the benefits of electrosprayed particles 
lies outside the scope of this work, and the reader is directed to some 
recent review articles which discuss these in detail.44, 45 In general, 
however, the sprayed particles can deliver the same functional per-
formance as electrospun fibres. There are some caveats though, and 
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in particular it can be very difficult to recover the particles if collecting 
them on a standard metal collector. A  mat of electrospun fibres is 
similar to a bowl of spaghetti, in that while the fibres are not covalently 
linked together they are intertwined and hard to separate. This makes 
it simple to peel the mat away from the collector. In contrast, no such 
entanglement exists with electrosprayed particles, and it is common 
to suffer poor yields as the particles produced adhere strongly to the 
collector.
Finally, we should note that a number of researchers have explored 
the combination of electrospinning and electrospraying. The basic idea is 
to use the fibre mat from electrospinning as a scaffold to provide certain 
mechanical or physical properties, for instance on which to grow cells 
or for tissue engineering, and to load this with electrosprayed particles 
containing a functional component. This can be undertaken either 
sequentially (spin the scaffold, and then spray particles on to it) or simul-
taneously (electrospin and spray at the same time). There are a number 
of examples of both approaches in the literature.
Figure 6.9  A schematic showing the effects of the processing 
parameters in electrospinning/ spraying on the morphology of the 
products produced. (Reproduced with permission from Zamani, M.; 
Prabhakaran, M. P.; Ramakrishna, S. ‘Advances in drug delivery via 
electrospun and electrosprayed nanomaterials.’ Int. J. Nanomedicine 8 
(2013): 2997– 3017. This is an open access article published under a 
Creative Commons Attribution (CC- BY- NC) License.)
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The first report of the combined technique came from Wang et al., 
who produced a construct for soft- tissue regeneration by simultaneously 
electrospinning poly(urethane- urea) fibres and spraying core/ shell 
poly(lactic- co- glycolic acid) (PLGA) particles loaded with the growth 
factor IFG- 1.46 The release rate of the growth factor could be controlled 
by varying the PLGA concentration and molecular weight, and the com-
posite scaffolds appeared to have good biocompatibility and to be able to 
promote cell growth.46
In another example, a recent study by Zhang’s team prepared a 
scaffold of PCL fibres by electrospinning, and then electrosprayed on 
to this core/ shell PLGA particles containing the protein bovine serum 
albumin.47 The resulting composite was found to accelerate the growth 
of cells, and proposed to have potential in neural regeneration.
Jaworek et  al. have compared the sequential and simultaneous 
approaches to assess their efficacy in the coating of Al2O3, MgO or TiO2 
nanoparticles on to poly(vinyl chloride), polysulfone or nylon fibres.48 
The simultaneous process was found to lead to a lower- density particle 
coating, but also a uniform distribution. The sequential approach gave 
denser layers of particles, but they were localised in the area of the fibre 
mat which was directly under the needle used for spraying. Thus, in 
order to ensure even coverage it was necessary to translate the needle or 
the fibre mat during the collection process.
In another example, Birajdar and Lee have produced fibres which 
released the embedded drug upon exposure to sonication.49 To do this, 
they combined electrospinning and electrospraying to produce core/ 
shell poly(l- lactic acid)/ PEO fibres with silica nanoparticles embedded 
in the shell. This process is illustrated in Figure 6.10(a). Different dyes 
were incorporated in the two compartments of the fibres to aid visualisa-
tion. Immediately after electrospinning, the nanoparticles were loosely 
attached to the surface of the fibres by weak electrostatic forces, but upon 
annealing the particles became embedded in the fibres (Figure 6.10(b) 
and (c)). It was found that the release of rhodamine B from the 
annealed fibres was much more rapid when sonication was applied 
(Figure 6.10(d)), thus demonstrating that these materials could be used 
for drug delivery triggered by sound energy.
The combination of electrospinning and spraying has only recently 
begun to be explored, and much work remains to be done to understand 
fully the benefits it can deliver. Two recent review articles discuss the 
concept in detail, and the interested reader is directed to these for more 
information.45d, 50 
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Figure 6.10  Core/ shell fibres for sonication- triggered release. 
(a) The experimental apparatus used to prepare poly(l- lactic acid)/ 
poly(ethylene oxide) fibres with SiO2 particles on the surface. In 
essence, this involves the simultaneous electrospinning of the fibres and 
electrospraying of SiO2 particles onto the same collector. (b) A schematic 
showing the release mechanism. (i) Immediately after electrospinning 
the particles are located on the surface of the fibres, but (ii) solvent 
vapour annealing causes them to become embedded (bottom). (iii) 
Sonication frees the embedded particles, exposing pores in the fibre 
surface through which the drug can escape into solution. (c) Scanning 
electron microscopy images demonstrating that annealing causes the 
particles to become embedded in the fibres. (d) Release data for the 
model drug rhodamine B, located only in the core of the fibres. It is clear 
that release is markedly faster after bursts of sonication, as denoted by 
the dashed blue lines. (Reproduced with permission from Birajdar, M. S.; 
Lee, J. ‘Sonication- triggered zero- order release by uncorking core– shell 
nanofibers.’ Chem. Eng. J. 288 (2016): 1– 8. Copyright Elsevier 2016.)
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6.9 Microfluidic spinning
Microfluidic spinning is based on the use of micro (sub- millimetre) 
channels. A  large number of these are located in a single microfluidic 
chip, and the rate and time of liquid expulsion from each channel are pre-
cisely controlled by computer. Microfluidic spinning can be coupled with 
electrospinning, as described in detail in a recent review by Cheng et al.51 
While the productivity of microfluidic methods is a major challenge in 
scale- up, the technique offers the ability to generate fibres with a high 
level of complexity not easily achievable by electrospinning. For example, 
using a digitally programmed microfluidic flow, Kang et al. created func-
tional microfibres with continuous spatiotemporal coding along the 
length of the fibre.52 The fibres contained varied chemical compositions 
and topography, and localised bioactive agents.
Microfluidic spinning therefore has the potential to enable very 
precisely tuneable loading of different drugs into a single fibre, allowing 
for programmable release in different parts of the body at different 
times. The technique is beginning to be explored for drug delivery 
applications. However, the materials used in microfluidics are usually 
hydrogels (crosslinked polymer networks solvated with water). These 
often have fast degradation rates and as a result can be unsuitable for 
the extended release of drugs, particularly small molecules. To help 
mitigate this problem, Chae et  al. developed a microfluidic spinning 
method using an isopropyl alcohol sheath flow with an aqueous 
alginate core flow.53 This innovation resulted in nanofibres made of 
highly ordered alginate molecules. Ahn et  al. loaded ampicillin into 
alginate fibres prepared in this manner,54 and found that the ordered 
structure delayed fibre degradation, allowing extended- release profile 
of ampicillin over 7 days.
6.10 Fibre production on the move
Researchers have expended significant effort to miniaturise nanofibre 
production equipment in order to make it portable. Edirisinghe’s group 
were the first to develop a handheld electrohydrodynamic ‘gun’, which 
can be used to produce wound dressings or tissue scaffolds at the site 
of need.55 This portable apparatus can be used for both electrospinning 
and electrospraying, as well as coaxial and multi- axial processes. Jiang 
et al. reported a handheld electroblowing device which could precisely 
deposit fibres on to wound sites,31 and as a result achieved rapid cessation 
of bleeding during liver resection in vivo. More recently, a series of 
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battery- operated or self- powered portable sets of electrospinning appar-
atus have been developed for both solution and melt spinning.56
These portable production approaches enable a non- contact appli-
cation of drug- loaded nanofibres to a patient, thereby minimising the 
need for manual contact with both the medicine and the treatment site. 
Such an approach has the potential to help preserve drug integrity, reduce 
the risk of wound infection and facilitate timely delivery of sophisticated 
nanofibre- based treatments, since the need to package and transport 
the product is eliminated. Mouthuy et al. analysed the performance of 
portable electrospinning using a wide range of commonly electrospun 
materials, and demonstrated that the portable approach can deliver fibre 
mats of quality comparable to those produced with larger benchtop set- 
ups.57 Haik et al. explored the use of a portable electrospinning device 
in wound care, and compared the electrospun dressing with traditional 
paraffin tulle gras dressings on partial- thickness wounds in pigs.58 They 
found no delayed wound healing or signs of infection with either dressing 
type. The portable apparatus was easy to operate, and could be used to 
apply different formulations and customisable materials.
6.11 Other techniques
Recently, authors have also begun to explore approaches in which 
polymerisation and fibre production occur in a single step, preparing a 
solvent- free mixture of monomers and then expelling these from a spin-
neret while exposing the jet to, for instance, heat or ultraviolet light to 
initiate polymerisation.59 Supercritical CO2 has also been explored as an 
alternative to traditional liquid solvents.60 These techniques have been 
shown to yield fibres, but have not yet been explored for drug delivery 
purposes. Their feasibility in this regard is thus not established, but the 
use of supercritical CO2 requires the use of high pressures and makes the 
experimental apparatus required more complex and expensive. In situ 
polymerisation could be more promising, but there is a risk of degrad-
ation of the active pharmaceutical ingredient during the process (either 
through chemical reaction with the monomers, or the heat or ultraviolet 
light used for polymerisation) which would need to be considered.
Another new technique which has been reported very recently is 
that of pull spinning.61 This uses a rotating disc with bristles at its sur-
face, which is fed polymer solution from a syringe. The disc spins very 
quickly, and as a result a solution jet is formed; this ultimately leads to 
nanoscale fibres. Pull spinning has yet to be applied to drug delivery but 
would appear to have significant potential in this area.
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Table 6.1 The advantages and disadvantages of the major fibre production approaches considered in this chapter
Technique Advantages Disadvantages
Direct current  
(DC) electro-
spinning
Simple and cheap to set up
No use of heat
Wide range of literature to build on
Many different types of drug delivery system can be produced
Can easily be used to make complex architectures
Can process a wide variety of fragile active ingredients, including proteins 
and cells
A relatively wide variety of solvents and polymers can be processed
Wide range of collector types can be used to align fibres or produce 
different- shaped scaffolds
Low- throughput batch process – only a few 100 mg of 
samples per hour can be produced
Reproducibly controlling environmental parameters can be 
difficult, leading to batch- to- batch variation
Uses volatile solvents with potential health and safety/ 
environmental implications
Alternating  
current 
electro-
spinning
Relatively simple and cheap to establish
No use of heat
Relatively high throughput (ca. eight times greater than DC spinning)
Drug delivery performance on a par with products from DC 
electrospinning
Fibre morphology can be less regular than from DC spinning
A reduced range of polymers can be processed
Little technological development has been undertaken, 
making new processes harder to establish
Uses volatile solvents with potential health and safety/
environmental implications
Melt  
electro-
spinning
No solvents are used – potentially a greener process than solvent spinning
Drug delivery performance on a par with products from DC 
electrospinning
Can offer improved drug delivery performance over solution- spun fibres
Use of heat may cause degradation of labile active 
ingredients or polymers
Apparatus more complex than in solution spinning
Fibres have larger diameters than those from solution 
spinning
Little technological development has been undertaken, 
making new processes harder to establish
new
genrtpdf
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Centrifugal  
spinning
Simple and cheap to set up
Can avoid the use of heat/ solvent as required
Drug delivery performance appears promising
Potentially larger- scale than solution electrospinning
Fibres have larger diameters than those from solution spinning
Little technological development has been undertaken, 
making new processes harder to establish
Use of one of heat or a volatile solvent is required, which 
may be problematic for labile drugs (heat) or have safety/ 
environmental problems (solvent)
Blowing Simple and cheap to set up
Can avoid the use of heat/ solvent as required
Fibre morphology/ uniformity can be as good as or better than from 
electrospinning
Drug delivery performance similar to fibres from solution electrospinning
Potentially larger- scale than solution electrospinning
Can process cells and other fragile active ingredients in the solution- 
blowing process
Little technological development has been undertaken, 
making new processes harder to establish
Use of one of heat or a volatile solvent is required, which 
may be problematic for labile drugs (heat) or have safety/ 
environmental problems (solvent)
Electroblowing Can overcome problems with needle clogging experienced in solution 
electrospinning
Higher throughput than standard DC solution electrospinning
Drug release behaviour very similar to solution electrospinning
Experimental apparatus somewhat more complex than the 
separate electrospinning or blowing processes
Little technological development has been undertaken, 
making new processes harder to establish
Fibre morphology less uniform than from solution 
electrospinning
Uses volatile solvents with potential health and safety/
environmental implications
Pressurised  
gyration
Experimental apparatus is relatively simple and easily scalable
Fibre diameter can be tuned over a wide range
Drug delivery properties are promising, and on a par with those of 
electrospun fibres
Can process fragile active ingredients such as proteins
Relatively little technological development has been 
undertaken, making new processes harder to establish
Fibres possibly wider than those produced by electrospinning
Generally uses volatile solvents with potential health and 
safety/environmental implications
new
genrtpdf
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6.12 Conclusions
This chapter has presented a brief overview of the alternative approaches 
to standard solution electrospinning which can be used to generate 
drug- loaded fibres. A  summary of the advantages and disadvantages 
of each is given in Table 6.1. Some of the techniques discussed involve 
the use of heat, which can be problematic with thermally labile active 
ingredients such as proteins or low- melting- point drugs. However, melt 
approaches are attractive because they obviate the need for volatile 
(and thus dangerous) solvents, and the use of plasticisers can reduce 
the temperatures required for processing. Several of the methods 
discussed are able to operate continuously and produce larger amounts 
of fibres than standard lab solution DC electrospinning – for instance, 
AC spinning and pressurised gyration. They are thus possibly more 
attractive for industry, since they facilitate scaling up. However, the vast 
majority of the research undertaken on drug- loaded nanofibres to date 
has used solution spinning with a DC current, and there are already on 
the market a number of options for scaling up this process. We will con-
sider these in Chapter 7.
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Moving from the bench to the clinic
7.1 Introduction
The previous chapters have enumerated the range of electrospinning 
approaches which can be implemented, and explored how the fibres 
thereby produced can be applied in drug delivery, as well as briefly intro-
ducing a range of other fibre production techniques. However, at the time 
of writing there are no electrospun fibre- based pharmaceutical products 
on the market, despite the distinct promise of the approach. This is 
because there are a large number of hurdles lying between exciting 
results obtained in the lab and being able to produce formulations in the 
commercial environment. We will discuss these in this chapter.
7.2 Scale- up
The standard lab electrospinning apparatus works at somewhere 
between 0.5 and 20 ml h– 1, and thus in a day of spinning at most some 
200 ml of fluid can be processed. With a typical polymer concentra-
tion of around 10% w/ v, this amounts to a maximum daily yield of 20 
g of fibres  – clearly a long way from the kilograms or tonnes per day 
required for an industrial process. The ability to produce fibres in much 
larger quantities is thus required, which necessitates that modifications 
be made to the experimental equipment. In order to scale up  the 
electrospinning process, attention must be paid to two key components 
of the apparatus: the spinneret and the collector.
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7.2.1 The spinneret
The design of the spinneret has been discussed in some detail previ-
ously (sections 2.6.3, 3.2.3 and 4.2.3), but in essence in most cases it 
comprises a flat- tipped metal needle. The earliest attempts to scale up the 
electrospinning process aimed to achieve this by simply using multiple 
needles and feeding these from a single reservoir of polymer solution. 
These can be arranged in a linear or circular manner (Figure 7.1).1
In order to generate fibres on a sufficiently large scale for commer-
cial production, however, the number of needles required is very high: of 
the order of thousands. The Toptec company has produced appar-
atus which works on this principle, with the needles ejecting solution 
upwards (contrary to the usual protocol in lab- based experiments, which 
spin horizontally or downwards) to avoid any polymer droplets falling 
on to the collector from the nozzles.2 Inovenso also use a multi- nozzle 
approach in their commercial- scale spinning equipment.3 A  number of 
problems exist with the multi- needle approach, however. The reliability 
of the process is often sub- optimal, and issues of needle clogging and 
other machine maintenance difficulties frequently arise. The consistency 
and reproducibility of the product can also be challenging to ensure.
One of the key issues with the multi- needle approach is that the 
electric field around a given needle is affected by the presence of other 
electrospinning jets in its vicinity, which can result in inhomogeneity in the 
products.4 This can be ameliorated to an extent by the use of auxiliary or 
secondary electrodes.5 Other researchers have successfully used a hollow 
tube with holes drilled in the side as a replacement for multiple needles,6 
which makes for a simpler structure. The channels of a microfluidic chip 
can also be used to this end.7 However, the problems caused by adjacent 
jets interfering with one another are still present in these cases.
A more robust solution to the issues of clogging and field inhomo-
geneity is to implement a needle- free process. Rather than ejecting a 
(a)
(b)
Figure 7.1  Different arrangements of needles in multi- needle 
electrospinning, showing (a) linear and (b) circular configurations.
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liquid through a needle, this uses an electric field to form a polymer 
jet from the surface of a liquid. This works in a similar way to standard 
electrospinning, except that an extended area of a polymer solution’s 
surface is charged. This causes Coulombic repulsions, as described 
in section 2.4, the formation of a large number of Taylor cones on 
the surface, and as a result the emission of numerous polymer jets 
(Figure 7.2).
Needleless electrospinning removes the possibility of clogging, 
but other challenges arise, because this process is likely to deposit large 
droplets as well as or instead of fibres. Specialised equipment is needed 
to ameliorate these challenges, such as the Nanospider technology 
developed by Elmarco.8 The original iteration of this equipment used a 
charged metal cylinder as the fibre generator. The cylinder is partially 
immersed into a polymer solution and rotated, ensuring that a thin layer 
of polymer solution coats the top of the cylinder (Figure 7.3). When an 
electrical current is applied, this results in the emission of a large number 
of liquid jets upwards from the top of the solution- covered cylinder 
(Figure 7.3). Higher voltages than in the standard spinning process are 
typically required (approximately 30– 120 kV for free- surface spinning, 
cf. 5– 20 kV for needle spinning).2 The jets which form are distributed 
across the electrode in the most energetically stable configuration pos-
sible. This is in sharp contrast to the multi- needle approach, where the 
needles are placed by human design. While modelling and calculations 
can help researchers to design efficient multi- needle spinnerets, the 
needle- free approach achieves an optimum distribution of Taylor cones 
without requiring any such modelling. The Nanospider is able to produce 
up to 50 million m2 of fibres per year.
(a) (b)
Figure 7.2  Needleless electrospinning of poly(vinyl alcohol) at 
(a) 32 and (b) 43 kV. (Reproduced with permission from Petrik, S., 
‘Industrial production technology for nanofibers.’ In Nanofibers – 
Production, Properties and Functional Applications, edited by Lin, T., 3– 16. 
Rijeka: InTech, 2011. Copyright InTech 2011. This is an open access article 
published under a Creative Commons Attribution (CC- BY) License.)
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The rotating drum approach is not the only type of free- surface 
electrospinning process, and others have reported using magnetic 
particles,9 wires,10 rings,11 discs,12 rods13 and balls12a or a fluid- filled bowl 
as the spinneret.14 The latter approach uses the edge of the bowl as the 
spinneret, termed ‘edge electrospinning’. These types of free- surface 
spinning can effectively resolve the problems of fibre inhomogeneity 
and needle clogging. However, there remain some concerns, because 
electrospinning typically works with volatile solvents with high vapour 
pressure, and thus there is a risk of solvent evaporation occurring inde-
pendently of the electric field. In extreme cases, there is an explosion 
risk with a large uncovered container of polymer solution being used for 
spinning.
Several teams of researchers have sought innovative solutions to 
reduce the exposed solution surface area. This can be achieved by, for 
instance, dropping the polymer solution slowly from a syringe on to the 
roller spinneret.15 In a slightly different approach, Lu et  al. employed 
a rotating cone electrode (Figure  7.4), onto which a polymer solution 
was steadily delivered.16 This reduced the exposed area, and the method 
could produce fibres on the 10 g min– 1 scale, some 1000- fold higher than 
standard lab electrospinning. Other scientists have used an angled flat 
plate as the spinneret.17
 The dropwise addition of polymer solution, angled plate or rotating 
cone arrangements can solve the problem of exposing a large area of solu-
tion, but it can be difficult to control the delivery of polymer to the spinneret 
and to ensure that this is even and at a constant rate. These approaches 
have gained traction with industry as well as in the research laboratory, 
however. Elmarco have, in the newer generations of the Nanospider tech-
nology, moved away from a rotating drum set- up to use a static wire con-
tinuously coated with a polymer solution as the spinneret (Figure 7.5).18
Collector
Electrospinning
jets
Polymer soluon
Rotang cylinder
Figure 7.3  The rotating drum electrode used in the Nanospider 
needleless electrospinning technology.
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Recent work by Molnar and Nagy has developed a novel technique 
to permit high- throughput spinning while minimising the surface area 
of solvent exposed to the environment.19 This uses a corona spinneret, in 
which the polymer solution can escape from its reservoir via a narrow cir-
cular gap, as depicted in Figure 7.6. The spinneret is rotated, and fed con-
tinuously with polymer solution. Taylor cones are generated at the edge 
of the corona when an electrical current is applied. This approach has the 
advantage of the free- surface approach, in that the positions of the Taylor 
cones are determined by the properties of the system being spun and the 
electrospinning parameters, and the cones will thus automatically be 
arranged in the most stable configuration. The corona spinneret allowed 
Electric motor
Polymer soluonRotang 
spinneret
Collector
HV
Figure 7.4  The rotating cone methodology used by Lu et al.16 HV: high 
voltage.
Collector
Wire
HV
Polymer soluon dispenser
Polymer jets
Figure 7.5  Surface electrospinning from a static wire. The wire is 
charged, and a polymer solution dispenser moves up and down the 
length of the wire, ensuring that all parts of it are continuously supplied 
with polymer. HV: high voltage.
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electrospinning to be performed without any manual intervention for 
many hours. When poly(vinyl pyrrolidone) and poly(acrylonitrile) 
(PAN) fibres were prepared with both the standard single- needle and the 
corona approach, these were almost indistinguishable in their morph-
ologies, although the PAN fibres were slightly narrower when prepared 
through corona spinning.
Since much of the work to scale up electrospinning has only begun in 
recent years, the majority of studies have considered the single- fluid pro-
cess. However, coaxial spinning can also be scaled up, as demonstrated 
by Wu et al.20 These authors essentially used the multi- needle approach, 
but rather than having needles protruding from a surface, they nested 
them inside a block such that the ends of the needles were flat with the 
edge of the mount. Core/ shell fibres with sizes very close to those from a 
standard coaxial needle were obtained.
The free- surface spinning methodology can also be used to prepare 
core/ shell structures, as reported by Forward et al.10 This study featured a 
system of two immiscible solutions, one layered on top of another. A wire 
electrode is raised upwards through these, generating a two- layer coating 
on the wires, as shown in Figure 7.7. The application of a voltage causes 
two- compartment Taylor cones to form on the wire surface and polymer 
jets to be emitted, ultimately yielding core/ shell fibres. A rotating spindle 
of wires was used to produce fibres in a continuous manner.
HV
Collector
Polymer
soluon
Narrow gap
Lid
Figure 7.6  The corona approach to high- speed electrospinning 
reported by Molnar and Nagy.19 The collector comprises a moving 
conveyor belt. HV: high voltage.
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This approach is potentially a powerful one, but is limited because 
it requires the two fluids involved to have low miscibility. This limitation 
can be overcome, and coaxial fibre production successfully scaled up to 
production rates of around 1 l h– 1, using a ‘slit surface’ method.21 This is 
shown in Figure 7.8. In essence, in this approach the two working fluids 
flow through separate channels but are brought together at a surface as 
they pass through the exit slits. The application of a high voltage results 
in compound Taylor cones forming, and thus the production of core/ 
shell fibres. A similar approach, using a polymer bilayer and a ‘weir’ spin-
neret, has been demonstrated by Vysloužilová et al. to be capable of gen-
erating core/ shell fibres.22 Janus fibres may also be produced via a similar 
needleless route.23
Emulsion spinning has also been successfully scaled up via a free- 
surface strategy, by feeding an emulsion between two parallel, charged, 
copper wires.24 Similar, unconfined, approaches can be applied to melt 
electrospinning. This has been reported by Wang et al., who melted poly-
ethylene on a heated plate and then applied an electric field between this 
and a collector.25 This resulted in the formation of ‘fingering perturbations’ 
at the edge of the plate, and these in turn emitted polymer jets and 
generated fibres. Needleless alternating current electrospinning has also 
been reported.26 Furthermore, as was noted in Chapter 6 (sections 6.4 
and 6.7) the approaches of centrifugal spinning and pressurised gyration 
are additionally amenable to scale up.27
Wire electrode
Figure 7.7  Using free- surface electrospinning from wire electrodes 
to generate core/ shell fibres, as reported by Forward et al.10 Two 
immiscible liquids are placed in a container, and the wire electrode 
is drawn up through these (left), thereby creating a bilayer of fluids 
around the electrode (right). Application of an electrical field results in 
the formation of a compound Taylor cone and thus core/ shell fibres are 
produced.
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7.2.2 The collector
In most lab- scale experiments, the collector is simply a flat grounded 
surface, often a sheet of metal wrapped in aluminium foil. This is 
perfectly adequate for the majority of experiments, and has the 
advantages of cost- effectiveness and simplicity. In more advanced 
Figure 7.8  The experimental apparatus used in the slit- surface spinning 
free- surface method, which permits core−shell fibres to be produced 
on the large scale. The arrangement of slits is shown in (a), and the 
complete apparatus in (b). (Reproduced with permission from Yan, 
X.; Marini, J.; Mulligan, R.; Deleault, A.; Sharma, U.; Brenner, M. P.; 
Rutledge, G. C.; Freyman, T.; Pham, Q. P. ‘Slit- surface electrospinning: A 
novel process developed for high- throughput fabrication of core–sheath 
fibers.’ PLoS ONE 10 (2015): e0125407. Copyright Yan et al. 2015.)
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set- ups, researchers have used rotating mandrels or parallel electrodes 
as the collectors to align the fibres produced (section 2.6.4). All of 
these, however, are inherently batch processes. There is a limit to the 
amount of fibres which can be collected in one experiment, because 
as the layer of material on the collector gets thicker the grounding is 
lost. For scale- up, a continuous process is required, which demands a 
different collector. This is usually a moving surface or conveyor belt 
set- up (Figure  7.6).1, 28 Such collector geometries can both achieve 
fibre alignment, if desired, and hugely aid the translation to industrial- 
scale continuous processes.
7.2.3 safety and environmental considerations
On the lab scale, when processing a few millilitres of liquid per hour, 
venting the evaporated solvent into the air in the laboratory is probably 
not a concern with the majority of solvents, and if required a fume cup-
board can be used to handle the vapour produced safely. When working 
on the scale of many litres per hour, however, there is a risk to the safety 
of the users operating the equipment from high concentrations of solvent 
in the air, and additionally an ignition risk. Thus, such procedures must 
take place with the evaporated solvent effectively extracted from the local 
environment through a robust ventilation system. A range of options exist 
for doing this, and commercial suppliers such as Nanospider and IME can 
already provide such systems.
The environment outside the production facility should also be 
considered, as should wastage. It is not environmentally friendly to vent 
large volumes of solvent to the atmosphere and then use fresh solvent 
for subsequent manufacturing, and thus it is desirable to establish facil-
ities which can collect the evaporated solvent, condense it and reuse it in 
a later spinning process. Venting solvents is tightly regulated by legisla-
tion, and robust measures will be required to ensure any facility complies 
with these.
7.2.4 scale- up in electrospun drug delivery systems: preliminary 
studies
A few groups have in recent years begun to compare the drug delivery 
properties of fibres prepared by standard single- needle and high- speed 
(scaled- up) electrospinning. Krogstad and Woodrow have under-
taken such a study looking to scale up the production of poly(vinyl 
alcohol) fibres loaded with tenofovir, an antiretroviral drug.29 The 
intended application here was as a topical vaginal microbicide for 
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anti- human immunodeficiency virus (HIV) treatment. Free- surface 
high- throughput spinning was undertaken using Nanospider appar-
atus fitted with parallel wire electrodes. The fibre properties were 
very similar regardless of production method, with those from the 
wire apparatus slightly narrower in diameter than the fibres produced 
on standard lab equipment. The stability and drug release proper-
ties were almost identical from both approaches. However, while the 
single- needle spinning yielded around 43– 135 mg h– 1 of product, the 
Nanospider could produce in the region of 2.9– 7.7 g h– 1, an increase of 
around 60– 70- fold in production capacity.
In other work, Nagy and colleagues have prepared fibres of 
poly(vinyl pyrrolidone/ vinyl acetate) (PVPVA) loaded with the antifungal 
drug itraconazole using their corona spinneret with a conveyor- belt col-
lector.30 In the single- needle experiment, they could work with a flow rate 
of 20 ml h– 1, corresponding to 6 g h– 1 of solid material being produced. The 
high- speed approach permitted a flow rate of 1500 ml h– 1 to be realised, 
yielding 450 g of material every hour: a 75- fold increase. The high- speed 
fibres had more bead- on- string morphology visible (Figure 7.9(a)–(d)), 
but in both cases the drug was amorphously distributed in the fibres and 
drug release was markedly faster than the dissolution of the raw material 
or a PVPVA/ itraconazole cast film, as can be seen in Figure 7.9(e). The 
resultant fibres could be processed into tablets.31
The long- term stability of electrospun formulations will be cru-
cial to successful clinical applications, and the relative stabilities of 
analogous formulations from high- throughput and standard single- 
needle spinning have been compared.32 Fibres were prepared com-
prising PVPVA or hydroxypropylmethylcellulose (HPMC) as the carrier 
polymer and itraconazole as a model drug. As noted above, the PVPVA- 
based fibres prepared in the high- speed approach contained more beads 
than those from single- fluid spinning, but all consisted of amorphous 
solid dispersions of drug in polymer. They were stable for 1 year when 
kept under sealed conditions at 25ºC and 60% relative humidity (RH), 
but when stored in open containers at 40ºC and 75% RH, phase separ-
ation of the drug and polymer and drug recrystallisation were observed 
after 3  months. The dissolution profiles of those stored at 25ºC/60% 
RH were indistinguishable from the fresh materials, showing markedly 
accelerated dissolution over a drug/ polymer physical mixture. In con-
trast, those stored at 40ºC/75% RH showed much slower dissolution 
owing to the recrystallisation of drug, exhibiting behaviour closer to the 
physical mixture. The high- speed spinning samples were slightly slower 
to dissolve than those from the single- needle spinning.
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In the case of HPMC, no recrystallisation was observed even 
after 12 months’ storage at 40ºC and 75% RH, but it was thought that 
some changes in the conformations of the drug and polymer occurred 
during this time since the dissolution rate was slower after storage. As 
for PVPVA, the dissolution rate of the high- speed spun fibres was slower 
than for the single- needle fibres, but 100% dissolution inside 2 h was still 
observed. Here, the stored samples behaved much more similarly to the 
fresh samples, owing to the lack of phase separation.
Scale- up has also been explored in the case of protein drugs.33 
Poly(vinyl alcohol) or poly(vinyl pyrrolidone) (PVP) fibres loaded with 
the enzyme β- galactosidase (lactase), widely used for the treatment 
of lactose intolerance, were generated. Experiments were initially 
performed on standard lab equipment, and then subsequently using 
the corona spinning approach. To avoid denaturation of the enzyme, 
water was employed as the solvent, requiring high voltages of 30 kV for 
successful spinning. Only minimal (< 5%) loss of enzyme activity was 
(e)(a) (b)
(c) (d)
Figure 7.9  A comparison of single- needle and high- speed corona 
electrospinning for the preparation of poly(vinyl pyrrolidone/ vinyl 
acetate)/ itraconazole (ITRA) fibres. Scanning electron microscopy 
images of (a) and (b) the single- needle fibres, and (c) and (d) the high- 
speed fibres are shown together with (e) dissolution profiles of high- 
speed electrospinning (HSES) and single- needle electrospinning (SNES) 
fibres, compared with analogous spray- dried or film- cast formulations 
and the raw material. (Adapted with permission from Nagy, Z. K.; 
Balogh, A.; Demuth, B.; Pataki, H.; Vigh, T.; Szabo, B.; Molnar, K.; 
Schmidt, B. T.; Horak, P.; Marosi, G.; Verreck, G.; Van Assche, I.; 
Brewster, M. E. ‘High speed electrospinning for scaled- up production 
of amorphous solid dispersion of itraconazole.’ Int. J. Pharm. 480 
(2015): 137– 142. Copyright Elsevier 2015.)
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seen with PVP, and the fibres produced on the large scale behaved very 
similarly to the small- scale batches.
Although the scaled- up production of electrospun drug delivery 
systems has only begun to be explored very recently, the preliminary 
results are very encouraging, and it would appear that the large number 
of small- scale lab studies which have been performed to date have very 
real potential to be translated to the industrial setting.
7.3 Regulatory requirements and GMP manufacturing
The path to taking a medicine to market is necessarily a long and rather 
bureaucratic one, since a large number of safeguards are required to 
ensure patient safety. Each jurisdiction will have its own regulatory 
body responsible for approving the sale of a new formulation (in the 
UK, this is the European Medicines Agency (EMA) for products centrally 
authorised in the European Union and the Medicines and Healthcare 
products Health Regulatory Agency (MHRA) for nationally authorised 
products). That said, although the precise procedures to be followed 
will differ from place to place, the principal stages of taking a medicinal 
product from the lab to the clinic are similar worldwide, and increasingly 
harmonised through the procedures of the International Conference on 
Harmonisation (ICH).34 For instance, today manufacturers typically con-
trol impurities in active pharmaceutical ingredients and validate analyt-
ical methods worldwide based on ICH guidelines (which cover the USA, 
Europe and Japan).
To obtain regulatory approval, the synthetic chemistry behind 
the active ingredient must be well established, and its chemical struc-
ture, stereochemistry, phase purity and impurity profile confirmed 
using appropriate analytical techniques. A robust manufacturing pro-
cess must be in place, with appropriate in- process controls to ensure 
that all products meet the required quality standards. The efficacy 
and safety of the drug, and the formulation, must be demonstrated 
in vitro, in vivo in animals and in clinical trials. The stability of the 
formulation and its shelf- life must be established and appropriate 
specifications established. These processes are complex, expensive and 
time-consuming, but all are carried out efficiently and successfully by a 
number of companies worldwide, and thus all aspects of the regulatory 
framework which can be directly translated to fibre products should 
be relatively straightforward to implement. In the view of the authors, 
the major difference between a fibre product and one prepared in more 
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conventional ways – for instance, through spray or freeze drying – lies in 
the manufacturing process, and thus here is where the major challenge 
to translation lies.
We have discussed above the requirement to produce large 
amounts of material, and it is clear that a number of plausible routes to 
scale- up exist. Making large volumes of material is not sufficient, how-
ever, and attention must also be paid to the quality and reproducibility 
of the formulations generated. For use in medical products, ultimately 
it will be necessary to perform electrospinning under good manufac-
turing practice (GMP) guidelines. GMP covers a range of aspects of a 
pharmaceutical manufacturing process, including the development, 
manufacture, packaging and testing of the product. It takes into con-
sideration the premises used for manufacture, the personnel involved, 
the different steps of the production process and the quality manage-
ment systems in place to assure product quality. Robust training regimes 
are required, as well as procedures for dealing with out- of- specification 
events, complaints and product recall. Thorough documentation must 
be produced, with a traceable audit trail for every batch of product 
generated.
A detailed discussion of GMP lies outside the scope of this chapter. 
In essence,  however, GMP ensures that products of the appropriate 
quality are consistently produced and controlled, and that manufactured 
materials and products comply with standards appropriate for their 
intended use as enforced by the appropriate regulatory authority (e.g. 
the EMA or MHRA). For instance, it is vital to ensure that the product 
contains the correct drug at the appropriate strength, that impurities 
and microbial content are controlled, and  where appropriate that  the 
drug is released at a pre- determined rate. The product must be packaged 
properly and protected against degradation or damage, and be cor-
rectly labelled. This is ensured by putting in place a pharmaceutical 
quality system which incorporates the requirements of GMP and quality 
risk management. The interested reader may find the EU and UK GMP 
guidelines helpful to understand the requirements in more detail.35
In essence, therefore, to meet GMP requirements it will be neces-
sary to produce large batches of electrospun fibres reproducibly with 
consistent properties and performance between batches. This is cur-
rently a problem because, although parameters such as temperature and 
RH can be precisely controlled through bespoke systems such as those 
produced by IME Technologies,36 these are expensive and to date there 
has been little convergence between precise control of the process and 
scale- up (i.e. it has been possible to produce relatively small amounts 
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of fibres with a very high level of control, or large amounts of materials 
with less control, but not both). That said, Elmarco now produce an air- 
conditioning attachment for their industrial apparatus to permit precise 
control of the environmental parameters, and these types of innovations 
can be expected to accelerate in the coming years.
To ensure product quality, in addition to controlling the processing 
parameters, some form of inline (i.e. live, in real time) monitoring 
of product quality will be required to ensure that if there are any 
problems during production they can be rapidly detected, and produc-
tion halted until the issues have been addressed. The use of a volatile 
solvent in electrospinning is also potentially problematic. Environmental 
regulations must be considered in the disposal of the solvent, and 
processes established to ensure that any residual solvent in the final 
products falls below acceptable limits.
Although challenging, electrospinning is no more complex than 
standard industry processes such as hot melt extrusion or spray drying 
(see section 1.5), and thus undertaking it under GMP conditions should 
be eminently achievable. This is shown by a report in the literature,37 
which placed Nanospider apparatus in a clean room operated to GMP 
conditions and generated fibres to be used as an artificial extracellular 
matrix for stem cell applications. Further, the UK- based Electrospinning 
Company also routinely performs electrospinning under GMP conditions 
using a clean room.38
7.4 Conclusions
In this chapter, we have briefly reviewed the further steps which need 
to be taken to translate the wide range of promising fibre formulations 
which have been prepared in the research laboratory to the clinic. 
Although there remain challenges and obstacles to overcome, the main 
barriers comprise the need to produce large amounts of materials in 
a reproducible and quality- controlled environment, and to move the 
products through the various stages of development towards regula-
tory approval. As has been discussed, there is still work to do in terms of 
the former, but very significant steps forward have been made in recent 
years. Pharmaceutical companies have a tremendous weight of experi-
ence in the latter, and thus it is to be expected that fibre- based drug 
delivery systems will have an excellent chance of making their way to the 
clinic in the relatively near future.
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Conclusions and outlook
In this volume, we have explored in detail the use of polymer nanofibres 
in drug delivery. The majority of attention was paid to electrospinning, 
since this is the route which has received by far the most research 
attention for fabricating drug- loaded fibres. The different electrospinning 
techniques have been introduced, and guidance provided on how to 
begin a new experimental process. The products formed are related to 
the type of electrospinning undertaken, and we have seen that monoaxial 
spinning of a polymer solution yields monolithic fibres, while emulsion 
or coaxial spinning tends to result in core/ shell structures. Three- liquid 
electrospinning can be used to prepare fibres with three layers, and side- 
by- side spinning to produce Janus fibres with two separate sides.
The types of drug delivery system that can be prepared with 
each electrospinning approach were described in detail, with a survey 
of examples from the literature presented to illustrate key points. In 
terms of monolithic fibres, a suitable choice of polymer can lead to 
fast- dissolving drug delivery systems (with a water- soluble hydrophilic 
polymer), extended release over hours or days (with insoluble or slowly 
degrading polymers) and targeted release (pH- sensitive polymers). 
Thermoresponsive systems can also be generated.
The monoaxial approach is advantageous because of its simplicity, 
but the high surface area of the fibres often causes an uncontrollable ini-
tial burst of release. This is a particular problem with high drug loadings. 
Electrospinning using suspensions or emulsions can help to ameliorate 
this issue. Emulsion spinning can also help to stabilise biomolecules such 
as proteins during the electrospinning process. Alternatively, a range 
of possibilities for making multilayer systems exist and can be used to 
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provide more sophisticated release patterns. As well as their use in drug 
delivery, monolithic fibres can be employed as sacrificial templates for 
the self- assembly of higher- order objects.
Coaxial electrospinning offers the potential to solve a number of the 
problems of monoaxial spinning. For instance, making a core/ shell fibre 
with the drug payload localised in the core can prevent burst release, 
although the formulation has to be carefully designed to do this suc-
cessfully. Other release profiles which can be provided through coaxial 
spinning include biphasic release (with two phases occurring at different 
rates) and pH- sensitive release, targeting delivery to the small intestine. 
Multiple components can be included in the different compartments of 
the fibre and freed at different times. Since only one of the two solutions 
used for spinning need be electrospinnable, the coaxial approach can 
provide protection to protein drugs by incorporating them into the core 
of the fibres, with a protein- friendly aqueous solvent used for the core 
liquid. Alternatively, a pure solvent or solution of small molecules can 
be employed as the outer liquid; this yields monolithic fibres, but can 
help to prevent blocking of the spinneret or provide surface functionality. 
Triaxial electrospinning offers opportunities to provide even more com-
plex products, but this comes at the cost of a more challenging fabrica-
tion process.
Janus fibres are difficult to prepare, because the two working 
liquids have a tendency to separate upon exiting the spinneret. They 
have thus received far less attention than monolithic or core/ shell fibres. 
There are some approaches which can be taken to solve this problem, and 
several novel experimental methods have been reported in recent years, 
but at the time of writing we could find only a few reports of Janus drug 
delivery systems fabricated by electrospinning.
In addition to standard electrospinning performed with direct 
current (DC), a range of other methods to produce fibres exist. 
Alternating current (AC) electrospinning can be higher- throughput than 
the DC approach, and although it can be more difficult to obtain good- 
quality fibres, the functional performance of materials prepared by AC 
and DC spinning is very similar. Polymer melts can also be electrospun, 
producing fibres with diameters usually on the micron scale. This method 
avoids the use of any organic solvent, and thus the concomitant hazards 
associated with these, but it does require heat, which can lead to drug 
degradation.
Other approaches to fibre production use different sources of 
energy for solvent evaporation. Polymer- based fibres made by centrifugal 
spinning (where centrifugal force is used to evaporate solvent), solution 
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blowing (exploiting a pressurised gas) and pressurised gyration (using 
both together) have all been explored for drug delivery, with prom-
ising results. Electrospinning can also be combined with blow spinning 
to produce drug- loaded fibres. These techniques are typically higher- 
throughput than standard lab electrospinning
Electrospinning has a sister technology, electrospraying, which 
uses the same principles but produces polymer- based particles. These 
also have an important role to play in drug delivery. Electrospraying and 
electrospinning can be combined to produce multi- functional materials.
Although electrospun fibres, and those prepared using the other 
techniques mentioned, have tremendous potential in drug delivery, the 
vast majority of studies to date have been undertaken on the lab scale. In 
the last few years, a number of technologies have emerged which permit 
the process to be scaled up to an industrial scale, and initial experiments 
using these have been very promising. However, more work is needed to 
explore scale- up and how the fibres prepared on the large scale compare 
with those made in the lab. The reproducibility of the materials prepared 
in different locations will need to be carefully established. There thus 
remains much work to be done before polymer fibre- based drug delivery 
systems can reach their full potential in improving human health and 
well- being.
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